

CITATION REPORT

List of articles citing

What are the functional consequences of neurocognitive deficits in schizophrenia?

DOI: 10.1176/ajp.153.3.321

American Journal of Psychiatry, 1996, 153, 321-30.

Source: <https://exaly.com/paper-pdf/27635303/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2357	Clinical symptomatology and drug compliance in schizophrenic patients. 1988 , 77, 74-6		161
2356	Social skills training for schizophrenia: Review and future directions. 1996 , 16, 599-617		55
2355	Is cognitive psychopathology plausible? Illustrations from memory research. 1996 , 41, S5-13		7
2354	Memory Impairment in Schizophrenia: Perspectives from Psychopathology and Pharmacotherapy. 1996 , 41, S27-S34		34
2353	Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy. 1996 , 41, S27-34		11
2352	The role of neurocognitive deficits in understanding adaptive functioning in severe psychiatric illness: commentary on Hawkins and Cooper. 1996 , 59, 389-92		3
2351	Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. <i>American Journal of Psychiatry</i> , 1997 , 154, 799-804	11.9	358
2350	Cognitive Impairment in Schizophrenia and Implications of Atypical Neuroleptic Treatment. 1997 , 2, 41-55		26
2349	Use of a sequencing task designed to stress the supervisory system in schizophrenic subjects. 1997 , 27, 1287-94		12
2348	Social cognition in schizophrenia. 1997 , 121, 114-32		433
2347	Current approaches to assessment and treatment of persons with serious mental illness.. 1997 , 28, 217-228		28
2346	Is it possible to be schizophrenic yet neuropsychologically normal?. 1997 , 11, 437-446		402
2345	The social perceptual deficits of schizophrenia. 1997 , 60, 309-26		34
2344	Rehabilitatie bij chronische schizofrenie: wat voegt cognitieveâfunctietraining toe?. 1997 , 17, 160-168		2
2343	The functional significance of symptomatology and cognitive function in schizophrenia. 1997 , 25, 21-31		271
2342	Normal neurocognitive performance after extended practice in patients with schizophrenia. 1997 , 26, 173-80		51
2341	The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients. 1997 , 27, 211-8		48

2340	Performance on tests sensitive to impaired executive ability in schizophrenia, mania and well controls: acute and subacute phases. 1997 , 26, 127-37		125
2339	Deficits in multiple systems of working memory in schizophrenia. 1997 , 27, 1-10		55
2338	Self-reported social functioning among older patients with schizophrenia. 1997 , 27, 199-210		50
2337	A comparative study of elderly patients with schizophrenia and bipolar disorder in nursing homes and the community. 1997 , 27, 181-90		97
2336	Is Wisconsin Card Sorting Test performance related to 'working memory' capacity?. 1997 , 27, 11-9		35
2335	Neurobiology of schizophrenia. 1997 , 7, 701-7		133
2334	Disease, transplantation and regeneration. 1997 , 7, 738-764		
2333	Does insight affect long-term inpatient treatment outcome in chronic schizophrenia?. 1997 , 38, 283-8		94
2332	Coping and cognition in schizophrenia and depression. 1997 , 38, 341-4		41
2331	Relationship between specific types of communication deviance and attentional performance in patients with schizophrenia. <i>Psychiatry Research</i> , 1997 , 70, 9-20	9.9	5
2330	The Effects of Risperidone vs Haloperidol on Cognitive Functioning in Treatment-Resistant Schizophrenia: The Trail Making Test. 1997 , 2, 60-64		15
2329	Treatment of the patient with long-term schizophrenia. 1997 , 3, 339-346		3
2328	Neurocognitive deficits in schizophrenia. <i>American Journal of Psychiatry</i> , 1997 , 154, 443-4	11.9	3
2327	Affiliation and neuropsychiatric disorders: the deficit syndrome of schizophrenia. 1997 , 807, 455-68		27
2326	Cognitive function in schizophrenia--do neuroleptics make a difference?. 1997 , 56, 789-95		106
2325	Psychological treatments for schizophrenia. 1997 , 2, 5-10		
2324	Schizophrenia, psychiatric rehabilitation, and healthy development: a theoretical framework. 1997 , 68, 155-66		11
2323	Attention and clinical symptoms in schizophrenia. 1997 , 68, 343-59		48

2322	Cognitive impairment in geriatric chronic schizophrenic patients: a cross-national study in New York and London. 1997 , 12, 1001-7		19
2321	Cognitive deficits and psychiatric rehabilitation outcomes in schizophrenia. 1998 , 69, 169-91		103
2320	Behavioral treatment of attentional dysfunction in chronic, treatment-refractory schizophrenia. 1998 , 69, 95-105		23
2319	Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. 1998 , 1, 318-23		487
2318	The Sustained Attention Test: a measure of attentional disturbance. 1998 , 14, 463-475		47
2317	Neurocognitive function and insight in schizophrenia: support for an association with impairments in executive function but not with impairments in global function. 1998 , 97, 297-301		96
2316	Cognitive impairment in late life schizophrenia: a suitable case for treatment?. 1998 , 13, 400-4		1
2315	Training professionals for rehabilitation teams. 1998 , 1998, 13-23		
2314	Evaluation of problem solving and communication skills of persons with schizophrenia. <i>Psychiatry Research</i> , 1998 , 78, 197-206	9.9	8
2313	Personality and psychosocial dysfunction in schizophrenia: the association of extraversion and neuroticism to deficits in work performance. <i>Psychiatry Research</i> , 1998 , 80, 61-8	9.9	54
2312	Correlates of functional status in older patients with schizophrenia. <i>Psychiatry Research</i> , 1998 , 80, 41-52	9.9	55
2311	Concurrent and predictive validity of the Allen Cognitive Levels Assessment. <i>Psychiatry Research</i> , 1998 , 80, 287-98	9.9	29
2310	Social perception and social skill in schizophrenia. <i>Psychiatry Research</i> , 1998 , 80, 275-86	9.9	94
2309	Effects of clozapine on auditory event-related potentials in schizophrenia. 1998 , 44, 716-25		195
2308	Facial affect recognition and information processing in schizophrenia and bipolar disorder. 1998 , 32, 171-81		368
2307	Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. 1998 , 21, 151-79		14
2306	Child and adolescent schizophrenia. 1998 , 21, 43-56		18
2305	Social skill as determinant of social networks and perceived social support in schizophrenia. 1998 , 29, 275-86		45

2304	Training schizophrenic patients to manage their symptoms: predictors of treatment response to the German version of the Symptom Management Module. 1998 , 31, 121-30		15
2303	Mini-Mental State Examination (MMSE) performance of partially remitted community-dwelling patients with schizophrenia. 1998 , 33, 45-52		13
2302	What are we changing with neurocognitive rehabilitation? Illustrations from two single cases of changes in neuropsychological performance and brain systems as measured by SPECT. 1998 , 34, 77-86		48
2301	Relationship between cognitive and social dysfunction in schizophrenia. 1998 , 34, 59-66		50
2300	Monetary reinforcement and Wisconsin Card Sorting performance in schizophrenia: why show me the money?. 1998 , 34, 67-75		37
2299	[The importance of recent neuropsychological and neurophysiological studies for social psychiatry]. 1998 , 7, 82-8		
2298	Quality of life and schizophrenia: No subjective differences among four living conditions. 1998 , 52, 277-283	10	
2297	Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. <i>American Journal of Psychiatry</i> , 1998 , 155, 1087-91	11.9	202
2296	Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. <i>American Journal of Psychiatry</i> , 1998 , 155, 1080-6	11.9	284
2295	Schizophrenia, sensory gating, and nicotinic receptors. 1998 , 24, 189-202		583
2294	Modeling schizophrenic behavior and testing drug efficacy using general mixture components.		
2293	Predicting rehabilitation outcome among patients with schizophrenia. 1998 , 49, 907-9		13
2292	Effectiveness of attention training in schizophrenia. 1998 , 24, 147-52		156
2291	Relevance of brain imaging studies for social psychiatry. 1998 , 7, 89-93		3
2290	Principles of the Individual Placement and Support model: Empirical support.. 1998 , 22, 11-23		150
2289	Schizophrenia and Related Conditions in Late Life. 1998 , 291-305		
2288	Cognitive deficit in schizophrenia and its neurochemical basis. 1999 , 174, 16-18		46
2287	Neuroscience and psychopharmacology into the next millennium. 1999 , 4, 36-52		

2286	Cognitive effects of conventional and atypical antipsychotics in schizophrenia. 1999 , 174, 44-51	60
2285	. 1999 ,	3
2284	Reply to "Studying the Effectiveness of Neurocognitive Remediation in Schizophrenia". 1999 , 25, 195-196	1
2283	Interventions for neurocognitive deficits: editor's introduction. 1999 , 25, 197-200	16
2282	Developmental theory for a cognitive enhancement therapy of schizophrenia. 1999 , 25, 677-92	82
2281	Effects of risperidone on auditory event-related potentials in schizophrenia. 1999 , 2, 299-304	103
2280	Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. 1999 , 56, 367-74	384
2279	The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. 1999 , 25, 201-22	563
2278	Cognitive functioning in schizophrenia: implications for psychiatric rehabilitation. 1999 , 25, 275-89	130
2277	Glucose-induced increase in memory performance in patients with schizophrenia. 1999 , 25, 321-35	68
2276	Practice principles of cognitive enhancement therapy for schizophrenia. 1999 , 25, 693-708	124
2275	Should schizophrenia be treated as a neurocognitive disorder?. 1999 , 25, 309-19	323
2274	The Relationship Between Medication Noncompliance and Cognitive Function in Patients With Schizophrenia. 1999 , 5, S2-S8	3
2273	Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. 1999 , 10, 59-90	122
2272	Dopamine receptors and schizophrenia: contribution of molecular genetics and clinical neuropsychology. 1999 , 2, 197-227	13
2271	Generalized cognitive deficits in schizophrenia: a study of first-episode patients. 1999 , 56, 749-54	333
2270	Cognition, schizophrenia, and the atypical antipsychotic drugs. 1999 , 96, 13591-3	93
2269	Cognitive Measures: What Can They Tell Us About Social Competence?. 1999 , 3, 99-123	2

2268	Shaping Procedures as Cognitive Retraining Techniques in Individuals with Severe and Persistent Mental Illness. 1999 , 3, 59-76	6
2267	Rehab rounds: cognitive modifiability as a measure of readiness for rehabilitation. 1999 , 50, 1411-3, 1419	50
2266	Women with schizophrenia and co-occurring substance use disorders: an increased risk for violent victimization and HIV. 1999 , 35, 401-19	46
2265	Stability of performance on neuropsychological tests in patients with schizophrenia. 1999 , 249, 299-304	7
2264	Cognitive deficits and cognitive training in schizophrenic patients: a review. 1999 , 100, 85-95	110
2263	Compliance in psychoses. 1999 , 100, 167-75	113
2262	Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. 1999 , 20, 106-18	442
2261	Cognition in Schizophrenia: Natural History, Assessment, and Clinical Importance. 1999 , 21, S203-S210	6
2260	Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. 1999 , 286, 105-7	159
2259	Therapeutic Synergism: Optimal Pharmacotherapy and Psychiatric Rehabilitation to Enhance Functional Outcome in Schizophrenia. 1999 , 3, 124-147	4
2258	How do neuroleptics affect cognitive dysfunctions in schizophrenia?. 1999 , 53, 121-125	6
2257	Neuropsychological assesment of psychogeriatric patients with limited education. 1999 , 13, 147-56	37
2256	Integrating Shaping and Skills Training Techniques in the Treatment of Chronic Treatment Refractory Individuals with Schizophrenia. 1999 , 3, 41-58	16
2255	The neuropathology of schizophrenia. A critical review of the data and their interpretation. 1999 , 122 (Pt 4), 593-624	1400
2254	Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia. <i>Psychiatry Research</i> , 1999 , 88, 1-13	9-9 45
2253	Schizophrenia. 1999 , 353, 1425-30	179
2252	Should schizophrenia be treated as a neurocognitive disorder?. 1999 , 9, 201-202	1
2251	Application of fMRI in studies on cognition. 1999 , 9, 202-203	

2250	Pharmacologic strategies for augmenting cognitive performance in schizophrenia. 1999 , 45, 1-16	127
2249	The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. 1999 , 46, 361-4	51
2248	Pharmacologic treatment of schizophrenia. 1999 , 46, 1396-408	116
2247	Cognitive and functional changes with aging in schizophrenia. 1999 , 46, 921-8	34
2246	Elementary phenotypes in the neurobiological and genetic study of schizophrenia. 1999 , 46, 8-18	115
2245	22q11 deletion syndrome: a genetic subtype of schizophrenia. 1999 , 46, 882-91	254
2244	Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. 1999 , 46, 1321-1327	58
2243	Conventional vs. Newer Antipsychotics in Elderly Patients. 1999 , 7, 70-76	90
2242	Application of cognitive scales to medical records of schizophrenia inpatients. 1999 , 35, 131-40	7
2241	Convergence of cognitive and adaptive decline in late-life schizophrenia. 1999 , 35, 77-84	91
2240	Discriminant cognitive factors in responder and non-responder patients with schizophrenia. 1999 , 14, 442-50	14
2239	Neuroleptic-induced extrapyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia. 1999 , 14, 84-8	17
2238	The relationship between medication noncompliance and cognitive function in patients with schizophrenia. 1999 , 5, S2-S8	2
2237	The behavioural assessment of the dysexecutive syndrome as a tool to assess executive functions in schizophrenia. 1999 , 13, 370-5	51
2236	Schizophrenie, approche spécialisée et continuité de soins. Le programme spécifique d'intervention Premier-épisode de l'hôpital-Dieu de Lévis. 1999 , 24, 121-135	3
2235	Addressing executive functioning and cognitive rehabilitation in the treatment of schizophrenia.. 1999 , 44, 403-410	1
2234	Impairment of consciously controlled use of memory in schizophrenia.. 1999 , 13, 54-61	46
2233	Functional mechanisms underlying impaired recognition memory and conscious awareness in patients with schizophrenia. 1999 , 56, 639-44	246

2232	Integration of Assessment with Intervention for Psychiatric Rehabilitation Introduction to Special Issue. 1999 , 3, 193-199	1
2231	The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. 1999 , 25, 233-55	850
2230	The effects of neurocognitive remediation on executive processing in patients with schizophrenia. 1999 , 25, 291-307	347
2229	Improving pharmacotherapy in a psychiatric hospital. 1999 , 50, 335-8	6
2228	Cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. 1999 , 50, 901-4	111
2227	Risperidone versus haloperidol on secondary memory: can newer medications aid learning?. 1999 , 25, 223-32	84
2226	Outcome studies in schizophrenia. 1999 , 16, 140-144	5
2225	Neurocognitive and social functioning in schizophrenia. 1999 , 25, 173-82	241
2224	Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?. 1999 , 29, 1-8	24
2223	Errorless learning and the cognitive rehabilitation of memory-impaired schizophrenic patients. 1999 , 29, 105-12	77
2222	Source monitoring deficits in patients with schizophrenia; a multinomial modelling analysis. 1999 , 29, 903-14	151
2221	Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. 1999 , 11, 481-9	26
2220	Best practices: managing performance indicators for physicians in community mental health centers. 1999 , 50, 1417-9	6
2219	Psychotherapy as an element in supported employment for persons with severe and persistent mental illness. 1999 , 62, 209-21	39
2218	Arbeidshukommelse ved schizofreni. 2000 , 52, 277-293	
2217	Practical geriatrics: directions for research and policy on schizophrenia and older adults: summary of the GAP committee report. 2000 , 51, 299-302	18
2216	Predictors of work adjustment in bipolar I patients: A naturalistic longitudinal follow-up.. 2000 , 68, 220-225	44
2215	Demographic, clinical, and neurocognitive correlates of everyday functional impairment in severe mental illness.. 2000 , 109, 134-138	23

2214	Learning and forgetting in schizophrenia.. 2000 , 109, 534-538		47
2213	The paradox of normal neuropsychological function in schizophrenia.. 2000 , 109, 743-752		143
2212	Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. <i>American Journal of Psychiatry</i> , 2000 , 157, 1317-23	11.9	170
2211	Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics. 2000 , 33, 48-51		50
2210	Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. 2000 , 26, 119-36		2332
2209	Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients. 2000 , 12, 257-64		29
2208	Neurocognition as a determinant of employment status in schizophrenia. 2000 , 6, 190-6		23
2207	Nithsdale schizophrenia surveys 21: a longitudinal study of National Adult Reading Test stability. 2000 , 30, 717-20		33
2206	Remediation of memory disorders in schizophrenia. 2000 , 30, 1451-9		76
2205	A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients. 2000 , 15, 513-519		11
2204	Phenotypic markers as risk factors in schizophrenia: neurocognitive functions. 2000 , 34, S74-S85		32
2203	Patient education in schizophrenia: a review. 2000 , 102, 98-106		52
2202	Posters. 2000 , 102, 68-81		17
2201	Psychological therapy in schizophrenia: what is the evidence?. 2000 , 102, 74-7		35
2200	Effects of amphetamine on visuospatial working memory performance in schizophrenia spectrum personality disorder. 2000 , 22, 14-8		47
2199	Psychiatric rehabilitation of schizophrenia: Unresolved issues, current trends, and future directions. 2000 , 9, 227-247		28
2198	Cognitive impairment in schizophrenia: its impact on social functioning. 2000 , 400, 11-6		322
2197	Executive dysfunction predicts nonresponse to fluoxetine in major depression. 2000 , 60, 13-23		171

2196	Cognitive function in euthymic bipolar patients, stabilized schizophrenic patients, and healthy controls. <i>Journal of Psychiatric Research</i> , 2000 , 34, 333-9	5.2	60
2195	Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. 2000 , 152, 283-8		104
2194	[Cognitive remediation. A new chance in rehabilitation of schizophrenic disorders?]. 2000 , 71, 19-29		23
2193	A study of visual and auditory verbal working memory in schizophrenic patients compared to healthy subjects. 2000 , 250, 79-85		23
2192	Nithsdale Schizophrenia Surveys. 20. Cognitive function in a catchment-area-based population of patients with schizophrenia. 2000 , 177, 348-53		33
2191	Functional Neuroimaging Studies of Schizophrenia. 2000 , 523-544		4
2190	Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life. 2000 , 176, 92-3		11
2189	Phenotypic Markers as Risk Factors in Schizophrenia: Neurocognitive Functions. 2000 , 34, A74-A85		21
2188	Phenotypic markers as risk factors in schizophrenia: neurocognitive functions. 2000 , 34 Suppl, S74-85		28
2187	Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. <i>American Journal of Psychiatry</i> , 2000 , 157, 549-59	11.9	733
2186	Preliminary evidence of improved verbal working memory performance and normalization of task-related frontal lobe activation in schizophrenia following cognitive exercises. <i>American Journal of Psychiatry</i> , 2000 , 157, 1694-7	11.9	138
2185	Specific cognitive deficits in neurologic and psychiatric disease: targets for treatment. 2000 , 54, 1215-7		2
2184	MS: the return of the B cell. 2000 , 54, 1214-5		12
2183	Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. <i>American Journal of Psychiatry</i> , 2000 , 157, 1141-9	11.9	339
2182	Vocational rehabilitation for persons with schizophrenia: recent research and implications for practice. 2000 , 26, 87-103		172
2181	Intervention research in psychosis: issues related to the assessment of quality of life. 2000 , 26, 557-64		78
2180	Insight, symptoms, and neurocognition in schizophrenia and schizoaffective disorder. 2000 , 26, 193-200		126
2179	Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. <i>American Journal of Psychiatry</i> , 2000 , 157, 55-9	11.9	180

2178	Neuropsychological differences between first-admission schizophrenia and psychotic affective disorders. <i>American Journal of Psychiatry</i> , 2000 , 157, 1453-60	11.9	101
2177	Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. 2000 , 57, 1139-47		478
2176	Community rehabilitation: past failures and future prospects. 2000 , 12, 197-205		9
2175	Utilization of Occupational Therapy in Mental Health Facilities in Western Pennsylvania. 2000 , 16, 33-51		4
2174	Cognitive impairment in schizophrenia. 2000 , 6, 161-168		74
2173	Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. 2000 , 57, 249-58		361
2172	Social functioning of patients with schizophrenia in high-income welfare societies. 2000 , 51, 223-8		41
2171	Emotional facial paresis of pontine origin. 2000 , 54, 1217		17
2170	Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients. <i>Psychiatry Research</i> , 2000 , 93, 21-32	9.9	45
2169	Catching up on schizophrenia: natural history and neurobiology. 2000 , 28, 325-34		590
2168	Psychophysiological correlates of social skills deficits in persons with schizophrenia. 2000 , 100, 155-67		14
2167	Prolonged reaction time to a verbal working memory task predicts increased power of posterior parietal cortical activation. 2000 , 12, 495-503		190
2166	Functional Impairment in Older Schizophrenic Persons: Toward a Conceptual Model. 2000 , 8, 237-244		11
2165	Opportunities and challenges presented by the new generation antipsychotics. 2000 , 4, 53-61		7
2164	The Rehabilitation of Cognitive Deficits. 2000 , 4, 234-248		1
2163	Schizophrenia and older adults. An overview: directions for research and policy. 2000 , 8, 19-28		78
2162	Practice-related improvement in information processing with novel antipsychotic treatment. 2000 , 46, 139-48		56
2161	Positive and negative symptoms are main predictors of community functioning. 2000 , 41, 165-166		

2160 Knowledge about schizophrenia in basic caregivers in Belgium. **2000**, 41, 166

2159 Visuospatial working memory in schizotypal personality disorder patients. **2000**, 41, 447-55 67

2158 The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. **2000**, 42, 47-55 75

2157 Neuropsychological deficits in pediatric patients with childhood-onset schizophrenia and psychotic disorder not otherwise specified. **2000**, 42, 135-44 79

2156 Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. **2000**, 44, 47-56 206

2155 The role of cognition in vocational functioning in schizophrenia. **2000**, 45, 175-84 269

2154 Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire. **2000**, 45, 223-34 35

2153 Cognition, antipsychotic drugs, and treatment response. **2000**, 10, 180-181

2152 Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas. **2000**, 47, 962-8 52

2151 Neuropsychological change in schizophrenia after 6 weeks of clozapine. **2001**, 48, 57-67 43

2150 Memory and attention deficits in drug naive patients with schizophrenia. **2001**, 48, 45-55 50

2149 Neurocognitive and social functioning in schizophrenia and other diagnoses. **2001**, 48, 367-8 21

2148 Social skills performance assessment among older patients with schizophrenia. **2001**, 48, 351-60 242

2147 Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. **2001**, 48, 17-28 124

2146 Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. **2001**, 50, 79-88 294

2145 Quetiapine--efficacy in different domains. **2001**, 11 Suppl 4, S385-90 8

2144 The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. **2001**, 49, 861-8 136

2143 Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. **2001**, 49, 374-84 56

2142	Prefrontal neurons and the genetics of schizophrenia. 2001 , 50, 825-44		618
2141	Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. 2001 , 50, 729-42		157
2140	Multidimensional assessment of psychosis: a factor-analytic validation study of the Routine Assessment of Patient Progress. 2001 , 42, 32-8		4
2139	Deficit in schizophrenia: the relationship between negative symptoms and neurocognition. 2001 , 42, 64-9		29
2138	The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. 2001 , 42, 306-13		47
2137	Is it time to develop a new cognitive therapy for psychosis--cognitive remediation therapy (CRT)?. 2001 , 21, 1227-56		93
2136	Neuropsychological impairments in the syndromes of schizophrenia: a comparison between different dimensional models. 2001 , 46, 153-9		29
2135	The changes of biological markers and treatment efficacy in schizophrenia. 2001 , 25, 323-35		10
2134	An analysis of the specificity and the syndromal correlates of verbal memory impairments in schizophrenia. <i>Psychiatry Research</i> , 2001 , 101, 23-31	9.9	57
2133	Memory impairment in schizophrenia: a study using event-related potentials in implicit and explicit tasks. <i>Psychiatry Research</i> , 2001 , 104, 157-73	9.9	56
2132	What has MMN revealed about the auditory system in schizophrenia?. 2001 , 42, 177-94		228
2131	Schizophrenia. 2001 , 85, 663-89		17
2130	Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. 2001 , 52, 503-17		262
2129	Costs of Schizophrenia: A Review. 2001 , 407-482		6
2128	First-episode psychosis: critical management issues during the first two years. 2001 , 9, 33-41		
2127	Cognitive and functional impairments in elderly patients with schizophrenia: a review of the recent literature. 2001 , 9, 59-68		18
2126	Self-monitoring enhances Wisconsin Card Sorting Test performance in patients with schizophrenia: performance is improved by simply asking patients to verbalize their sorting strategy. 2001 , 7, 344-52		39
2125	The neurobiology of the stress cascade and its potential relevance for schizophrenia. 2001 , 7, 3-14		34

2124	Neurocognitive enhancement therapy with work therapy: effects on neuropsychological test performance. 2001 , 58, 763-8		256
2123	Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. <i>American Journal of Psychiatry</i> , 2001 , 158, 1797-808	11.9	88
2122	Association of estrogen levels with neuropsychological performance in women with schizophrenia. <i>American Journal of Psychiatry</i> , 2001 , 158, 1134-9	11.9	84
2121	Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. <i>American Journal of Psychiatry</i> , 2001 , 158, 1411-22	11.9	166
2120	Correlates of long-term unemployment among inner-city adults with serious and persistent mental illness. 2001 , 52, 101-3		52
2119	Consumer-run service participation, recovery of social functioning, and the mediating role of psychological factors. 2001 , 52, 493-500		69
2118	Duration of untreated psychosis and cognitive functioning in first-episode patients. 2001 , 179, 340-5		96
2117	Schizophrenia Spectrum Disorders: A Review. 2001 , 311-405		4
2116	Neurocognitive correlates of helplessness, hopelessness, and well-being in schizophrenia. 2001 , 189, 457-62		38
2115	Shaping attention span: an operant conditioning procedure to improve neurocognition and functioning in schizophrenia. 2001 , 27, 247-57		71
2114	A prospective analysis of work in schizophrenia. 2001 , 27, 281-96		260
2113	First-line atypical antipsychotics for schizophrenia are appropriate with psychosocial interventions. 2001 , 25, 287-288		2
2112	Treatment-refractory schizophrenia. 2001 , 3, 393-400		5
2111	Psychosocial treatments for schizophrenia. 2001 , 3, 407-12		4
2110	Cognition in schizophrenia. 2001 , 3, 423-8		51
2109	Long-term illness and patterns of medicine taking: are people with schizophrenia a unique group?. 2001 , 8, 197-204		9
2108	Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments. 2001 , 103, 335-46		26
2107	Neuropsychological impairment in patients treated with depot neuroleptics: a longitudinal study. 2001 , 104, 75-80		5

2106	Visual binding abilities in the initial and advanced stages of schizophrenia. 2001 , 103, 171-80	99
2105	Neuropsychological impairments in patients with schizophrenia: stability and prediction of outcome. 2001 , 104, 60-4	22
2104	Schizophrenia--progressive and massive decline in response readiness by episodes. 2001 , 104, 65-74	8
2103	Cognitive impairment and functional status in elderly institutionalized patients with schizophrenia. 2001 , 16, 631-8	10
2102	Probing the human hippocampus using rCBF: contrasts in schizophrenia. 2001 , 11, 543-50	209
2101	Cognitive impairment in elderly patients with schizophrenia: age related changes. 2001 , 16 Suppl 1, S78-85	29
2100	The effects of cognitive impairment and substance abuse on psychiatric hospitalizations. 2001 , 37, 303-12	18
2099	Approaches to cognitive remediation of neuropsychological deficits in schizophrenia: a review and meta-analysis. 2001 , 11, 197-210	139
2098	Unique issues in assessing work function among individuals with psychiatric disabilities. 2001 , 11, 217-32	40
2097	Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning. 2001 , 11, 45-67	68
2096	Psychosis and the disintegration of dialogical self-structure: Problems posed by schizophrenia for the maintenance of dialogue. 2001 , 74, 23-33	63
2095	Ourselves, our bodies, our realities: an HIV prevention intervention for women with severe mental illness. 2001 , 78, 162-75	35
2094	The future of cognitive and behavioral therapies in the prevention and early management of psychosis: Opportunities and risks. 2001 , 32, 693-724	2
2093	A compensatory mirror cortical mechanism for facial affect processing in schizophrenia. 2001 , 25, 915-24	34
2092	Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. <i>American Journal of Psychiatry</i> , 2001 , 158, 176-84	11.9 515
2091	Intact implicit learning in schizophrenia. <i>American Journal of Psychiatry</i> , 2001 , 158, 944-8	11.9 88
2090	Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. 2001 , 21, 479-83	49
2089	Gender differences in poor outcome patients with lifelong schizophrenia. 2001 , 27, 103-13	129

2088	Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. 2001 , 27, 697-708	95
2087	The remediation of problem-solving skills in schizophrenia. 2001 , 27, 259-67	110
2086	When symptoms persist: clozapine augmentation strategies. 2001 , 27, 615-28	100
2085	Attentional characteristics of schizophrenia patients differing in learning proficiency on the Wisconsin Card Sorting Test. 2001 , 27, 687-95	32
2084	Work rehabilitation in schizophrenia: does cognitive impairment limit improvement?. 2001 , 27, 269-79	118
2083	The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. 2001 , 4, 239-50	36
2082	Effectiveness of an attention- and memory-training program on neuropsychological deficits in schizophrenia. 2001 , 15, 75-80	23
2081	Implementation of a cognitive rehabilitation program in an iprt setting. 2001 , 5, 403-425	7
2080	Multiple dimensions of recovery in early psychosis. 2002 , 14, 273-283	64
2079	Parental reports of executive dysfunction in adolescents with bipolar disorder. 2002 , 8, 285-95	27
2078	The psychopathology, medical management and dental implications of schizophrenia. 2002 , 133, 603-10; quiz 624-5	69
2077	Neuropsychological profiles delineate distinct profiles of schizophrenia, an interaction between memory and executive function, and uneven distribution of clinical subtypes. 2002 , 24, 765-80	63
2076	Correlates of change in functional status of institutionalized geriatric schizophrenic patients: focus on medical comorbidity. <i>American Journal of Psychiatry</i> , 2002 , 159, 1388-94	11.9 58
2075	Effects of 10 mg and 15 mg oral procyclidine on critical flicker fusion threshold and cardiac functioning in healthy human subjects. 2002 , 16, 183-7	7
2074	Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. 2002 , 32, 1109-19	115
2073	Teaching Grocery Shopping Skills to People with Schizophrenia. 2002 , 22, 90S-91S	3
2072	Executive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome. 2002 , 71, 39-46	146
2071	Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study. 2002 , 14, 454-60	16

2070	A randomized single-blind pilot study of compensatory strategies in schizophrenia outpatients. 2002 , 28, 283-92		86
2069	Impact on cognition of the use of antipsychotics. 2002 , 18 Suppl 3, s13-7		14
2068	Clozapine in patients with chronic schizophrenia: serum level, EEG and memory performance. 2002 , 35, 190-4		17
2067	Cognitive correlates of job tenure among patients with severe mental illness. <i>American Journal of Psychiatry</i> , 2002 , 159, 1395-402	11.9	222
2066	Schizophrenia and diabetes. 2002 , 51, 481-501		15
2065	Donepezil for memory dysfunction in schizophrenia. 2002 , 16, 267-70		19
2064	Cognitive assessment of geriatric schizophrenic patients with severe impairment. 2002 , 17, 611-623		21
2063	Schizophrenia. 2002 , 374-384		
2062	A controlled trial of cognitive remediation in schizophrenia. 2002 , 28, 167-76		91
2061	Are cognitive impairments associated with sensitivity to stress in schizophrenia? An experience sampling study. <i>American Journal of Psychiatry</i> , 2002 , 159, 443-9	11.9	82
2060	Visuospatial memory and learning in first-episode schizophreniform psychosis and established schizophrenia: a functional correlate of hippocampal pathology?. 2002 , 32, 429-38		80
2059	Psychosocial outcomes in patients with schizophrenia: quality of life and reintegration. 2002 , 15, 31-36		17
2058	Insight and work performance in schizophrenia. 2002 , 190, 142-6		85
2057	Disclosure of Psychiatric Disabilities in Vocational Rehabilitation. 2002 , 8, 67-80		10
2056	Everyday memory and laboratory memory tests: general function predictors in schizophrenia and remitted depression. 2002 , 190, 677-82		22
2055	Motivational interviewing to improve insight and treatment adherence in schizophrenia. 2002 , 26, 23-32		85
2054	Vorhersage des Erfolgs schizophrener Patienten in einem psychoedukativen Behandlungsprogramm durch Indikatoren des Verfünderungspotentials im Wisconsin Card Sorting Test. 2002 , 12, 90-96		4
2053	Applications of errorless learning for improving work performance in persons with schizophrenia. <i>American Journal of Psychiatry</i> , 2002 , 159, 1921-6	11.9	73

2052	Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. <i>American Journal of Psychiatry</i> , 2002 , 159, 838-44	11.9	119
2051	Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. <i>American Journal of Psychiatry</i> , 2002 , 159, 1035-43	11.9	33
2050	Ziprasidone and migraine headache. <i>American Journal of Psychiatry</i> , 2002 , 159, 1435-6	11.9	3
2049	Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. <i>American Journal of Psychiatry</i> , 2002 , 159, 1435	11.9	53
2048	Intact suppression of increased false recognition in schizophrenia. <i>American Journal of Psychiatry</i> , 2002 , 159, 1506-13	11.9	38
2047	Improving social functioning in schizophrenia by playing the train game. 2002 , 53, 799-801		20
2046	The Neuropsychology of Schizophrenia. 631-647		2
2045	Review of antipsychotic medication administration: a proposal of intermittent dosing. 2002 , 28, 203-22		16
2044	Recent studies on the neurocognitive effects of second-generation antipsychotic medications. 2002 , 15, 25-29		14
2043	Executive function in schizophrenia: is it linked to psychosis and poor life functioning?. 2002 , 190, 725-32		34
2042	The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. 2002 , 51, 972-8		170
2041	Another view of therapy for cognition in schizophrenia. 2002 , 51, 969-71		95
2040	Neuropsychological performance in schizotypal personality disorder: evidence regarding diagnostic specificity. 2002 , 52, 1175-82		65
2039	Arithmetic fact retrieval and working memory in schizophrenia. 2002 , 53, 219-27		18
2038	De-coupling of cognitive performance and cerebral functional response during working memory in schizophrenia. 2002 , 53, 45-56		98
2037	Effects of risperidone on information processing and attention in first-episode schizophrenia. 2002 , 53, 7-16		27
2036	The relationship between cognitive dysfunction and coping abilities in schizophrenia. 2002 , 55, 259-67		78
2035	Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving. 2002 , 55, 205-15		135

2034	Independence and overlap among neurocognitive correlates of community functioning in schizophrenia. 2002 , 56, 161-70		73
2033	Recovery from psychosis in schizophrenia and schizoaffective disorder: symptoms and neurocognitive rate-limiters for the development of social behavior skills. 2002 , 55, 229-37		72
2032	Verbal and procedural memory in schizophrenia with milder symptoms: implications for psychosocial intervention. 2002 , 53, 263-5		5
2031	The relationship between positive symptoms and instrumental work functioning in schizophrenia: a 10 year follow-up study. 2002 , 56, 95-103		69
2030	Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. 2002 , 55, 139-46		87
2029	Remediation of problem-solving skills in schizophrenia: evidence of a persistent effect. 2002 , 57, 165-71		74
2028	Adherence to anti-psychotic medications and health behavior theories. 2002 , 11, 243-254		19
2027	Cognitive experimental approaches to investigating impaired cognition in schizophrenia: a paradigm shift. 2002 , 24, 873-82		44
2026	Operational criteria and factors related to recovery from schizophrenia. 2002 , 14, 256-272		303
2025	Cognitive functioning and social problem-solving skills in schizophrenia. 2002 , 7, 81-95		11
2024	Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. 2002 , 16, 473-84		131
2023	Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia. 2002 , 43, 469-73		13
2022	Cognitive assessment of geriatric schizophrenic patients with severe impairment. 2002 , 17, 611-623		2
2021	Dual Diagnosis Motivational Interviewing: a modification of Motivational Interviewing for substance-abusing patients with psychotic disorders. 2002 , 23, 297-308		55
2020	Schizophrenic patients without neuropsychological deficits: subgroup, disease severity or cognitive compensation?. <i>Psychiatry Research</i> , 2002 , 112, 1-11	9.9	64
2019	Changes in cognitive functioning following comprehensive treatment for first episode patients with schizophrenia spectrum disorders. <i>Psychiatry Research</i> , 2002 , 113, 69-81	9.9	36
2018	Schizophrenia and memory impairment: evidence for a neurocognitive subtype. <i>Psychiatry Research</i> , 2002 , 113, 93-105	9.9	38
2017	Neurocognitive deficits and quality of life in outpatients with schizophrenia. 2002 , 26, 1217-9		42

2016	Social and clinical consequences of cognitive deficits in early psychosis: a two-year follow-up study of first-admitted patients. 2002 , 56, 149-59	61
2015	Neurobiology of Schizophrenia. 197-236	
2014	. 2002 ,	6
2013	Neuropsychological Research in Psychiatry. 181-196	
2012	Subjective cognitive dysfunction in first-episode patients predicts symptomatic outcome: a replication. 2002 , 35, 367-8	6
2011	Schizophrenia and Brain Imaging. 649-661	
2010	Prefrontal dopamine D1 receptors and working memory in schizophrenia. 2002 , 22, 3708-19	610
2009	Itemized clinician ratings versus global ratings of symptom severity in patients with schizophrenia. 2002 , 11, 45-53	2
2008	Neurocognitive performance in first-episode and chronic schizophrenic patients. 2002 , 252, 33-7	28
2007	The influence of neurocognitive deficits and symptoms on disability in schizophrenia. 2002 , 105, 196-201	53
2006	Could the hypofrontality pattern in schizophrenia be modified through neuropsychological rehabilitation?. 2002 , 105, 202-8	42
2005	Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. 2002 , 27, 441-51	25
2004	Enhancement of executive functioning skills: an additional tier in the treatment of schizophrenia. 2002 , 38, 403-12	3
2003	Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders. 2002 , 27, 1049-63	91
2002	A brief neuropsychological testing battery for evaluating patients with schizophrenia. 2003 , 39, 253-62	10
2001	Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. 2003 , 13, 43-77	257
2000	Cognitive functioning in schizophrenia. 2003 , 1, 22-27	
1999	Profiles of neuropsychologic function in schizophrenia. 2003 , 5, 299-302	7

1998	Neurocognitive rehabilitation for schizophrenia. 2003 , 5, 303-10	22
1997	Cognitive rehabilitation in schizophrenia: a quantitative analysis of controlled studies. 2003 , 169, 376-82	134
1996	Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. 2003 , 169, 404-11	114
1995	Comparison of the effects of antipsychotics on a delayed radial maze task in the rat. 2003 , 168, 410-6	42
1994	Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications. 2003 , 169, 383-9	19
1993	Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. 2003 , 169, 398-403	51
1992	Cognition in schizophrenia: from basic science to clinical treatment. 2003 , 169, 213-4	19
1991	Premorbid IQ and schizophrenia. Increasing cognitive reduction by episodes. 2003 , 253, 84-8	22
1990	Potential of statins for the treatment of multiple sclerosis. 2003 , 2, 9-10	9
1989	Characterisation of cognitive impairment in schizophrenia. 2003 , 2, 10	3
1988	Cognitive deficits in schizophrenia: early course and treatment. 2003 , 3, 17-22	8
1987	Preclinical effects of conventional and atypical antipsychotic drugs: defining the mechanisms of action. 2003 , 3, 34-46	16
1986	Cognitive effects and antipsychotic treatment. 2003 , 28 Suppl 1, 27-38	52
1985	Pre-clinical models of cognitive dysfunction in schizophrenia: new avenues to addressing unmet needs. 2003 , 3, 303-313	13
1984	Anxiety-based cognitive-behavioral therapy for paranoid beliefs. 2003 , 34, 97-115	6
1983	Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. 2003 , 18, 820-9	60
1982	Refining pharmacogenetic research in schizophrenia: Control for patient-related variables. 2003 , 60, 164-171	3
1981	Cognitive remediation of working memory deficits: durability of training effects in severely impaired and less severely impaired schizophrenia. 2003 , 108, 101-9	93

1980	Dysexecutive syndrome and social adjustment in schizophrenia. 2003 , 37, 340-6	20
1979	A Canadian programme for early intervention in non-affective psychotic disorders. 2003 , 37, 407-13	121
1978	Correlation between performance on the Continuous Performance Test and economic costs in patients with schizophrenia. 2003 , 57, 373-7	15
1977	Psychosocial rehabilitation. 2003 , 38, 151-60	2
1976	Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. 2003 , 65, 75-86	157
1975	Treatment of schizophrenia: preventing the progression of disease. 2003 , 26, 367-79	8
1974	The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. 2003 , 53, 422-30	113
1973	Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia. 2003 , 53, 48-55	129
1972	Schizophrenia. 2003 , 349, 1738-49	539
1971	Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. 2003 , 26, 25-40	252
1970	Distinct contributions of glutamate receptor subtypes to cognitive set-shifting abilities in the rat. 2003 , 1003, 464-7	18
1969	An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. 2003 , 59, 29-33	86
1968	Longitudinal study of symptoms and cognitive function in chronic schizophrenia. 2003 , 59, 137-46	149
1967	Social perception and early visual processing in schizophrenia. 2003 , 59, 233-41	96
1966	Learning (potential) and social functioning in schizophrenia. 2003 , 59, 287-96	30
1965	Verbal memory in schizophrenia: sex differences over repeated assessments. 2003 , 61, 235-43	19
1964	Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. 2003 , 63, 49-58	124
1963	Glucose effects on cognition in schizophrenia. 2003 , 62, 93-103	40

1962	Neuropsychological practice effects and change detection in people with schizophrenia. 2003 , 62, 191-4		17
1961	Generalized cognitive dysfunction, symptomatology, and specific cognitive processes in relation to functioning of schizophrenia patients. 2003 , 64, 191-3		8
1960	Basic neuropsychological dimensions in schizophrenia. 2003 , 65, 105-16		50
1959	Effect of the 5-HT ₂ antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. 2003 , 13, 123-8		56
1958	A cognitive training for mentally ill offenders with treatment-resistant schizophrenia. 2003 , 14, 554-568		10
1957	Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. 2003 , 27, 1145-58		103
1956	Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. 2003 , 60, 49-56		376
1955	Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia. 2003 , 44, 331-40		128
1954	N-methyl-D-aspartate receptor in working memory impairments in schizophrenia: event-related potential study of late stage of working memory process. 2003 , 27, 993-9		21
1953	The relations between cognition and the independent living skill of shopping in people with schizophrenia. <i>Psychiatry Research</i> , 2003 , 117, 103-12	9.9	105
1952	Effects of Attention Process Training on cognitive functioning of schizophrenic patients. <i>Psychiatry Research</i> , 2003 , 119, 41-53	9.9	44
1951	Behavioural dysregulation of decision-making in deficit but not nondeficit schizophrenia patients. <i>Psychiatry Research</i> , 2003 , 119, 293-306	9.9	22
1950	Cognitive disparity in schizophrenics with and without cocaine dependency. 2003 , 24, 75-9		17
1949	The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients. 2003 , 68, 11-11		
1948	Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. 2003 , 13, 817-32		20
1947	Caring for Persons with Serious Mental Illness: Policy and Practice Suggestions. 2003 , 1, 1-17		8
1946	Neurocognitive functioning is associated with employment status: a quantitative review. 2003 , 25, 1186-91		65
1945	Implications for the neural basis of social cognition for the study of schizophrenia. <i>American Journal of Psychiatry</i> , 2003 , 160, 815-24	11.9	386

1944	Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study. 2003 , 47, 212-8	24
1943	Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. 2003 , 9, 274-82	49
1942	Coping with voices: selective attention training for persistent auditory hallucinations in treatment refractory schizophrenia. 2003 , 66, 255-61	15
1941	Reliable change indexes for memory performance in schizophrenia as a means to determine drug-induced cognitive decline. 2003 , 10, 115-20	12
1940	Effects of acute procyclidine administration on prepulse inhibition of the startle response in schizophrenia: a double-blind, placebo-controlled study. 2003 , 17, 89-95	33
1939	Development of an abbreviated schizophrenia quality of life scale using a new method. 2003 , 28, 773-7	57
1938	Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia. 2003 , 28, 2029-36	16
1937	The schizophrenia prodrome revisited: a neurodevelopmental perspective. 2003 , 29, 633-51	290
1936	The stress cascade and schizophrenia: etiology and onset. 2003 , 29, 671-92	319
1935	The ecological validity of pediatric neuropsychological tests of attention. 2003 , 17, 170-81	14
1934	Evaluation of bizarre-idiosyncratic thinking scale as a measure of thought disorder in children and adolescents with severe psychiatric disorders. 2003 , 97, 207-14	1
1933	Childhood antecedents of schizophrenia: developmental sequencing and specificity of problem behavior. 2003 , 92, 793-803	3
1932	Effects of the 5-HT _{2A} agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. 2003 , 28, 170-81	130
1931	Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. 2003 , 191, 300-8	47
1930	Initial and final work performance in schizophrenia: cognitive and symptom predictors. 2003 , 191, 87-92	85
1929	A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. 2003 , 23, 400-4	20
1928	A review of cognitive training in schizophrenia. 2003 , 29, 359-82	251
1927	Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. 2003 , 29, 45-55	97

1926	Does 'errorless learning' compensate for neurocognitive impairments in the work rehabilitation of persons with schizophrenia?. 2003 , 33, 433-42	49
1925	Spatial working memory ability is a marker of risk-for-psychosis. 2003 , 33, 1239-47	188
1924	. 2003 , 191, 295-299	8
1923	. 2003 , 191, 87-92	28
1922	. 2003 , 191, 300-308	11
1921	. 2003 , 191, 80-86	33
1920	Eye movements and neurocognitive function in treatment resistant schizophrenia: a pilot study. 2003 , 20, 6-10	4
1919	Neural correlates of episodic encoding and recognition of words in unmedicated patients during an acute episode of schizophrenia: a functional MRI study. <i>American Journal of Psychiatry</i> , 2003 , 160, 1802-8 ^{1.9}	36
1918	Social cognition and neurocognitive deficits in schizophrenia. 2003 , 191, 295-9	15
1917	Cognitive functioning and employment in severe mental illness. 2003 , 191, 789-98	52
1916	Personality dimensions in schizophrenia: associations with symptoms and coping. 2003 , 191, 80-6	47
1915	Economics of Schizophrenia: A Review. 2003 , 413-488	5
1914	Relationship Between Clock-Drawing and Neuropsychological and Functional Status in Elderly Institutionalized Patients With Schizophrenia. 2003 , 11, 621-628	12
1913	Long-term memory deficits in schizophrenia: primary or secondary dysfunction?. 2003 , 17, 539-47	56
1912	Retour à l'école de jeunes patients souffrant de troubles mentaux graves : premier regard sur un projet pilote montréalais. 2003 , 28, 273-290	1
1911	The effect of housing interventions on neuropsychological functioning among homeless persons with mental illness. 2003 , 54, 905-8	40
1910	Dual effects of nicotine on dopamine neurons mediated by different nicotinic receptor subtypes. 2003 , 6, 1-11	89
1909	Cognitive therapy and schizophrenia. 2003 , 315-332	1

1908 Neuroscience of Schizophrenia. 267-297

1907 Análisis del efecto de aprendizaje en tareas atencionales simples y duales. Un estudio comparativo entre personas diagnosticadas de esquizofrenia y personas sin diagnóstico psiquiátrico. **2003**, 8, 211

1906 . **2003**,

12

1905 Getting real about experience. **2004**, 27, 801-802

1904 Schizophrenia: A disorder of affective consciousness. **2004**, 27, 804-805

1903 Psychopathology of psychosis: Towards integration from an idealist perspective. **2004**, 27, 808-830

1902 Good science, bad philosophy. **2004**, 27, 791-792

1901 Hallucinations and antipsychotics: The role of the 5-HT_{2A} receptor. **2004**, 27, 795-796

1

1900 Cortico-â[(thalamo) â]cortical interactions, gamma resonance, and auditory hallucinations in schizophrenia. **2004**, 27, 797-798

1

1899 A possible role for non-gamma oscillations in conscious perception: Implications for hallucinations in schizophrenia. **2004**, 27, 798-798

1898 Probing cortico-cortical interactions that underlie the multiple sensory, cognitive, and everyday functional deficits in schizophrenia. **2004**, 27, 799-799

3

1897 Deregulation of the balance between data and conceptually driven processing: A shift toward the conceptual. **2004**, 27, 800-801

1896 Underconstrained thalamic activation + underconstrained top-down modulation of cortical input processing = underconstrained perceptions. **2004**, 27, 803-804

1895 Distinguishing schizophrenia from the mechanisms underlying hallucinations. **2004**, 27, 805-806

1894 Brainstem-thalamic neurons implicated in hallucinations. **2004**, 27, 806-807

1893 [Interpersonal techniques for optimizing positive outcomes in the inpatient psychiatric rehabilitation of schizophrenia]. **2004**, 29, 45-63

1

1892 Problems with crystallizing phenomenology and nosology in adolescent psychiatry. **2004**, 49, 78-9

1891 Thalamocortical dysfunction and complex visual hallucinations in brain disease â[Are the primary disturbances in the cerebral cortex?]. **2004**, 27, 789-790

24

1890	Perception and psychoses: The role of glutamatergic transmission within the nucleus accumbens septi. 2004 , 27, 792-793	7
1889	Underconstrained perception or underconstrained theory?. 2004 , 27, 787-788	7
1888	Hallucinations and nonsensory correlates of neural activity. 2004 , 27, 796-796	3
1887	Belief in the primacy of fantasy is misleading and unnecessary. 2004 , 27, 802-803	1
1886	Absorption, hallucinations, and the continuum hypothesis. 2004 , 27, 793-794	6
1885	Hallucinations and acetylcholine: Signal or noise?. 2004 , 27, 790-791	3
1884	Underconstraint and overconstraint in psychiatry. 2004 , 27, 788-789	
1883	Paradoxical sleep and schizophrenia have the same neurobiological support. 2004 , 27, 794-795	1
1882	Gains in speeded information processing following clozapine treatment of schizophrenia. 2004 , 49, 77-8	
1881	Age at onset and cognitive functioning in schizophrenia. 2004 , 185, 215-9	69
1880	Invited commentary on: Older people with long-standing mental illness: the graduates. 2004 , 10, 34-36	3
1879	Cognitive Dysfunction in Homeless Adults: A Systematic Review. 2004 , 97, 375-379	41
1878	Course of cognitive functioning in first episode schizophrenia spectrum disorders. 2004 , 4, 61-8	35
1877	Effects of nicotine on cognitive deficits in schizophrenia. 2004 , 29, 1378-85	203
1876	Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. <i>American Journal of Psychiatry</i> , 2004 , 161, 473-9	11.9 436
1875	New antipsychotics and schizophrenia: a review on efficacy and side effects. 2004 , 11, 343-58	87
1874	Gamma rhythms as liminal operators in sensory processing. 2004 , 27, 807-808	
1873	Cognitive factors in schizophrenia: causes, impact, and treatment. 2004 , 9, 15-24	47

1872 Thalamus, a theory of everything?. **2004**, 27, 800-800

1871 Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. **2004**, 72, 757-66 562

1870 Association between cognitive functioning and employment status of persons with bipolar disorder. **2004**, 55, 54-8 139

1869 [Executive function remediation in schizophrenia: possible strategies and methods]. **2004**, 13, 55-65 1

1868 Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. *American Journal of Psychiatry*, **2004**, 161, 985-95 11.9 253

1867 Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. **2004**, 18, 156-72 42

1866 Older people with long-standing mental illness: the graduates. **2004**, 10, 27-34 26

1865 Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program. **2004**, 30, 87-100 75

1864 Followup of psychotic outpatients: dimensions of delusions and work functioning in schizophrenia. **2004**, 30, 147-61 25

1863 Coping style in schizophrenia: associations with neurocognitive deficits and personality. **2004**, 30, 113-21 87

1862 Heightened interpersonal dependency in schizophrenia: associations with graver impairment in neurocognition but not with negative or positive symptoms. **2004**, 68, 164-73 4

1861 Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. *American Journal of Psychiatry*, **2004**, 161, 116-24 11.9 258

1860 Selective effects of acute serotonin and catecholamine depletion on memory in healthy women. **2004**, 18, 32-40 86

1859 Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. **2004**, 18, 457-74 180

1858 Effects of neurocognitive enhancement therapy in schizophrenia: normalisation of memory performance. **2004**, 9, 199-211 18

1857 Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. **2004**, 61, 866-76 393

1856 Modification of performance on the Span of Apprehension Task in a group of young people with early onset psychosis. **2004**, 45, 55-60 3

1855 Neurocognitive functioning and quality of life among dually diagnosed and non-substance abusing schizophrenia inpatients. **2004**, 13, 282-91 48

1854	Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia. 2004 , 29, 471-81		7
1853	Cognitive performance of male adolescents is lower than controls across psychiatric disorders: a population-based study. 2004 , 110, 471-5		36
1852	Comparison of characteristics between geriatric and younger subjects with schizophrenia in community. <i>Journal of Psychiatric Research</i> , 2004 , 38, 417-24	5.2	14
1851	Abnormal brain response of chronic schizophrenia patients despite normal performance during a visual vigilance task. 2004 , 130, 245-57		35
1850	Differential impairment on measures of attention in patients with paranoid and nonparanoid schizophrenia. <i>Journal of Psychiatric Research</i> , 2004 , 38, 145-52	5.2	20
1849	Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. 2004 , 24, 1759-83		35
1848	Association between demographic and diagnostic factors and employment outcomes for people with psychiatric disabilities: a synthesis of recent research. 2004 , 6, 9-21		67
1847	Cognitive functioning predicts outpatient service utilization in schizophrenia. 2004 , 6, 185-8		30
1846	Schizophrenia and employment - a review. 2004 , 39, 337-49		546
1845	Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. 2004 , 172, 324-32		63
1844	Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. 2004 , 174, 143-50		197
1843	Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. 2004 , 174, 111-25		150
1842	Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. 2004 , 174, 3-16		389
1841	Preattentional and attentional cognitive deficits as targets for treating schizophrenia. 2004 , 174, 75-85		159
1840	The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. 2004 , 177, 207-16		184
1839	Treating the cognitive deficits of schizophrenia. 2004 , 2, 73-77		0
1838	A controlled randomized treatment study: the effects of a cognitive remediation program on adolescents with early onset psychosis. 2004 , 109, 70-4		61
1837	CALCYON gene variation, schizophrenia, and cocaine dependence. 2004 , 125B, 25-30		10

1836	Understanding sexual offending in schizophrenia. 2004 , 14, 108-20	28
1835	The Rivermead Behavioural Memory Test can predict social functioning among schizophrenic patients treated with clozapine. 2004 , 8, 245-9	4
1834	Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective. 2004 , 22, 701-18	27
1833	Impact of atypical antipsychotics on quality of life in patients with schizophrenia. 2004 , 18, 877-93	93
1832	A study of sensitivity of the sustained attention to response task in patients with schizophrenia. 2004 , 18, 114-21	20
1831	Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment. 2004 , 27, 1-18, vii	72
1830	The Expanding Role of Neuropsychology in Geriatric Psychiatry. 2004 , 12, 338-341	3
1829	Correlates of cognitive deficits in first episode schizophrenia. 2004 , 68, 1-9	147
1828	Impairment of verbal memory and learning in antipsychotic-naïve patients with first-episode schizophrenia. 2004 , 68, 127-36	96
1827	The Penn Conditional Exclusion Test (PCET): relationship to the Wisconsin Card Sorting Test and work function in patients with schizophrenia. 2004 , 68, 95-102	26
1826	Neurocognitive deficits and history of childhood abuse in schizophrenia spectrum disorders: associations with Cluster B personality traits. 2004 , 68, 87-94	34
1825	Visuospatial deficits in schizophrenia: central executive and memory subsystems impairments. 2004 , 68, 217-23	25
1824	P300 alterations in schizophrenic patients experiencing auditory hallucinations. 2004 , 14, 227-36	16
1823	A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. 2004 , 55, 1013-22	243
1822	Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICES conference to select cognitive domains and test criteria. 2004 , 56, 301-7	700
1821	Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. 2004 , 56, 560-9	221
1820	Cortical effects of quetiapine in first-episode schizophrenia: a preliminary functional magnetic resonance imaging study. 2004 , 56, 938-42	47
1819	Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. 2004 , 56, 677-82	122

1818	A failure of sleep-dependent procedural learning in chronic, medicated schizophrenia. 2004 , 56, 951-6	95
1817	Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. 2004 , 66, 143-50	26
1816	The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients. 2004 , 68, 11-9	51
1815	Verbal memory, problem-solving skills and community status in schizophrenia. 2004 , 68, 149-58	35
1814	Assessment of executive dysfunction during activities of daily living in schizophrenia. 2004 , 69, 289-300	116
1813	Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. 2004 , 66, 101-13	79
1812	Comparative neuropsychological function in obsessive-compulsive disorder and schizophrenia with and without obsessive-compulsive symptoms. 2004 , 69, 75-83	87
1811	Self-efficacy and neurocognition may be related to coping responses in recent-onset schizophrenia. 2004 , 69, 343-52	58
1810	Co-administration of atypical antipsychotics and antidepressants disturbs contrast detection in schizophrenia. 2004 , 70, 81-9	7
1809	The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. 2004 , 68, 283-97	958
1808	Psychosocial functioning on the Independent Living Skills Survey in older outpatients with schizophrenia. 2004 , 69, 307-16	21
1807	Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. 2004 , 70, 175-86	103
1806	Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. 2004 , 70, 263-75	60
1805	Neurocognitive, social and clinical correlates of two domains of hopelessness in schizophrenia. 2004 , 70, 277-85	20
1804	Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia. 2004 , 70, 331-42	129
1803	A brief cognitive assessment for use with schizophrenia patients in community clinics. 2004 , 71, 273-83	54
1802	Self-awareness of cognitive functioning in schizophrenia. 2004 , 71, 331-8	61
1801	Neuropsychological correlates of symptom profiles in first episode schizophrenia. 2004 , 71, 323-30	45

1800	Clinical constructs and therapeutic discovery. 2004 , 72, 69-73		34
1799	NIMH-MATRICES survey on assessment of neurocognition in schizophrenia. 2004 , 72, 11-9		92
1798	Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. 2004 , 72, 41-51		1034
1797	Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. 2004 , 72, 5-9		305
1796	Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition. <i>Health and Quality of Life Outcomes</i> , 2004 , 2, 15	3	73
1795	The effect of sulpiride on amphetamine-induced disruption of overshadowing in the rat. 2004 , 28, 1249-53		9
1794	Durability of cognitive remediation training in schizophrenia: performance on two memory tasks at 6-month and 12-month follow-up. <i>Psychiatry Research</i> , 2004 , 125, 1-7	9.9	62
1793	Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. <i>Psychiatry Research</i> , 2004 , 126, 51-61	9.9	97
1792	Does social cognition influence the relation between neurocognitive deficits and vocational functioning in schizophrenia?. <i>Psychiatry Research</i> , 2004 , 128, 155-65	9.9	213
1791	Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status. <i>Psychiatry Research</i> , 2004 , 129, 45-53	9.9	156
1790	The crucial role of sustained attention in community functioning in outpatients with schizophrenia. <i>Psychiatry Research</i> , 2004 , 129, 171-7	9.9	35
1789	The Penn Conditional Exclusion Test: a new measure of executive-function with alternate forms of repeat administration. 2004 , 19, 191-201		71
1788	A comprehensive analysis of verbal fluency deficit in geriatric schizophrenia. 2004 , 19, 289-303		23
1787	Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study. 2004 , 65, 57-69		
1786	Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. 2004 , 29, 1363-73		221
1785	Tools for measuring clinical effectiveness. 2004 , 14 Suppl 4, S435-44		11
1784	Adjunctive use of reboxetine in schizophrenia. 2004 , 19, 366-9		20
1783	Improvement in prosocial functioning after a switch to ziprasidone treatment. 2004 , 9, 357-64		17

1782	Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. 2004 , 18, 457-474		193
1781	Neurocognitive correlates of therapeutic alliance in schizophrenia. 2004 , 192, 508-10		22
1780	Selective attention in schizophrenia: sparing and loss of executive control. <i>American Journal of Psychiatry</i> , 2004 , 161, 872-81	11.9	28
1779	Blink rate does matter: a study of blink rate, sustained attention, and neurological signs in schizophrenia. 2004 , 192, 781-3		22
1778	Cognitive dysfunction in homeless adults: a systematic review. 2004 , 97, 375-9		36
1777	Anterior cingulate cortex activation during cognitive interference in schizophrenia. <i>American Journal of Psychiatry</i> , 2004 , 161, 707-15	11.9	80
1776	Neuropsychological dysfunction in antipsychotic-naïve first-episode unipolar psychotic depression. <i>American Journal of Psychiatry</i> , 2004 , 161, 996-1003	11.9	112
1775	The impact of antipsychotics on psychomotor performance with regards to car driving skills. 2004 , 24, 155-60		47
1774	Can patients at risk for persistent negative symptoms be identified during their first episode of psychosis?. 2004 , 192, 455-63		87
1773	The role of attention in affect perception: an examination of Mirsky's four factor model of attention in chronic schizophrenia. 2004 , 30, 727-38		30
1772	The Texas medication algorithm project: clinical results for schizophrenia. 2004 , 30, 627-47		69
1771	Hallucinations in schizophrenia, sensory impairment, and brain disease: a unifying model. 2004 , 27, 771-87; discussion 787-830		131
1770	Memory and attention performance in psychiatric patients: lack of correspondence between clinician-rated and patient-rated functioning with neuropsychological test results. 2004 , 10, 623-33		120
1769	Treatment of cognitive dysfunction in psychiatric disorders. 2004 , 10, 17-25		38
1768	Apports de la neuropsychologie aux recherches en psychopathologie. 2004 , 1, 1-5		
1767	Skills training for people with severe mental illness. 2004 , 27, 375-91		96
1766	Correlates of treatment-related decision-making capacity among middle-aged and older patients with schizophrenia. 2004 , 61, 230-6		112
1765	[Techniques for improving attentiveness and treatment engagement among "treatment refractory" schizophrenia patients with severe cognitive impairment]. 2004 , 29, 65-88		1

1764	[Cognitive remediation and work therapy in the outpatient treatment of patients with schizophrenia]. 2004 , 29, 117-42	2
1763	Bibliography for Schizophrenia. 2004 , 2, 31-33	1
1762	[Cognitive rehabilitation of schizophrenia: a pragmatic approach of the integration process to battle against refractory symptoms]. 2004 , 29, 89-116	1
1761	EMPLOYMENT SUCCESS FOR PEOPLE WITH SERIOUS MENTAL ILLNESS: A QUESTION OF PERSON-ENVIRONMENT FIT?. 15-39	3
1760	First-episode psychosis, early intervention, and outcome: what have we learned?. 2005 , 50, 881-91	68
1759	Integrating non-drug treatments in early schizophrenia. 2005 , 48, s65-71	21
1758	Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. 2005 , 8, 315-27	64
1757	Predictors of remediation success on a trained memory task. 2005 , 193, 602-8	54
1756	Verbal Intelligence and Criminal Offending Among Men With Schizophrenia. 2005 , 4, 191-200	12
1755	The employment of people with mental illness. 2005 , 4, 129-171	49
1754	Effective adjunctive use of pergolide with quetiapine for cognitive impairment and negative symptoms in schizophrenia. 2005 , 25, 281-3	2
1753	The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. 2005 , 28, 139-41	38
1752	Multiple Facets of Schizophrenia. 2005 , 10, 2-3	
1751	Levofloxacin-related seizure activity in a patient with Alzheimer's disease: assessment of potential risk factors. 2005 , 25, 287-8	8
1750	Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study. 2005 , 25, 311-7	25
1749	Personality differences in schizophrenia are related to performance on neuropsychological tasks. 2005 , 193, 714-21	20
1748	Recurrence of clozapine-induced agranulocytosis. 2005 , 25, 276-7	4
1747	The effects of bupropion on heart rate variability in healthy volunteers. 2005 , 25, 283-5	3

1746	Efficacy and tolerability of low-dose donepezil in schizophrenia. 2005 , 28, 179-84	39
1745	Perospirone improves food refusal in elderly patients with mental disorders. 2005 , 25, 288-90	0
1744	The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia--preliminary results of a facial electromyogram study. 2005 , 25, 278-81	8
1743	Integrated versus sealed-over recovery in schizophrenia: BORRTI and executive function. 2005 , 193, 3-8	10
1742	Narrative qualities in schizophrenia: associations with impairments in neurocognition and negative symptoms. 2005 , 193, 244-9	34
1741	Antidepressant pharmacoepidemiology in a general population sample. 2005 , 25, 285-7	9
1740	Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. 2005 , 25, 277-8	33
1739	Prevalence and predictors of mental incapacity in psychiatric in-patients. 2005 , 187, 379-85	120
1738	Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. 2005 , 20, 183-98	69
1737	Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients. 2005 , 35, 829-37	68
1736	Neurocognitive correlates of recovery from schizophrenia. 2005 , 35, 1165-73	45
1735	Working memory consolidation is abnormally slow in schizophrenia. 2005 , 114, 279-90	45
1734	Environmental cognitive remediation in schizophrenia: ethical implications of "smart home" technology. 2005 , 50, 281-91	21
1733	Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for the Treatment of Schizophrenia and Related Disorders. 2005 , 39, 1-30	167
1732	The relationship among insight, cognitive function of patients with schizophrenia and their relatives' perception. 2005 , 59, 657-60	18
1731	Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. 2005 , 39, 1-30	225
1730	Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. 2005 , 30, 65-71	10
1729	Cortical inhibitory neurons and schizophrenia. 2005 , 6, 312-24	1798

1728	PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. 2005 , 21, 1070-6		160
1727	Cognitive remediation for adolescents with early onset psychosis: a 1-year follow-up study. 2005 , 111, 193-201		67
1726	Metacognition amidst narratives of self and illness in schizophrenia: associations with neurocognition, symptoms, insight and quality of life. 2005 , 112, 64-71		371
1725	Attention and executive functions in remitted major depression patients. 2005 , 89, 125-35		345
1724	Psychometric properties of the web-based work-readiness cognitive screen used as a neuropsychological assessment tool for schizophrenia. 2005 , 80, 93-102		6
1723	Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. 2005 , 81, 575-84		97
1722	Low dose quetiapine reverses deficits in contextual and cued fear conditioning in rats with excitotoxin-induced hippocampal neuropathy. 2005 , 82, 263-9		10
1721	Dorsolateral prefrontal cortex morphology and short-term outcome in first-episode schizophrenia. 2005 , 140, 147-55		55
1720	Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. <i>Journal of Psychiatric Research</i> , 2005 , 39, 101-8	5.2	39
1719	Dimensions of intelligence in schizophrenia: evidence from patients with preserved, deteriorated and compromised intellect. <i>Journal of Psychiatric Research</i> , 2005 , 39, 11-9	5.2	56
1718	The treatment of cognitive dysfunction in schizophrenia. 2005 , 4, 46-48		
1717	Differential dopaminergic modulation of executive control in healthy subjects. 2005 , 178, 420-30		43
1716	Selective serotonin 5-HT _{2A} receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. 2005 , 179, 725-32		43
1715	Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. 2005 , 181, 358-63		59
1714	Cognitive impairment in schizophrenia spectrum personality. 2005 , 3, 147-151		
1713	Amphetamine, psychosis, and cognition in the schizophrenia spectrum. 2005 , 3, 176-181		1
1712	Rflexions cliniques sur le premier épisode psychotique: vers une intervention spécifique de plus en plus précoce. 2005 , 3, S42-S52		
1711	Schizophrenia and the experience of intersubjectivity as threat. 2005 , 4, 335-352		32

1710	Qualitative evaluation of divergent thinking in patients with schizophrenia. 2005 , 16, 217-24		18
1709	Cognitive Impairment in Schizophrenia. 2005 , 10, 7-9		2
1708	Partial Dopamine Agonists and the Treatment of Psychosis. 2005 , 3, 3-8		5
1707	Overcome by or Overcoming Loss: A Call for the Development of Therapy for Individuals Mourning Vocational Loss in Schizophrenia. 2005 , 13, 279-291		2
1706	GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia. 2005 , 3, 45-62		29
1705	Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients. 2005 , 31, 175-82		45
1704	Driving ability in schizophrenic patients: effects of neuroleptics. 2005 , 9, 168-74		5
1703	Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. 2005 , 31, 167-74		83
1702	A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia. <i>American Journal of Psychiatry</i> , 2005 , 162, 520-9	11.9	240
1701	Learning potential and the prediction of work skill acquisition in schizophrenia. 2005 , 31, 67-72		40
1700	Relationship of individual cognitive abilities to specific components of decisional capacity among middle-aged and older patients with schizophrenia. 2006 , 32, 98-106		66
1699	Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment. 2006 , 32, 666-78		66
1698	Neurocognitive enhancement therapy with work therapy: Productivity outcomes at 6- and 12-month follow-ups. 2005 , 42, 829-38		85
1697	Cognitive strategies versus self-management skills as adjunct to vocational rehabilitation. 2005 , 31, 55-66		87
1696	Toxic Psychoses as Pharmacological Models of Schizophrenia. 2005 , 1, 23-32		8
1695	The choice of antipsychotic drugs for schizophrenia. 2005 , 353, 1286-8		57
1694	Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. 2005 , 30, 381-90		63
1693	Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats. 2005 , 30, 1511-20		32

1692	Developing drugs for cognitive impairment in schizophrenia. 2005 , 31, 816-22		22
1691	Predicting drug efficacy for cognitive deficits in schizophrenia. 2005 , 31, 830-53		95
1690	The micro-module learning tests: work-sample assessments of responsiveness to skills training. 2005 , 31, 73-83		8
1689	Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. 2005 , 62, 649-59		287
1688	Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside Adolescent High Risk Studies. 2006 , 32, 507-24		107
1687	fMRI study of maintenance and manipulation processes within working memory in first-episode schizophrenia. <i>American Journal of Psychiatry</i> , 2005 , 162, 1849-58	11.9	132
1686	Neuropsychological performance in schizotypal personality disorder: importance of working memory. <i>American Journal of Psychiatry</i> , 2005 , 162, 1896-903	11.9	90
1685	Relationship between cognition and work functioning among patients with schizophrenia in an urban area of India. 2005 , 56, 1423-8		42
1684	Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. <i>American Journal of Psychiatry</i> , 2005 , 162, 495-506	11.9	658
1683	Working memory impairments in schizophrenia: a meta-analysis. 2005 , 114, 599-611		601
1682	Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia?'. 2005 , 2, 399-406		2
1681	Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. 2006 , 32, 474-85		129
1680	Searching for the liability to schizophrenia: concepts and methods underlying genetic high-risk studies of adolescents. 2005 , 15, 403-17		33
1679	Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. 2005 , 9, 204-12		16
1678	Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. 2005 , 62, 127-36		315
1677	Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. 2005 , 31, 910-21		85
1676	Financial capacity in persons with schizophrenia and serious mental illness: clinical and research ethics aspects. 2006 , 32, 81-91		45
1675	Cognitive remediation and vocational rehabilitation for schizophrenia. 2005 , 31, 931-41		138

1674	A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. 2005 , 8, 457-72		449
1673	A Review of Current Drug Targets and Pharmacology of Antipsychotic Treatment. 2005 , 2, 177-182		1
1672	Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia. 2005 , 31, 810-5		46
1671	Abstracts. 2005 , 36, 207-256		
1670	Being Interrupted: The Self and Schizophrenia. <i>Journal of Speculative Philosophy</i> , 2005 , 19, 1-21	0.3	36
1669	Delusional mood and delusional perception -- a phenomenological analysis. 2005 , 38, 133-9		60
1668	Saying goodbye: exploring attachments as a therapist leaves a group of chronically ill persons. 2005 , 55, 281-303; discussion 305-15		3
1667	Patient outcomes in schizophrenia II: the impact of cognition. 2005 , 20, 395-402		105
1666	Expanding the response space in chronic schizophrenia: the relevance of left prefrontal cortex. 2005 , 25, 952-7		13
1665	History, aetiology and symptomatology of schizophrenia. 2005 , 4, 2-6		1
1664	Neuropsychological deficits, syndromes, and cognitive competency in schizophrenia. 2005 , 10, 361-78		6
1663	Effects of a neuropsychological rehabilitation programme on schizophrenic patients' subjective perception of improvement. 2005 , 15, 605-18		4
1662	A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICES project. 2005 , 31, 954-61		13
1661	What predicts a good response to cognitive remediation interventions?. 2005 , 31, 942-53		158
1660	Older people with chronic schizophrenia. 2005 , 9, 315-24		27
1659	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. 2005 , 6, 132-91		216
1658	Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. 2005 , 10, 827-44		44
1657	Electrophysiological indices associated with social functioning outcome in schizophrenia: a 5-year follow-up study. 2005 , 51, 215-8		3

1656	Changes in the neuropsychological correlates of clinical dimensions between the acute and stable phase of schizophrenia. 2005 , 57, 93-101		3
1655	On the trail of a cognitive enhancer for the treatment of schizophrenia. 2005 , 29, 219-32		62
1654	Effects of quetiapine on cognitive functions in schizophrenia. 2005 , 29, 233-8		25
1653	Is quality of life associated with cognitive impairment in schizophrenia?. 2005 , 29, 239-44		89
1652	Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study. 2005 , 29, 944-51		9
1651	Medial temporal and prefrontal lobe activation during verbal encoding following glucose ingestion in schizophrenia: A pilot fMRI study. 2005 , 83, 54-64		34
1650	Disability in schizophrenia: clinical correlates and prediction over 1-year follow-up. <i>Psychiatry Research</i> , 2005 , 135, 103-11	9.9	40
1649	Social cognitive problem-solving in schizophrenia: associations with fluency and verbal memory. <i>Psychiatry Research</i> , 2005 , 134, 123-9	9.9	20
1648	Event-related potentials elicited by distractors in an auditory oddball paradigm in schizophrenia. <i>Psychiatry Research</i> , 2005 , 137, 49-59	9.9	12
1647	Developing therapeutics for schizophrenia and other psychotic disorders. 2005 , 2, 579-89		19
1646	The biological, functional and personal consequences of stress. 2005 , 20 Suppl 3, S301		
1645	Stress axis dysfunction in schizophrenia. 2005 , 20 Suppl 3, S307-12		10
1644	Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa. 2005 , 58, 337-43		18
1643	Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. 2005 , 58, 97-104		197
1642	Disorganization of semantic memory underlies alogia in schizophrenia: an analysis of verbal fluency performance in Japanese subjects. 2005 , 74, 91-100		57
1641	The FOCIS international survey on psychiatrists' opinions on cognition in schizophrenia. 2005 , 74, 253-61		14
1640	Neurocognitive impairment across the lifespan in schizophrenia: an update. 2005 , 74, 15-26		187
1639	Kinetics of tyrosine transport and cognitive functioning in schizophrenia. 2005 , 74, 81-9		19

1638	Sensorimotor gating, orienting and social perception in schizophrenia. 2005 , 73, 319-25	40
1637	Relationship of impaired processing speed and flexibility of abstract thought to improvements in work performance over time in schizophrenia. 2005 , 75, 211-8	34
1636	Tropisetron improves deficits in auditory P50 suppression in schizophrenia. 2005 , 76, 67-72	113
1635	Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. 2005 , 77, 43-58	167
1634	Prefrontal functioning during context processing in schizophrenia and major depression: an event-related fMRI study. 2005 , 76, 199-206	119
1633	Self-efficacy and psychosocial functioning in schizophrenia: a mediational analysis. 2005 , 78, 187-97	49
1632	Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. 2005 , 77, 343-53	101
1631	Associative interference does not affect recognition memory in schizophrenia. 2005 , 80, 185-96	5
1630	Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia. 2005 , 77, 167-77	7
1629	Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. 2005 , 78, 27-34	195
1628	Biosocial pathways to functional outcome in schizophrenia. 2005 , 80, 213-25	329
1627	Remediation of impairments in facial affect recognition in schizophrenia: efficacy and specificity of a new training program. 2005 , 80, 295-303	251
1626	The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. 2005 , 80, 99-106	22
1625	Modern antipsychotic drugs: a critical overview. 2005 , 172, 1703-11	261
1624	Cognition in schizophrenia: impairments, determinants, and functional importance. 2005 , 28, 613-33, 626	173
1623	Rapid visual information processing in schizophrenic patients: the impact of cognitive load and duration of stimulus presentation. A pilot study. 2005 , 52, 130-4	14
1622	A review of the effects of modafinil on cognition in schizophrenia. 2007 , 33, 1298-306	42
1621	Adherence to Antipsychotic Treatment in Schizophrenia. 2006 , 14, 207-214	7

1620	Ketamine : from medicine to misuse. 2006 , 20, 199-218	126
1619	Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia. 2006 , 24, 1233-48	1
1618	Virtual reality assessment of medication compliance in patients with schizophrenia. 2006 , 9, 224-9	12
1617	Functional outcome in TBI II: verbal memory and information processing speed mediators. 2006 , 28, 581-91	42
1616	Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. 2006 , 63, 1325-35	276
1615	Patterns and clinical correlates of neuropsychologic deficits in patients with schizophrenia. 2006 , 105, 978-91	19
1614	[Relevance of cognitive tools for early diagnosis of schizophrenia]. 2006 , 32, S889-92; discussion S893	
1613	[Non-pharmacological reality in the treatment of schizophrenia]. 2006 , 32 Pt 3, S1051-5	1
1612	Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. 2006 , 29, 545-56	46
1611	Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms. 2006 , 16 Suppl 3, S135-41	17
1610	Real-world cognitive--and metacognitive--dysfunction in schizophrenia: a new approach for measuring (and remediating) more "right stuff". 2006 , 32, 310-26	228
1609	Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. 2006 , 75, 72-84	160
1608	Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. 2006 , 59, 97-105	105
1607	Decreased encoding efficiency in schizophrenia. 2006 , 59, 740-6	35
1606	Dopaminergic modulation of semantic priming in healthy volunteers. 2006 , 60, 604-11	30
1605	Impact of neurocognitive function on academic difficulties in pediatric bipolar disorder: A clinical translation. 2006 , 60, 951-6	54
1604	Galantamine improves cognition in schizophrenic patients stabilized on risperidone. 2006 , 60, 530-3	117
1603	Re-conceptualizing schizophrenia as a disorder of cognitive and emotional processing: a shot in the arm for translational research. 2006 , 60, 1169-70	9

1602	One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. 2006 , 81, 1-15	101
1601	Prose memory deficits associated with schizophrenia. 2006 , 81, 199-209	6
1600	The components of executive functioning in a cohort of patients with chronic schizophrenia: a multiple single-case study design. 2006 , 81, 173-89	53
1599	Specific cognitive deficits and differential domains of social functioning impairment in schizophrenia. 2006 , 81, 227-38	56
1598	Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. 2006 , 81, 29-39	35
1597	Self-initiated encoding facilitates object working memory in schizophrenia: implications for the etiology of working memory deficit. 2006 , 82, 65-74	11
1596	Change in neurocognition by housing type and substance abuse among formerly homeless seriously mentally ill persons. 2006 , 83, 77-86	33
1595	Gray matter abnormalities associated with duration of untreated psychosis. 2006 , 83, 145-53	73
1594	Does cognition predict community function only in schizophrenia?: a study of schizophrenia patients, bipolar affective disorder patients, and community control subjects. 2006 , 84, 121-31	68
1593	Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia. 2006 , 83, 237-45	78
1592	Perception of socially relevant stimuli in schizophrenia. 2006 , 83, 257-67	55
1591	Neurocognitive performance and functional disability in the psychosis prodrome. 2006 , 84, 100-11	211
1590	Genetic analysis of the human ENTH (Epsin 4) gene and schizophrenia. 2006 , 84, 236-43	10
1589	Facial affect recognition: a mediator between cognitive and social functioning in psychosis?. 2006 , 85, 142-50	255
1588	Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. 2006 , 85, 73-83	71
1587	Impact of intellectual status on response to cognitive task training in patients with schizophrenia. 2006 , 87, 261-9	44
1586	Antipsychotic medication and cognitive function in schizophrenia. 2006 , 86, 138-46	106
1585	Impairment on the hippocampal-dependent virtual Morris water task in schizophrenia. 2006 , 87, 67-80	81

1584	Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients?. 2006 , 87, 246-53		65
1583	The functional significance of social cognition in schizophrenia: a review. 2006 , 32 Suppl 1, S44-63		890
1582	The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats. 2006 , 168, 236-42		32
1581	Effects of phencyclidine on spatial learning and memory: nitric oxide-dependent mechanisms. 2006 , 171, 147-53		44
1580	Phencyclidine affects memory in a nitric oxide-dependent manner: working and reference memory. 2006 , 174, 49-55		43
1579	Cognitive functioning and expressed emotion among patients with first-episode severe psychiatric disorders. 2006 , 47, 152-8		6
1578	Neuropsychological profile of cognitively impaired patients with schizophrenia. 2006 , 47, 136-43		57
1577	Prefrontal cortical projections to the midbrain in primates: evidence for a sparse connection. 2006 , 31, 1627-36		91
1576	Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples. <i>Psychiatry Research</i> , 2006 , 144, 153-66	9.9	41
1575	Learning potential as a predictor of readiness for psychosocial rehabilitation in schizophrenia. <i>Psychiatry Research</i> , 2006 , 143, 159-66	9.9	46
1574	Neuropsychological correlates of reality distortion in schizophrenic patients. <i>Psychiatry Research</i> , 2006 , 145, 49-60	9.9	35
1573	Perospirone in the treatment of schizophrenia: effect on verbal memory organization. 2006 , 30, 204-8		26
1572	Differential effects of classical neuroleptics and a newer generation antipsychotics on the MK-801 induced behavioural primitivization in mouse. 2006 , 30, 521-30		15
1571	Community dysfunction in schizophrenia: rate-limiting factors. 2006 , 30, 463-70		36
1570	Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial. 2006 , 30, 934-45		15
1569	The effect of perospirone on auditory P300 in schizophrenia: a preliminary study. 2006 , 30, 1083-90		5
1568	Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial. 2006 , 30, 1515-22		13
1567	Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice. 2006 , 30, 1486-95		29

1566	Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. 2006 , 52, 155-68		1469
1565	Investigating principles of human brain function underlying working memory: what insights from schizophrenia?. <i>Neuroscience</i> , 2006 , 139, 59-71	3.9	50
1564	Socioaffective factors modulate working memory in schizophrenia patients. <i>Neuroscience</i> , 2006 , 139, 373-84	3.9	17
1563	Measuring memory impairment in community-based patients with schizophrenia. Case-control study. 2006 , 189, 132-6		20
1562	Los trastornos cognitivos de la esquizofrenia. 2006 , 44, 215		1
1561	Left prefrontal function and semantic organization during encoding and retrieval in healthy and psychiatric populations. 178-198		
1560	Avaliaç� neuropsicol�gica dos circuitos pr�frontais relacionados � tomada de decis� na esquizofrenia: uma revis� sistem�tica da literatura. 2006 , 28, 330-341		3
1559	Long-term course of cognitive impairment in schizophrenia. 2006 , 189, 556-7		29
1558	An ethnographic study of job seeking among people with severe mental illness. 2006 , 30, 15-22		30
1557	Behavioral rehabilitation of the "treatment-refractory" schizophrenia patient: Conceptual foundations, interventions, and outcome data.. 2006 , 3, 145-169		27
1556	Group treatment approaches to address cognitive deficits. 2006 , 30, 38-45		6
1555	Support for limited brain availability of tyrosine in patients with schizophrenia. 2006 , 9, 247-55		12
1554	Correlates of health-related quality of well-being in older patients with schizophrenia. 2006 , 194, 335-40		21
1553	Impaired perception of affective prosody in schizophrenia. 2006 , 18, 81-5		56
1552	Dissociable mechanisms for memory impairment in bipolar disorder and schizophrenia. 2006 , 36, 1085-95		27
1551	Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. 2006 , 18, 429-36		26
1550	Translating basic attentional paradigms to schizophrenia research: reconsidering the nature of the deficits. 2006 , 18, 831-51		26
1549	Stability and validity of memory-based subtypes of schizophrenia. 2006 , 12, 782-91		9

1548 Analysis of the Cognitive Enhancing Effects of Modafinil in Schizophrenia. **2006**, 1, 133-147

1547 Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. **2006**, 12, 348-63 44

1546 Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. **2006**, 57, 1094-101 106

1545 Procedural memory predicts social skills in persons with schizophrenia. **2006**, 194, 625-7 6

1544 Cognitive functions among Hong Kong Chinese people with schizophrenia. **2006**, 29, 261-5 2

1543 Phonetic mismatch negativity predicts verbal memory deficits in schizophrenia. **2006**, 17, 1043-6 54

1542 Effect of subjective reasoning and neurocognition on medication adherence for persons with schizophrenia. **2006**, 57, 1203-5 22

1541 The neural basis of relational memory deficits in schizophrenia. **2006**, 63, 356-65 109

1540 The catechol O-methyltransferase Val158Met polymorphism and herpes simplex virus type 1 infection are risk factors for cognitive impairment in bipolar disorder: additive gene-environmental effects in a complex human psychiatric disorder. **2006**, 8, 124-32 34

1539 Relation between social functioning and neurocognitive test results using the Optional Thinking Test in schizophrenia. **2006**, 60, 63-9 11

1538 Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. **2006**, 60, 473-9 24

1537 Background factors related to and/or influencing occupation in mentally disordered offenders. **2006**, 20, 331-8 8

1536 Neuropsychological functions predict 1- and 3-year outcome in first-episode psychosis. **2006**, 113, 102-11 56

1535 Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents. **2006**, 31, 57-65 14

1534 Pathophysiologically based treatment interventions in schizophrenia. **2006**, 12, 1016-22 280

1533 Subtyping schizophrenia: implications for genetic research. **2006**, 11, 815-36 191

1532 Clinical characteristics and objective living conditions in relation to quality of life among community-based individuals of schizophrenia in Hong Kong. **2006**, 15, 1459-69 13

1531 Co-location of health care for adults with serious mental illness and HIV infection. **2006**, 42, 345-61 11

1530	Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: timing and patterns. 2006 , 256, 364-71		33
1529	Cognitive predictors of skill acquisition on social problem solving in patients with schizophrenia. 2006 , 256, 388-94		19
1528	The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. 2006 , 187, 312-20		103
1527	The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements. 2006 , 187, 356-63		42
1526	Toward the implementation of mental health consumer provider services. 2006 , 33, 176-95		96
1525	The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps?. 2006 , 10, 211-20		124
1524	Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. 2006 , 542, 108-15		43
1523	Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of alpha7 nicotinic receptors. 2006 , 553, 191-5		41
1522	Variability, regularity, and complexity of time series generated by schizophrenic patients and control subjects. 2006 , 53, 210-8		48
1521	Challenges to HIV prevention in psychiatric settings: perceptions of South African mental health care providers. 2006 , 63, 979-90		14
1520	Remission and cognitive ability in a cohort of patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2006 , 40, 738-45	5.2	73
1519	Neuroprotective effects of olanzapine in a rat model of neurodevelopmental injury. 2006 , 83, 208-13		14
1518	Decisional capacity in mental illness and substance use disorders: empirical database and policy implications. 2006 , 24, 607-28		32
1517	Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia. 2006 , 21, 711-8		26
1516	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. 2006 , 7, 5-40		118
1515	Enactment in schizophrenia: capacity for dialogue and the experience of the inability to commit to action. 2006 , 69, 81-93		12
1514	Use of environmental supports among patients with schizophrenia. 2006 , 57, 219-24		38
1513	Targeting schizophrenia research to patient outcomes. <i>American Journal of Psychiatry</i> , 2006 , 163, 353-5	11.9	15

1512	Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. 2006 , 63, 731-40		210
1511	Barriers to employment for people with schizophrenia. <i>American Journal of Psychiatry</i> , 2006 , 163, 411-7	11.9	327
1510	Understanding the glass ceiling for functional outcome in schizophrenia. <i>American Journal of Psychiatry</i> , 2006 , 163, 356-8	11.9	24
1509	Symptoms versus neurocognitive skills as correlates of everyday functioning in severe mental illness. 2006 , 6, 47-56		43
1508	Intellectual decline in schizophrenia: evidence from a prospective birth cohort 28 year follow-up study. 2006 , 28, 225-42		88
1507	Evidence that specific executive functions predict symptom variance among schizophrenia patients with a predominantly negative symptom profile. 2006 , 11, 13-32		41
1506	An "errorful" learning deficit in schizophrenia?. 2006 , 28, 101-10		24
1505	The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. 2006 , 28, 260-9		106
1504	Cognitive behavior therapy for schizophrenia. <i>American Journal of Psychiatry</i> , 2006 , 163, 365-73	11.9	165
1503	Development of a brief scale of everyday functioning in persons with serious mental illness. 2007 , 33, 1364-72		292
1502	Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. <i>American Journal of Psychiatry</i> , 2006 , 163, 448-54	11.9	262
1501	Validity and stability of performance-based estimates of premorbid educational functioning in older patients with schizophrenia. 2006 , 28, 178-92		22
1500	The NIMH-MATRICES consensus statement on negative symptoms. 2006 , 32, 214-9		846
1499	Baseline neurocognitive deficits in the CATIE schizophrenia trial. 2006 , 31, 2033-46		374
1498	Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. 2006 , 9, 135-45		37
1497	The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. <i>American Journal of Psychiatry</i> , 2006 , 163, 426-32	11.9	277
1496	Prognostic variables at intake and long-term level of function in schizophrenia. <i>American Journal of Psychiatry</i> , 2006 , 163, 433-41	11.9	98
1495	Of pride and prejudice: the role of sociology and social networks in integrating the health sciences. 2006 , 47, 189-208		187

1494	Untangling social function and social cognition: a review of concepts and measurement. 2006 , 69, 47-68		68
1493	Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. <i>American Journal of Psychiatry</i> , 2006 , 163, 1918-25	11.9	94
1492	The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. 2006 , 20, 335-46		45
1491	Negative symptoms and cognitive deficits: what is the nature of their relationship?. 2006 , 32, 250-8		323
1490	Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. 2006 , 40, 725-41		151
1489	A contextual study of daily living strategies in neurocognitively impaired adults with schizophrenia. 2006 , 16, 1217-35		9
1488	Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. <i>American Journal of Psychiatry</i> , 2006 , 163, 418-25	11.9	573
1487	The role of neurocognition and social context in predicting community functioning among formerly homeless seriously mentally ill persons. 2007 , 33, 1388-96		22
1486	Cognitive reserve in neuropsychiatry. 2006 , 36, 1053-64		204
1485	Closing the Gap Between Cognitive Performance and Real-World Functional Outcome in Schizophrenia: The Importance of Metacognition. 2006 , 2, 189-198		6
1484	Symptom domains of schizophrenia: the role of atypical antipsychotic agents. 2006 , 20, 6-19		37
1483	Functional outcome in TBI I: neuropsychological, emotional, and behavioral mediators. 2006 , 28, 567-80		35
1482	Sertindole: efficacy and safety in schizophrenia. 2006 , 7, 1825-34		21
1481	Neuropsychological function and employment status in a welfare-to-work sample. 2006 , 13, 141-50		5
1480	Cognition and aging in psychopathology: focus on schizophrenia and depression. 2006 , 2, 389-409		34
1479	Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. 2006 , 103, 19878-83		429
1478	Transcriptome alterations in schizophrenia: disturbing the functional architecture of the dorsolateral prefrontal cortex. 2006 , 158, 141-52		12
1477	Schizophrenie und verwandte Störungen âNeurobiologie. 2006 , 345-386		2

1476	Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. 2007 , 33, 1120-30	152
1475	Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. 2007 , 17 Suppl 1, i171-81	195
1474	Intrusion errors in explicit memory: their differential relationship with clinical and social outcome in chronic schizophrenia. 2007 , 12, 112-27	10
1473	Judgments of Financial Abilities of Severely Mentally Ill Individuals: A Comparison of Self-Report and an Objective Measure. 2007 , 14, 315-326	4
1472	Acute serotonin and dopamine depletion improves attentional control: findings from the stroop task. 2007 , 32, 1600-10	67
1471	Psychomotor slowing in schizophrenia. 2007 , 33, 1038-53	163
1470	Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia. 2008 , 34, 494-506	20
1469	Wayne Fenton's impact on academic neuroscience. 2007 , 33, 1156-9	
1468	Performance-based measures of functional skills: usefulness in clinical treatment studies. 2007 , 33, 1138-48	194
1467	Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative. 2008 , 34, 613-8	38
1466	Issues in Rehabilitation of Cognitive Deficits in Schizophrenia: A Critical Review. 2007 , 3, 186-195	1
1465	Cognitive Rehabilitation for Schizophrenia: A Review of Recent Advances. 2007 , 3, 213-221	9
1464	Serotonin receptor 2A gene and the influence of childhood maternal nurturance on adulthood depressive symptoms. 2007 , 64, 356-60	70
1463	Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. 2007 , 33, 1131-7	222
1462	A dynamical systems hypothesis of schizophrenia. 2007 , 3, e228	112
1461	An intersubjective perspective on negative symptoms of schizophrenia: implications of simulation theory. 2007 , 12, 144-64	37
1460	New paradigms for treatment development. 2007 , 33, 1093-9	18
1459	Relapse Prevention for Schizophrenia. 2007 , 117-140	3

1458	Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. 2007 , 64, 156-67		90
1457	Cognitive dysfunction in first-episode psychosis: the processing speed hypothesis. 2007 , 51, s107-10		90
1456	The quest for developing new treatments from imaging techniques: promises, problems and future potential. 2007 , 2, 1029-33		2
1455	Glycine Transporter-1 Inhibitors as Novel Therapeutic Drugs for Schizophrenia. 2007 , 7, 177-182		9
1454	Dopamine, Prefrontal Cortex and Working Memory Functioning in Schizophrenia. 2007 , 40, S62-S72		5
1453	Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. <i>American Journal of Psychiatry</i> , 2007 , 164, 1061-71	11.9	210
1452	Poison or cure: meanings of medication in schizophrenia. 2007 , 35, 189-201		8
1451	Statistical Fluctuations in Attractor Networks Related to Schizophrenia. 2007 , 40, S78-S84		18
1450	No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. 2007 , 12, 412-21		30
1449	Neuropsychological functioning and brain structure in schizophrenia. 2007 , 19, 325-36		54
1448	Very poor outcome schizophrenia: clinical and neuroimaging aspects. 2007 , 19, 345-57		59
1447	Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders. 2007 ,		13
1446	Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. <i>American Journal of Psychiatry</i> , 2007 , 164, 1585-92	11.9	100
1445	Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. 2007 , 64, 633-47		781
1444	Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. 2007 , 33, 688-702		390
1443	The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. <i>American Journal of Psychiatry</i> , 2007 , 164, 1593-602	11.9	329
1442	Molecular targets for treating cognitive dysfunction in schizophrenia. 2007 , 33, 1100-19		184
1441	Cognition in young schizophrenia outpatients: comparison of first-episode with multipisode patients. 2008 , 34, 544-54		43

1440	Persistent negative symptoms in schizophrenia: an overview. 2007 , 33, 1013-22	294
1439	Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. 2007 , 33, 805-22	168
1438	Relationships between occupational factors and health and well-being in individuals with persistent mental illness living in the community. 2007 , 74, 303-13	73
1437	Prediction of psychosis: setting the stage. 2007 , 51, s1-8	59
1436	Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. 2007 , 64, 1115-22	313
1435	The NIMH MATRICS Initiative: Development of a Consensus Cognitive Battery. 2007 , 2, 173-186	1
1434	Self-report of Cognitive Functioning and Learning in Schizophrenia. 2007 , 13, 93-100	9
1433	How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. 2007 , 33, 1247-56	140
1432	Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function. 2008 , 34, 93-108	22
1431	Cognition as an outcome measure in schizophrenia. 2007 , 50, s46-51	63
1430	Evolution of outcome measures in schizophrenia. 2007 , 50, s1-6	41
1429	ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders. 2007 , 64, 863-876	11
1428	Functional mechanisms of episodic memory impairment in schizophrenia. 2007 , 52, 693-701	99
1427	[Kitchen and schizophrenia: a crossroad activity of an ecological, occupational and neuropsychological assessment]. 2007 , 32, 159-79	3
1426	Étude de convivialité de l'utilisation d'un agenda électronique par des personnes souffrant de schizophrénie. 2007 , 32, 209-224	6
1425	Coercion and empowerment in the treatment of individuals with serious mental illness: A preliminary investigation.. 2007 , 4, 96-106	11
1424	Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings. 2007 , 133, 833-58	400
1423	How well do patients with schizophrenia track multiple moving targets?. 2007 , 21, 319-25	6

1422	Everyday action in schizophrenia: performance patterns and underlying cognitive mechanisms. 2007 , 21, 439-447		32
1421	Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. 2007 , 15, 563-8		30
1420	Designing websites for persons with cognitive deficits: Design and usability of a psychoeducational intervention for persons with severe mental illness. 2007 , 4, 202-224		107
1419	The significance of family history in first-episode schizophrenia spectrum disorder. 2007 , 195, 846-52		14
1418	Criterion B (social dysfunction) in persons with schizophrenia: the puzzle. 2007 , 20, 582-7		9
1417	The effect of long-acting risperidone on working memory in schizophrenia: a functional magnetic resonance imaging study. 2007 , 27, 560-70		21
1416	Executive function and employment status among veterans with bipolar disorder. 2007 , 58, 1441-7		42
1415	The association between cognitive functioning and occupational status in persons with a recent onset of psychosis. 2007 , 195, 566-71		19
1414	A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. 2007 , 22, 63-8		73
1413	Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. <i>American Journal of Psychiatry</i> , 2007 , 164, 992-4	11.9	42
1412	Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration. 2007 , 27, 15-21		30
1411	Neurocognitive Effects of Nicotine and Tobacco in Individuals with Schizophrenia. 2007 , 3, 61-77		8
1410	The neural substrates of impaired prosodic detection in schizophrenia and its sensorial antecedents. <i>American Journal of Psychiatry</i> , 2007 , 164, 474-82	11.9	106
1409	Translating laboratory research into practice: foundations, functions and future of cognitive remediation therapy for anorexia nervosa. 2007 , 4, 285-292		22
1408	Preserved memory monitoring but impaired memory control during episodic encoding in patients with schizophrenia. 2007 , 13, 219-27		24
1407	Impaired emotion perception in schizophrenia: a differential deficit. <i>Psychiatry Research</i> , 2007 , 149, 279-84		33
1406	Psychopathological and neuropsychological correlates of source monitoring impairment in schizophrenia. <i>Psychiatry Research</i> , 2007 , 150, 51-9	9.9	35
1405	Phonetic mismatch negativity predicts social skills acquisition in schizophrenia. <i>Psychiatry Research</i> , 2007 , 152, 261-5	9.9	72

1404	The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS). <i>Psychiatry Research</i> , 2007 , 151, 55-66	9.9	45
1403	Facial expressivity during the clinical interview as a predictor functional disability in schizophrenia. a pilot study. 2007 , 31, 475-81		51
1402	Contribution of divergent thinking to community functioning in schizophrenia. 2007 , 31, 517-24		25
1401	Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: A FDG-PET study. 2007 , 31, 807-13		54
1400	Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. 2007 , 31, 1101-7		21
1399	The amphetamine-induced sensitized state as a model of schizophrenia. 2007 , 31, 1556-71		151
1398	Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. 2007 , 184, 31-8		196
1397	Neuropsychological and activity of daily living script performance in patients with positive or negative schizophrenia. 2007 , 48, 293-302		20
1396	Self-reported cognitive and everyday functioning in persons with psychosis: the Patient Perception of Functioning Scale. 2007 , 48, 597-604		9
1395	Stress-reactivity in psychosis: evidence for an affective pathway to psychosis. 2007 , 27, 409-24		444
1394	Identifying mechanisms of treatment effects and recovery in rehabilitation of schizophrenia: longitudinal analytic methods. 2007 , 27, 696-714		17
1393	Schizophrenic patients exhibit hyper-reflexivity in a semantic categorical priming task. 2007 , 20, 197-220		3
1392	Schizophrenia and phenotypic plasticity: schizophrenia may represent a predictive, adaptive response to severe environmental adversity that allows both bioenergetic thrift and a defensive behavioral strategy. 2007 , 69, 383-94		14
1391	Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. 2007 , 17, 145-55		189
1390	ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004. 2007 , 17, 70-7		17
1389	Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. 2007 , 17, 725-34		11
1388	Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients. 2007 , 22, 365-70		26
1387	Cognition and functional outcome among deaf and hearing people with schizophrenia. 2007 , 94, 187-96		5

1386	Schizophrenia and the alpha7 nicotinic acetylcholine receptor. 2007 , 78, 225-46	174
1385	[Memory, memories: exploration of autobiographical memory in schizophrenia]. 2007 , 33 Pt 3, S365-8	0
1384	Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. 2007 , 78, 109-31	83
1383	Social/communication skills, cognition, and vocational functioning in schizophrenia. 2007 , 33, 1213-20	94
1382	Methods for treating cognitive deficits in schizophrenia. 2007 , 7, 281-7	10
1381	Context processing and negative symptoms in schizophrenia. 2007 , 29, 428-35	10
1380	Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. 2007 , 21, 699-714	21
1379	Dysfunctions of Spatial Cognition in Schizophrenic Patients. 2007 , 7, 287-309	12
1378	The Recovery Process and People with Serious Mental Illness Living in the Community. 2007 , 23, 51-73	15
1377	Using event related potentials to explore stages of facial affect recognition deficits in schizophrenia. 2008 , 34, 679-87	74
1376	AKT1 and neurocognition in schizophrenia. 2007 , 41, 169-77	12
1375	Stimulating the development of drug treatments to improve cognition in schizophrenia. 2007 , 3, 159-80	60
1374	Neuropsychological and psychiatric profiles in acute encephalitis in adults. 2007 , 17, 478-505	26
1373	The course of neurocognition and social functioning in individuals at ultra high risk for psychosis. 2007 , 33, 772-81	121
1372	Rehabilitation and recovery in schizophrenia. 2007 , 30, 535-48	18
1371	Cognitive functioning in the schizophrenia prodrome. 2007 , 33, 761-71	187
1370	Orofacial dyskinesia, frontal lobe dysfunction, and coping in older people with psychosis. 2007 , 15, 800-6	4
1369	Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships?. 2007 , 89, 330-8	119

1368	Cognitive enhancement therapy improves emotional intelligence in early course schizophrenia: preliminary effects. 2007 , 89, 308-11	90
1367	A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. 2007 , 89, 211-24	111
1366	RBANS neuropsychological profiles within schizophrenia samples recruited from non-clinical settings. 2007 , 89, 232-42	36
1365	Theory of mind, neurocognition, and functional status in schizotypy. 2007 , 89, 278-86	131
1364	Stability of attention deficits in schizophrenia. 2007 , 91, 107-11	16
1363	The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. 2007 , 94, 99-106	41
1362	Heterogeneity in recovery of psychosocial functioning during psychiatric rehabilitation: an exploratory study using latent growth mixture modeling. 2007 , 93, 186-93	22
1361	A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. 2007 , 93, 42-50	76
1360	A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. 2007 , 94, 332-41	70
1359	Social cognitive impairments in first episode psychosis. 2007 , 95, 124-33	95
1358	Empirical validation of competing definitions of schizophrenia: a poly-diagnostic study of cognitive impairment in non-affective psychosis. 2007 , 95, 39-47	12
1357	Improved cognitive function in schizophrenia after one year of cognitive training and vocational services. 2007 , 96, 156-61	58
1356	Cognitive predictors of symptom change for participants in vocational rehabilitation. 2007 , 96, 162-8	13
1355	NCAM1 and neurocognition in schizophrenia. 2007 , 61, 902-10	70
1354	Intentionality as a link between the neuropsychology and the symptoms of schizophrenia. 2007 , 40, 221-8	13
1353	Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism. 2007 , 19, 417-27	121
1352	Severe and Persistent Mental Illness. 1-20	4
1351	Schizophrenia. 2007 ,	

1350	Memory and schizophrenia. 2007 , 52, 691-2	3
1349	Alterações cognitivas na esquizofrenia: consequências funcionais e abordagens terapêuticas. 2007 , 34, 179-183	3
1348	Erratum. 2007 , 52, 692-692	
1347	Avaliação das habilidades de vida independente e comportamento social de pacientes psiquiátricos desospitalizados. 2007 , 29, 294-304	4
1346	Theory of mind functioning in mentally disordered offenders detained in high security psychiatric care: its relationship to clinical outcome, need and risk. 2007 , 17, 300-11	13
1345	Executive function in schizophrenia: what impact do antipsychotics have?. 2007 , 22, 397-406	37
1344	Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. 2007 , 22, 445-54	22
1343	The Development of a Substance Abuse Treatment Program for Forensic Patients With Cognitive Impairment. 2007 , 27, 66-81	2
1342	Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. 2007 , 31, 60-78	131
1341	Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. 2007 , 1, 71-8	48
1340	Towards a muscarinic hypothesis of schizophrenia. 2007 , 12, 232-46	206
1339	The pipeline and future of drug development in schizophrenia. 2007 , 12, 904-22	153
1338	Video-based assessment of interpersonal problem solving skills in patients with schizophrenia, their siblings and non-psychiatric controls. 2008 , 49, 77-82	8
1337	Brief assessment of cognition in schizophrenia: validation of the Japanese version. 2007 , 61, 602-9	166
1336	Cognitive alterations in groups at risk for psychosis: neutral markers of genetic risk or indicators of social disability?. 2007 , 116, 253-62	12
1335	Schizophrenia: disease, syndrome, or dimensions?. 2007 , 46, 199-206	14
1334	Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. 2007 , 1154, 154-62	65
1333	Hippocampal abnormalities and memory deficits: new evidence of a strong pathophysiological link in schizophrenia. 2007 , 54, 92-112	138

1332	Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsychotic potential. 2007 , 573, 148-60	12
1331	Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. 2007 , 572, 160-70	117
1330	Neuropsychological predictors of everyday functioning in adults with intellectual disabilities. 2008 , 52, 18-28	12
1329	Cortical activation during two verbal fluency tasks in schizophrenic patients and healthy controls as assessed by multi-channel near-infrared spectroscopy. 2007 , 156, 1-13	101
1328	Episodic memory and neuroimaging of hippocampus and fornix in chronic schizophrenia. 2007 , 155, 21-8	71
1327	Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study. 2007 , 45, 454-8	101
1326	Cognitive dimensions in first-episode schizophrenia spectrum disorders. <i>Journal of Psychiatric Research</i> , 2007 , 41, 968-77	5.2 71
1325	The amino acid L-lysine blocks the disruptive effect of phencyclidine on prepulse inhibition in mice. 2007 , 192, 9-15	12
1324	Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. 2007 , 193, 225-33	70
1323	Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. 2007 , 257, 203-10	38
1322	Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. 2007 , 257, 360-70	41
1321	Prediction of community outcome in schizophrenia 1 year after discharge from inpatient treatment. 2008 , 258, 48-58	38
1320	Relationship between functional capacity and community responsibility in patients with schizophrenia: differences between independent and assisted living settings. 2008 , 44, 385-91	20
1319	Developing translational animal models for symptoms of schizophrenia or bipolar mania. 2008 , 14, 71-8	75
1318	Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths. 2008 , 14, 79-96	5
1317	Cognitive functioning and negative symptoms in first episode schizophrenia: different patterns of correlates. 2008 , 14, 227-35	7
1316	Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia. 2008 , 14, 237-48	71
1315	Is processing speed predictive of functional outcome in psychosis?. 2008 , 43, 437-44	5

1314	Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC. 2008 , 196, 269-80		35
1313	Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. 2008 , 199, 89-98		96
1312	Sexualdelinquenz bei Schizophrenie. 2008 , 2, 249-254		
1311	Better pharmacotherapy for schizophrenia: what does the future hold?. 2008 , 10, 352-8		21
1310	Auditory Oddball fMRI in Schizophrenia: Association of Negative Symptoms with Regional Hypoactivation to Novel Distractors. 2008 , 2, 132-145		38
1309	The Brief Assessment of Cognition in Schizophrenia. Normative data for the Italian population. 2008 , 29, 85-92		98
1308	Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRN2) with schizophrenia in the Japanese population. 2008 , 115, 1457-61		10
1307	Multivariate genomewide linkage scan of neurocognitive traits and ADHD symptoms: suggestive linkage to 3q13. 2008 , 147B, 1399-411		39
1306	Narrative accounts of illness in schizophrenia: association of different forms of awareness with neurocognition and social function over time. 2008 , 17, 1143-51		17
1305	Attention training in the cognitive rehabilitation of schizophrenic patients:a review of efficacy studies. 2008 , 103, 15-23		7
1304	Computational models of schizophrenia and dopamine modulation in the prefrontal cortex. 2008 , 9, 696-709		273
1303	Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?. 2008 , 107, 1188-95		71
1302	Predictors of subjective and objective quality of life in outpatients with schizophrenia. 2008 , 62, 404-11		67
1301	Cognitive functions in bipolar affective disorder and schizophrenia: comparison. 2008 , 62, 515-25		24
1300	Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. 2008 , 109, 286-99		216
1299	Delay of gratification and executive performance in individuals with schizophrenia: putative role for eating behavior and body weight regulation. <i>Journal of Psychiatric Research</i> , 2008 , 42, 98-105	5.2	18
1298	Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. <i>Journal of Psychiatric Research</i> , 2008 , 42, 320-7	5.2	104
1297	Nitric oxide synthase inhibition attenuates phencyclidine-induced disruption of cognitive flexibility. 2008 , 89, 352-9		19

1296	History, aetiology, and symptomatology of schizophrenia. 2008 , 7, 404-409	6
1295	Clinical global impression of cognition in schizophrenia (CGI-CogS): reliability and validity of a co-primary measure of cognition. 2008 , 106, 59-69	62
1294	Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. 2008 , 99, 192-9	55
1293	Subjective and objective quality of life in schizophrenia. 2008 , 98, 201-8	159
1292	Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): psychometric properties of a brief scale for cognitive evaluation in schizophrenia. 2008 , 99, 139-48	60
1291	Reduced frontopolar activation during verbal fluency task in schizophrenia: a multi-channel near-infrared spectroscopy study. 2008 , 99, 250-62	221
1290	Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. 2008 , 100, 206-11	58
1289	Neuropsychological predictors of functional outcome in Cognitive Behavioral Social Skills Training for older people with schizophrenia. 2008 , 100, 133-43	44
1288	Adjunctive psychosocial therapies for the treatment of schizophrenia. 2008 , 100, 108-19	75
1287	Processing speed mediates the relationship between verbal memory, verbal fluency, and functional outcome in chronic schizophrenia. 2008 , 101, 225-33	59
1286	Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview. 2008 , 100, 4-19	232
1285	Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia. 2008 , 103, 326-7	24
1284	Communication abnormalities predict functional outcomes in chronic schizophrenia: differential associations with social and adaptive functions. 2008 , 103, 240-7	73
1283	1-year follow-up study of cognitive function in first-episode non-affective psychosis. 2008 , 104, 165-74	38
1282	Temperament and executive dysfunctions in schizophrenia. 2008 , 104, 175-84	10
1281	Temporal relationship between change in cognition and change in functioning in schizophrenia. 2008 , 105, 105-13	41
1280	Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. 2008 , 105, 1-9	70
1279	Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. 2008 , 106, 156-63	55

1278	APPRAISALS, PSYCHOTIC SYMPTOMS AND AFFECT IN DAILY LIFE. 2008 , 102, 233		
1277	MOBUS, A PROGRAM IMPLEMENTED AS A PERSONAL DIGITAL ASSISTANT TO HELP PEOPLE WITH SCHIZOPHRENIA PLAN DAILY ACTIVITIES: APRELIMINARY STUDY. 2008 , 102, 233		0
1276	PSYCHOPATHOLOGY IN SCHIZOPHRENIC PATIENTS & QUALITY OF LIFE PERCEIVED BY THEIR CAREGIVERS: A PRE AND POST INTERVENTION ANALYSIS. 2008 , 102, 233-234		
1275	Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. 2008 , 63, 92-7		97
1274	Diffusion tensor imaging of the superior longitudinal fasciculus and working memory in recent-onset schizophrenia. 2008 , 63, 512-8		273
1273	The cognitive neuroscience of memory function and dysfunction in schizophrenia. 2008 , 64, 18-25		192
1272	Cognitive neuroscience and schizophrenia: translational research in need of a translator. 2008 , 64, 2-3		19
1271	Cognitive enhancing drugs for schizophrenia. 2008 , 5, 145-150		1
1270	Development and Pilot Testing of a Novel Compensatory Cognitive Training Intervention for People with Psychosis. 2008 , 11, 144-163		65
1269	The Medical Basis of Psychiatry. 2008 ,		4
1268	Relationship between Theory of Mind and executive function in schizophrenia: a systematic review. 2008 , 41, 206-13		93
1267	Assessment of executive functions: review of instruments and identification of critical issues. 2008 , 23, 201-16		764
1266	Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study. 2008 , 23, 271-82		11
1265	A relationship between neurocognitive impairment and functional impairment in bipolar disorder: a pilot study. <i>Psychiatry Research</i> , 2008 , 157, 289-93	9.9	49
1264	Verbal memory, negative symptomatology and prediction of psychosocial functioning in schizophrenia. <i>Psychiatry Research</i> , 2008 , 158, 11-7	9.9	31
1263	Errorless learning and memory performance in schizophrenia. <i>Psychiatry Research</i> , 2008 , 159, 180-8	9.9	12
1262	Analysis of cognitive performance in schizophrenia patients and healthy individuals with unsupervised clustering models. <i>Psychiatry Research</i> , 2008 , 159, 167-79	9.9	33
1261	Schizotypal traits and cognitive function in healthy adults. <i>Psychiatry Research</i> , 2008 , 161, 162-9	9.9	60

1260	Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. <i>Psychiatry Research</i> , 2008 , 159, 140-6	9.9	38
1259	Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. <i>Psychiatry Research</i> , 2008 , 161, 213-24	9.9	143
1258	Tone duration mismatch negativity deficits predict impairment of executive function in schizophrenia. 2008 , 32, 95-9		54
1257	Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. 2008 , 32, 336-9		75
1256	[Cognitive predictors of the community functioning dimensions in schizophrenia: state of the art and future directions]. 2008 , 34, 360-8		8
1255	[Adolescent psychosis, can neuroscience improve prediction?]. 2008 , 34, 153-60		1
1254	Evaluation of a neurodevelopmental model of schizophrenia--early postnatal PCP treatment in attentional set-shifting. 2008 , 190, 160-3		60
1253	Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat. 2008 , 194, 230-5		42
1252	A scientific agenda for the concept of recovery as it applies to schizophrenia. 2008 , 28, 1108-24		252
1251	Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes. 2008 , 49, 123-31		42
1250	Alterations of dopamine and serotonin transmission in schizophrenia. 2008 , 172, 117-40		61
1249	Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. 2008 , 102, 312-9		58
1248	Classifying antipsychotic agents : need for new terminology. 2008 , 22, 1047-59		12
1247	Response to Cognitive Rehabilitation in Older Versus Younger Persons with Severe Mental Illness. 2008 , 11, 90-105		42
1246	Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. 2008 , 325, 681-90		240
1245	Factors Influencing Occupational Competence in Schizophrenia. 2008 , 24, 5-30		1
1244	Neurocognitive Enhancement Therapy and Competitive Employment in Schizophrenia: Effects on Clients with Poor Community Functioning. 2008 , 11, 109-122		16
1243	Developmental disruptions in neural connectivity in the pathophysiology of schizophrenia. 2008 , 20, 1297-327		114

1242	Emerging drugs for schizophrenia. 2008 , 13, 479-95		38
1241	Insight into neurocognitive dysfunction in schizophrenia. 2008 , 34, 1221-30		117
1240	Definitions of the term 'recovered' in schizophrenia and other disorders. 2008 , 41, 271-8		20
1239	Improvements in autobiographical memory in schizophrenia patients after a cognitive intervention: a preliminary study. 2008 , 41, 388-96		40
1238	Prospective memory in schizophrenia: the impact of varying retrospective-memory load. 2008 , 30, 777-88		33
1237	Possible dose-side effect relationship of antipsychotic drugs: relevance to cognitive function in schizophrenia. 2008 , 1, 791-802		11
1236	Cognitive Adaptation Training: Establishing Environmental Supports to Bypass Cognitive Deficits and Improve Functional Outcomes. 2008 , 11, 164-180		22
1235	The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. 2008 , 33, 480-90		195
1234	Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. 2008 , 33, 1217-28		116
1233	Attentional capture in schizophrenia and schizotypy: effect of attentional load. 2008 , 13, 89-111		16
1232	The future of supported employment for people with severe mental illness. 2008 , 31, 367-76		73
1231	No evidence for a differential deficit of reality monitoring in schizophrenia: a meta-analysis of the associative memory literature. 2008 , 13, 369-84		15
1230	Neuroplasticity of neocortical circuits in schizophrenia. 2008 , 33, 141-65		296
1229	New Approaches to Treatment of Schizophrenia by Enhancing N-methyl-d-aspartate Neurotransmission. 2008 , 3,		
1228	Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. <i>American Journal of Psychiatry</i> , 2008 , 165, 1585-93	11.9	234
1227	Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. 2008 , 42, 496-504		73
1226	Kognitive Störungen bei schizophrenen Patienten - Ihre Relevanz in Wissenschaft und klinischer Praxis. 2008 , 34, 191-199		1
1225	Relationship of cognition and psychopathology to functional impairment in schizophrenia. <i>American Journal of Psychiatry</i> , 2008 , 165, 978-87	11.9	149

1224	New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life. <i>American Journal of Psychiatry</i> , 2008 , 165, 940-3	11.9	4
1223	Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. 2008 , 33, 2657-66		111
1222	[Sexual offending in schizophrenia - a comparative trial]. 2008 , 76, 655-61		3
1221	Kognitive Beeinträchtigung und Alltagsfunktion bei an Schizophrenie erkrankten Patienten â Entscheidende Faktoren fr den Langzeitverlauf. 2008 , 34, 457-460		
1220	Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. 2008 , 193, 203-9		97
1219	The Neuropsychological Educational Approach to Cognitive Remediation (NEAR) Model: Practice Principles and Outcome Studies. 2008 , 11, 123-143		93
1218	Emotional memory in schizophrenia. 2008 , 34, 875-87		66
1217	Inclusion of cognitive impairment in the DSM diagnosis of schizophrenia: if not now, when?. 2008 , 7, 37-8		3
1216	MTHFR 677C --> T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val --> Met. 2008 , 105, 17573-8		79
1215	Predictors of outcome in first-episode schizophrenia over the first 4 years of illness. 2008 , 38, 1141-6		34
1214	Memory and executive impairment in schizophrenia: comparison with frontal and temporal brain damage. 2008 , 38, 833-42		13
1213	Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia. 2008 , 14, 110-8		18
1212	Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. 2008 , 38, 1257-66		43
1211	Emotion perception and learning potential: mediators between neurocognition and social problem-solving in schizophrenia?. 2008 , 14, 279-88		44
1210	Interrelated neuropsychological and anatomical evidence of hippocampal pathology in the at-risk mental state. 2008 , 38, 843-51		65
1209	Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. 2008 , 14, 209-21		35
1208	Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study. 2008 , 14, 479-88		82
1207	Cognitive Behavior Therapy for Schizophrenia. 2008 , 6, 257-266		1

1206	Deficits in neurocognition, theory of mind, and social functioning in patients with schizophrenic disorders: are they related?. 2008 , 196, 153-6	18
1205	Neurocognition as a Treatment Target in Schizophrenia. 2008 , 6, 180-183	2
1204	Impaired implicit learning in schizophrenia. 2008 , 22, 606-17	57
1203	Grasping behavior in schizophrenia suggests selective impairment in the dorsal visual pathway. 2008 , 117, 799-811	14
1202	Cognition in schizophrenia. 2008 , 419-446	1
1201	Muscarinic agonists for the treatment of cognition in schizophrenia. 2008 , 13, 985-96	43
1200	Predictors of employment for people with severe mental illness: results of an international six-centre randomised controlled trial. 2008 , 192, 224-31	150
1199	Heterogeneity in behavioral treatment response in severe mental illness. 2008 , 196, 198-206	5
1198	Bibliography Schizophrenia. 2008 , 6, 197-199	
1197	Dynamic Assessment of Executive Functioning: (How) Can We Measure Change?. 2008 , 7, 368-387	15
1196	Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. 2008 , 28, 485-93	49
1195	A longitudinal study of learning potential and rehabilitation outcome in schizophrenia. 2008 , 59, 248-55	35
1194	An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia. 2008 , 21, 98-103	32
1193	The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. 2008 , 21, 630-9	89
1192	The role of synchronous gamma-band activity in schizophrenia. 409-430	
1191	Origins of spatial working memory deficits in schizophrenia: an event-related fMRI and near-infrared spectroscopy study. 2008 , 3, e1760	84
1190	Catechol-O-methyltransferase Val158Met genotype in healthy and personality disorder individuals: Preliminary results from an examination of cognitive tests hypothetically differentially sensitive to dopamine functions. 2007 , 3, 925-34	5
1189	The neural basis of attention. 105-116	

1188	Associative memory. 96-104		
1187	Neuropsychological methods in mental disorders research: illustrations from methamphetamine dependence. 194-205		1
1186	Psychopharmacological modeling of psychiatric illness. 252-270		
1185	The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. 2009 , 25		10
1184	Working memory assessment in schizophrenia and its correlation with executive functions ability. 2009 , 31, 219-26		12
1183	Convergent approaches for defining functional imaging endophenotypes in schizophrenia. 2009 , 3, 37		30
1182	Cannabis use and cognition in schizophrenia. 2009 , 3, 53		65
1181	Using the Wisconsin Card Sorting Test to assess learning potential in normal IQ schizophrenia: does it have potential?. 2009 , 63, 405-11		4
1180	Hippocampus. 2009 , 313-330		
1179	Role of the cholinergic system in the pathology and treatment of schizophrenia. 2009 , 9, 73-86		31
1178	Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. <i>American Journal of Psychiatry</i> , 2009 , 166, 805-11	11.9	329
1177	Neurocognition in first-episode schizophrenia: a meta-analytic review. 2009 , 23, 315-36		794
1176	Clarifying the diversity of first-episode psychosis: Neuropsychological correlates of clinical symptoms. 2009 , 63, 493-500		11
1175	Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). <i>American Journal of Psychiatry</i> , 2009 , 166, 675-82	11.9	249
1174	Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models. 2009 , 3, 129-37		19
1173	Prefrontal activation deficits during episodic memory in schizophrenia. <i>American Journal of Psychiatry</i> , 2009 , 166, 863-74	11.9	202
1172	Evidence-based psychosocial practices and recovery from schizophrenia. 2009 , 72, 307-20		15
1171	Multimodal cognitive therapy: combining treatments that bypass cognitive deficits and deal with reasoning and appraisal biases. 2009 , 35, 884-93		12

1170	Neurocognition, social cognition, perceived social discomfort, and vocational outcomes in schizophrenia. 2009 , 35, 738-47	180
1169	Role of processing speed and premorbid IQ on visual recognition in patients with schizophrenia. 2009 , 31, 302-11	6
1168	Social disinterest attitudes and group cognitive-behavioral social skills training for functional disability in schizophrenia. 2009 , 35, 874-83	52
1167	Errorless learning for training individuals with schizophrenia at a community mental health setting providing work experience. 2009 , 35, 807-15	26
1166	A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. 2009 , 31, 848-59	124
1165	Brain-performance correlates of working memory retrieval in schizophrenia: a cognitive modeling approach. 2009 , 35, 32-46	20
1164	Subchronic MK-801 behavioural deficits in rats: partial reversal by the novel nitrate GT 1061. 2009 , 91, 495-502	22
1163	Social memory in mice: disruption with an NMDA antagonist and attenuation with antipsychotic drugs. 2009 , 92, 236-42	36
1162	Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. 2009 , 122, 150-202	256
1161	Symptomatic and functional correlates of regional brain physiology during working memory processing in patients with recent onset schizophrenia. 2009 , 173, 177-82	12
1160	Working memory and long-term memory deficits in schizophrenia: is there a common substrate?. 2009 , 174, 89-96	28
1159	Attention training in schizophrenia: differing responses to similar tasks. <i>Journal of Psychiatric Research</i> , 2009 , 43, 490-6	5.2 8
1158	GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice. 2009 , 602, 101-4	40
1157	Abnormal medial temporal activity for bound information during working memory maintenance in patients with schizophrenia. 2010 , 20, 936-48	19
1156	Family-directed cognitive adaptation for schizophrenia. 2009 , 65, 854-67	11
1155	Exploring predictors of outcome in the psychosis prodrome: implications for early identification and intervention. 2009 , 19, 280-93	52
1154	What do we know about neuropsychological aspects of schizophrenia?. 2009 , 19, 365-84	222
1153	Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study. 2009 , 202, 287-93	84

1152	A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia. 2009 , 202, 237-58	33
1151	Recent advances in treating cognitive impairment in schizophrenia. 2009 , 202, 259-73	38
1150	The effects of psychotomimetic and putative cognitive-enhancing drugs on the performance of a n-back working memory task in rats. 2009 , 202, 67-78	14
1149	Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions. 2009 , 202, 295-306	47
1148	Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. 2009 , 206, 631-40	46
1147	Atypical and typical antipsychotics in the schools. 2009 , 46, 869-884	2
1146	Study protocol for the development of a European measure of best practice for people with long term mental health problems in institutional care (DEMoBinc). 2009 , 9, 36	22
1145	Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. 2009 , 9, 44	49
1144	A systematic review of the international published literature relating to quality of institutional care for people with longer term mental health problems. 2009 , 9, 55	74
1143	The self-assessment scale of cognitive complaints in schizophrenia: a validation study in Tunisian population. 2009 , 9, 66	8
1142	Effect of quetiapine on cognitive function in schizophrenia: a mismatch negativity potentials study. 2009 , 21, 26-33	6
1141	Advocacy for mothers with psychiatric illness: a clinical perspective. 2009 , 18, 53-61	29
1140	Use of the Perceive, Recall, Plan and Perform System of Task Analysis for persons with schizophrenia: a preliminary study. 2009 , 56, 189-99	25
1139	Relationship between psychosocial adjustment and executive function in patients with bipolar disorder and schizophrenia in remission: the mediating and moderating effects of insight. 2009 , 11, 190-7	21
1138	Factors associated with functional psychosocial status in first-episode psychosis. 2009 , 3, 35-43	5
1137	Cognitive deterioration and duration of untreated psychosis. 2009 , 3, 157-60	11
1136	Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications. 2009 , 111, 891-900	73
1135	Poor response inhibition: at the nexus between substance abuse and attention deficit/hyperactivity disorder. 2009 , 33, 690-8	114

1134	Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance. 2009 , 185, 66-9	25
1133	The role of attention and immediate memory in vulnerability to interpersonal criticism during family transactions in schizophrenia. 2009 , 48, 21-9	4
1132	Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. 2009 , 31, 462-71	52
1131	The Effects of Task Engagement and Interpersonal Rapport on WCST Performance in Schizophrenia. 2009 , 12, 57-72	3
1130	Schizophrenia. 2009 ,	
1129	Strategies used by psychotic individuals to cope with life stress and symptoms of illness: a systematic review. 2009 , 22, 371-410	70
1128	Remission in schizophrenia: analysis in a naturalistic setting. 2009 , 50, 200-8	33
1127	[Cognitive remediation and cognitive assistive technologies in schizophrenia]. 2009 , 35, 160-7	19
1126	[Learning potential and cognitive remediation in schizophrenia]. 2009 , 35, 353-60	13
1125	The importance of nitric oxide in social dysfunction. 2009 , 200, 113-6	18
1124	Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate. 2009 , 204, 352-62	51
1123	The genetics of schizophrenia. <i>Neuroscience</i> , 2009 , 164, 288-99	3.9 48
1122	The short-term impact of generic versus individualized environmental supports on functional outcomes and target behaviors in schizophrenia. <i>Psychiatry Research</i> , 2009 , 168, 94-101	9.9 27
1121	Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. <i>Psychiatry Research</i> , 2009 , 169, 97-100	9.9 41
1120	Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. 2009 , 33, 373-9	29
1119	Cognitive training for divergent thinking in schizophrenia: a pilot study. 2009 , 33, 1533-6	15
1118	Stroop interference effect in schizophrenic patients: an electrophysiological approach. 2009 , 71, 248-57	18
1117	Approche cognitivocomportementale des patients prsentant un premier pisode psychotique. 2009 , 167, 158-166	1

1116	Tentative de diagnostic différentiel des psychoses fonctionnelles non affectives au moyen des tests neuropsychologiques dans une population congolaise. 2009 , 167, 767-773	
1115	IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. 2009 , 107, 55-60	90
1114	A comparison of remediation techniques on the Wisconsin Card Sorting Test in schizophrenia. 2009 , 107, 76-82	17
1113	Do sex differences affect prefrontal cortex associated cognition in schizophrenia?. 2009 , 107, 255-61	23
1112	Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. 2009 , 107, 275-85	35
1111	Negative symptoms and concordant impairments in attention in schizophrenia: associations with social functioning, hope, self-esteem and internalized stigma. 2009 , 110, 165-72	60
1110	Pathways to functional outcomes in schizophrenia: the role of premorbid functioning, negative symptoms and intelligence. 2009 , 110, 40-6	36
1109	Schizophrenia, "just the facts" 4. Clinical features and conceptualization. 2009 , 110, 1-23	636
1108	Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. 2009 , 113, 189-99	370
1107	Executive functioning in schizophrenia: a thorough examination of performance on the Hayling Sentence Completion Test compared to psychiatric and non-psychiatric controls. 2009 , 114, 84-90	19
1106	The importance of cross-sectional remission in schizophrenia for long-term outcome: a clinical prospective study. 2009 , 115, 67-73	22
1105	FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia. 2009 , 114, 161-71	26
1104	Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia. 2009 , 115, 74-81	156
1103	Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms. 2009 , 115, 82-7	164
1102	Explicit identification and implicit recognition of facial emotions: II. Core domains and relationships with general cognition. 2009 , 31, 278-91	80
1101	Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. 2009 , 6, 319-31	21
1100	Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. 2009 , 14, 277-98	76
1099	Cognitive rehabilitation of the updating sub-component of working memory in schizophrenia: a case study. 2009 , 19, 244-73	17

1098	Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. 2009 , 135, 157-71	188
1097	Psychosocial treatments to promote functional recovery in schizophrenia. 2009 , 35, 347-61	168
1096	Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia. 2009 , 35, 222-32	69
1095	Work, recovery, and comorbidity in schizophrenia: a randomized controlled trial of cognitive remediation. 2009 , 35, 319-35	200
1094	Innovative Therapeutics for Schizophrenia. 2009 , 44, 17-23	
1093	Innovative Therapeutics for Schizophrenia. 2009 , 44, 24	
1092	The predictive value of measures of social cognition for community functioning in schizophrenia: implications for neuropsychological assessment. 2009 , 15, 239-47	68
1091	Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. 2009 , 194, 439-45	44
1090	At-risk mental state and prediction. 83-106	
1089	Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. 2009 , 70, 104-12	40
1088	A systematic review of cognitive deficits in homeless adults: implications for service delivery. 2009 , 54, 123-33	47
1087	What do ERPs and ERFs reveal about the effect of antipsychotic treatment on cognition in schizophrenia?. 2009 , 15, 2573-93	26
1086	Depression, avolition, and attention disorders in patients with schizophrenia: associations with verbal memory efficiency. 2009 , 21, 206-15	14
1085	Remédiation cognitive des patients schizophréniques dans les pays francophones. 2009 , 6, 1-6	2
1084	Neuroimaging Studies of Substance Abuse in Schizophrenia. 2009 , 5, 250-260	3
1083	Conditioned avoidance response in the development of new antipsychotics. 2010 , 16, 358-70	64
1082	Prefrontal cortical circuits in schizophrenia. 2010 , 4, 485-508	78
1081	Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. 2010 , 13, 891-903	45

1080	Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. 2010 , 16, 522-37	210
1079	Client predictors of employment outcomes in high-fidelity supported employment: a regression analysis. 2010 , 198, 556-63	60
1078	UCSD SORT Test (U-SORT): Examination of a newly developed organizational skills assessment tool for severely mentally ill adults. 2010 , 198, 916-9	1
1077	Linguistic ability and mental health outcomes among deaf people with schizophrenia. 2010 , 198, 634-42	6
1076	Pharmacotherapy of First-Episode Schizophrenia. 2010 , 45, 41-48	1
1075	[Preclinical approaches for drugs targeting cognitive deficits of schizophrenia]. 2010 , 136, 133-6	1
1074	Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations With Cognition, Functional Capacity, and Symptoms. 2010 , 8, 638-646	1
1073	Episodic memory and impairment of an early encoding process in schizophrenia. 2010 , 24, 101-8	19
1072	The dot pattern expectancy task: reliability and replication of deficits in schizophrenia. 2010 , 22, 131-41	41
1071	Scene construction in schizophrenia. 2010 , 24, 608-15	32
1070	Neurocognition in early-onset schizophrenia and schizoaffective disorders. 2010 , 49, 52-60	7
1069	[Treatment of cognitive deficits in schizophrenia. Part 1: Diagnostic and psychological training]. 2010 , 81, 556-63	8
1068	Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. 2010 , 208, 23-36	61
1067	Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. 2010 , 210, 407-18	39
1066	Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model. 2010 , 212, 635-42	15
1065	Social skills and neurocognitive individualized training in schizophrenia: comparison with structured leisure activities. 2010 , 260, 305-15	35
1064	Alterations of cortical GABA neurons and network oscillations in schizophrenia. 2010 , 12, 335-44	202
1063	Polymorphism of serotonin receptor genes (5-HTR2A) and Dysbindin (DTNBP1) and individual components of short-term verbal memory processes in Schizophrenia. 2010 , 40, 934-40	20

1062	MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPE: relevance to negative symptoms associated with schizophrenia?. 2010 , 95, 223-9	59
1061	Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. 2010 , 128, 419-32	402
1060	Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. 2010 , 11, 118	239
1059	Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. 2010 , 25, 116-25	45
1058	A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. 2010 , 9, 27	67
1057	Brief neuropsychological profiles in psychosis: a pilot study using the Audio Recorded Cognitive Screen (ARCS). 2010 , 22, 243-52	6
1056	Is late-onset schizophrenia a subtype of schizophrenia?. 2010 , 122, 414-26	70
1055	Metacognition as a mediator of the effects of impairments in neurocognition on social function in schizophrenia spectrum disorders. 2010 , 122, 405-13	118
1054	Abnormal neural oscillations and synchrony in schizophrenia. 2010 , 11, 100-13	1386
1053	Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. 2010 , 64, 62-9	38
1052	Relationship of the Brief UCSD Performance-based Skills Assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder. 2010 , 12, 45-55	95
1051	Cognition and disability in bipolar disorder: lessons from schizophrenia research. 2010 , 12, 364-75	115
1050	Neurocognition. 97-119	2
1049	Functional imaging of schizophrenia. 30-47	
1048	Neuropsychology. 2010 , 121-140	4
1047	Characterization of the cognitive impairments induced by prenatal exposure to stress in the rat. 2010 , 4, 173	83
1046	Emerging role of sertindole in the management of schizophrenia. 2010 , 6, 429-41	11
1045	Risperidone for Individuals with Refractory Schizophrenia. 2010 , 2, CMT.S3567	

1044	Neural correlates of set-shifting: decomposing executive functions in schizophrenia. 2010 , 35, 321-9	44
1043	A Fair Deal for mental health includes local rehabilitation services. 2010 , 34, 265-267	8
1042	Predictive factors of social functioning in patients with schizophrenia: exploration for the best combination of variables using data mining. 2010 , 7, 93-101	25
1041	Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders. 2010 , 19, 3797-805	29
1040	Positron emission tomography in schizophrenia: a new perspective. 2010 , 51, 511-20	41
1039	Expectancy-value theory in persistence of learning effects in schizophrenia: role of task value and perceived competency. 2010 , 36, 957-65	51
1038	Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. <i>American Journal of Psychiatry</i> , 2010 , 167, 1116-24	11.9 336
1037	Sustained attention and planning deficits but intact attentional set-shifting in neuroleptic-naïve first-episode schizophrenia patients. 2010 , 61, 79-86	27
1036	A randomized controlled trial of cognitive remediation in schizophrenia. 2010 , 36, 419-27	61
1035	Relations between a computerized shopping task and cognitive tests in a group of persons diagnosed with schizophrenia compared with healthy controls. 2010 , 16, 180-9	15
1034	Prognostic value of cognitive functioning for global functional recovery in first-episode schizophrenia. 2010 , 40, 935-44	50
1033	New Opportunities in the Treatment of Cognitive Impairments Associated With Schizophrenia. 2010 , 19, 264-269	6
1032	Use of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to investigate group and gender differences in schizophrenia and bipolar disorder. 2010 , 44, 220-9	53
1031	Core of schizophrenia: estrangement, dementia or neurocognitive disorder?. 2010 , 43, 300-11	19
1030	Sex differences in neuropsychological functioning among schizophrenia patients. 2010 , 44, 333-41	38
1029	Association of demographic characteristics, symptomatology, retrospective and prospective memory, executive functioning and intelligence with social functioning in schizophrenia. 2010 , 44, 1112-7	15
1028	Neural changes associated with relational learning in schizophrenia. 2010 , 36, 496-503	21
1027	Neurophysiological measures of sensory registration, stimulus discrimination, and selection in schizophrenia patients. 2010 , 4, 283-309	32

1026	Different sides of the same coin? Intercorrelations of cognitive biases in schizophrenia. 2010 , 15, 406-21	71
1025	Cognitive function, social functioning and quality of life in first-episode psychosis: A 1-year longitudinal study. 2010 , 14, 33-40	12
1024	Effect of second-generation antipsychotics on cognition: current issues and future challenges. 2010 , 10, 43-57	162
1023	Computer-aided neurocognitive remediation in schizophrenia: durability of rehabilitation outcomes in a follow-up study. 2010 , 20, 659-74	30
1022	A multimodal assessment of the genetic control over working memory. 2010 , 30, 8197-202	61
1021	Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. 2010 , 67, 578-88	338
1020	Structured floral arrangement programme for improving visuospatial working memory in schizophrenia. 2010 , 20, 624-36	5
1019	Declarative and nondeclarative memory in schizophrenia: What is impaired? What is spared?. 2010 , 32, 1017-27	18
1018	A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries. 2010 , 32, 937-52	32
1017	Psychiatry and the Hirsch h-index: The relationship between journal impact factors and accrued citations. 2010 , 18, 207-19	53
1016	Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. 2010 , 35, 1053-62	90
1015	The Relevance of Neurocognition and Social Cognition for Outcome and Recovery in Schizophrenia. 2010 , 23-36	5
1014	The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia. 2010 , 36, 935-48	88
1013	Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. 2010 , 43, 50-7	42
1012	Definition and Measurement of Neurocognition and Social Cognition. 2010 , 1-22	4
1011	How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up. 2010 , 36, 192-204	39
1010	Audiovisual matching in speech and nonspeech sounds: a neurodynamical model. 2010 , 22, 240-7	1
1009	Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. 2010 , 10, 1347-59	110

1008	Alterations in metabotropic glutamate receptor 1 and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. <i>American Journal of Psychiatry</i> , 2010 , 167, 1489-98	11.9	101
1007	ToMRemed : une technique de remédiation cognitive centrée sur la théorie de l'esprit pour les patients schizophréniques. 2010 , 20, 16-21		23
1006	SOCIAL: an integrative framework for the development of social skills. 2010 , 136, 39-64		314
1005	Psychosocial function in schizophrenia and bipolar disorder: Relationship to neurocognition and clinical symptoms. 2010 , 16, 771-83		51
1004	Mismatch negativity, social cognition, and functioning in schizophrenia patients. 2010 , 67, 940-7		138
1003	Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. 2010 , 68, 41-50		332
1002	Use of eye movement monitoring to examine item and relational memory in schizophrenia. 2010 , 68, 610-6		33
1001	The role of the corpus callosum in transcranial magnetic stimulation induced interhemispheric signal propagation. 2010 , 68, 825-31		85
1000	[Cognitive complaints in schizophrenia: relationship with insight and other cognitive measures]. <i>Revista De Psiquiatria Y Salud Mental</i> , 2010 , 3, 55-60	2.7	8
999	Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). 2010 , 116, 243-51		40
998	Executive function in schizophrenia: influence of substance use disorder history. 2010 , 118, 34-40		17
997	A comparison of insight into clinical symptoms versus insight into neuro-cognitive symptoms in schizophrenia. 2010 , 118, 134-9		49
996	Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission. 2010 , 116, 9-15		62
995	A reappraisal of the association between Dysbindin (DTNBP1) and schizophrenia in a large combined case-control and family-based sample of German ancestry. 2010 , 118, 98-105		15
994	P50 gating in deficit and nondeficit schizophrenia. 2010 , 119, 183-90		30
993	Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. 2010 , 118, 189-200		44
992	Is perseveration uniquely characteristic of schizophrenia?. 2010 , 118, 128-33		29
991	Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. 2010 , 119, 138-44		28

990	Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. 2010 , 120, 191-8	20
989	An investigation of 3 neurocognitive subtypes in schizophrenia. 2010 , 121, 32-8	19
988	An evidence map of interventions across premorbid, ultra-high risk and first episode phases of psychosis. 2010 , 123, 37-44	26
987	Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. 2010 , 122, 1-23	255
986	Neural markers of remission in first-episode schizophrenia: a volumetric neuroimaging study of the hippocampus and amygdala. 2010 , 122, 72-80	26
985	The catechol-O-methyl transferase (COMT) gene and its potential association with schizophrenia: findings from a large German case-control and family-based sample. 2010 , 122, 24-30	19
984	The relationship between psychotic-like symptoms and neurocognitive performance in a general adolescent psychiatric sample. 2010 , 123, 77-85	40
983	Cannabis use and cognitive functioning in first-episode schizophrenia patients. 2010 , 124, 142-51	48
982	Cognitive Complaints in Schizophrenia: Relationship With Insight and Other Cognitive Measures. 2010 , 3, 55-60	2
981	Neurocognition in Early-Onset Schizophrenia and Schizoaffective Disorders. 2010 , 49, 52-60	21
980	Neurocognition in schizophrenia. 2010 , 4, 373-90	109
979	Relation of Positive and Negative Symptoms of Schizophrenia to Financial Capacity. 2010 , 17, 574-581	
978	Negative symptoms and concomitant attention deficits in schizophrenia: associations with prospective assessments of anxiety, social dysfunction, and avoidant coping. 2010 , 19, 184-92	23
977	The ecological validity of everyday cognition in hospitalized patients with serious mental illness. 2010 , 32, 299-308	10
976	Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. 2010 , 36, 211-8	138
975	Progress in defining optimal treatment outcome in schizophrenia. 2010 , 24, 9-20	51
974	[Neuro-anatomic activations of prepotent responses in schizophrenia in Hayling's task]. 2010 , 36, 277-84	7
973	Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat. 2010 , 208, 132-6	38

972	Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. 2010 , 214, 240-7		37
971	Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. 2010 , 34, 463-8		40
970	Impaired MMN/P3a complex in first-episode psychosis: cognitive and psychosocial associations. 2010 , 34, 822-9		121
969	Deficient inhibition of return in chronic but not first-episode patients with schizophrenia. 2010 , 34, 961-7		6
968	Reduced prefrontal cortex activation during divergent thinking in schizophrenia: a multi-channel NIRS study. 2010 , 34, 1327-32		15
967	Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. 2010 , 34, 1333-41		21
966	A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. 2010 , 65, 585-96		326
965	Post weaning social isolation influences spatial cognition, prefrontal cortical synaptic plasticity and hippocampal potassium ion channels in Wistar rats. <i>Neuroscience</i> , 2010 , 169, 214-22	3.9	80
964	The effect of viewpoint on visual stimuli: a study of episodic memory in schizophrenia. <i>Psychiatry Research</i> , 2010 , 176, 126-31	9.9	1
963	Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. <i>Psychiatry Research</i> , 2010 , 178, 57-62	9.9	20
962	Cognitive deficits in nonaffective functional psychoses: a study in the Democratic Republic of Congo. <i>Psychiatry Research</i> , 2010 , 180, 86-92	9.9	9
961	The Social Cognition and Interaction Training (SCIT): an extension to individuals with schizotypal personality features. <i>Psychiatry Research</i> , 2010 , 178, 208-10	9.9	17
960	A qualitative investigation of individual and contextual factors associated with vocational recovery among people with serious mental illness. 2010 , 80, 185-94		39
959	The Letter-Number Sequencing Test and its association with potential to work among people with psychotic illness. 2010 , 25, 101-4		5
958	Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. 2010 , 49, 2783-90		73
957	Aspectos semánticos y pragmáticos en personas con esquizofrenia. 2010 , 30, 84-93		8
956	Isolation rearing impairs novel object recognition and attentional set shifting performance in female rats. 2010 , 24, 57-63		73
955	Prefrontal cortical changes following cognitive training in patients with chronic schizophrenia: effects of practice, generalization, and specificity. 2010 , 35, 1850-9		133

954	Serotonin and Schizophrenia. 2010 , 21, 585-620	11
953	Role of Clozapine in Treatment-Resistant Schizophrenia. 2010 , 114-128	14
952	Trends and Prospects in Metacognition Research. 2010 ,	22
951	Hippocampal pathology in schizophrenia. 2010 , 4, 529-53	131
950	Evaluation of the clinical efficacy of asenapine in schizophrenia. 2010 , 11, 2107-15	21
949	Animal models of schizophrenia. 2010 , 4, 391-433	62
948	Behavioral Neurobiology of Schizophrenia and Its Treatment. 2010 ,	6
947	The diagnosis of mental disorders: the problem of reification. 2010 , 6, 155-79	584
946	Measurement of functional capacity: a new approach to understanding functional differences and real-world behavioral adaptation in those with mental illness. 2010 , 6, 139-54	38
945	Occupational Balance in People With Schizophrenia. 2010 , 26, 1-17	46
944	Neurophysiological and computational principles of cortical rhythms in cognition. 2010 , 90, 1195-268	1250
943	Gamma oscillatory power is impaired during cognitive control independent of medication status in first-episode schizophrenia. 2010 , 35, 2590-9	176
942	Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. 2010 , 24, 303-17	52
941	¿Estamos estudiando y tratando correctamente la esquizofrenia?. 2011 , 18, 168-178	1
940	Clinical and cognitive correlates of psychiatric comorbidity in delusional disorder outpatients. 2011 , 45, 416-25	20
939	Theory of mind in schizophrenia: exploring neural mechanisms of belief attribution. 2011 , 6, 569-81	58
938	Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. 2011 , 25, 567-620	294
937	Sleep correlates of cognition in early course psychotic disorders. 2011 , 131, 231-4	52

936	Neuropsychological profiles in different at-risk states of psychosis: executive control impairment in the early--and additional memory dysfunction in the late--prodromal state. 2011 , 37, 861-73	105
935	Thinking about the future cognitive remediation therapy--what works and could we do better?. 2011 , 37 Suppl 2, S80-90	163
934	Response inhibition and response monitoring in a saccadic countermanding task in schizophrenia. 2011 , 69, 55-62	221
933	A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. 2011 , 69, 442-9	132
932	Standardization, integration, and sharing-leveraging research investments. 2011 , 70, 5-6	10
931	Schizophrenia: treatment targets beyond monoamine systems. 2011 , 51, 189-209	51
930	Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. 2011 , 45, 93-108	125
929	Vocational rehabilitation improves cognition and negative symptoms in schizophrenia. 2011 , 126, 265-9	30
928	Cognitive and symptomatic predictors of functional disability in schizophrenia. 2011 , 126, 257-64	137
927	Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. 2011 , 125, 267-77	56
926	Executive functioning correctly classified diagnoses in patients with first-episode psychosis: evidence from a 2-year longitudinal study. 2011 , 126, 77-80	16
925	Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. 2011 , 125, 221-35	126
924	Is cognitive enhancement therapy equally effective for patients with schizophrenia and schizoaffective disorder?. 2011 , 125, 291-4	37
923	What can eye movements tell us about Symbol Digit substitution by patients with schizophrenia?. 2011 , 127, 137-43	19
922	Neurocognition, insight into illness and subjective quality-of-life in schizophrenia: what is their relationship?. 2011 , 127, 157-62	59
921	Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. 2011 , 127, 93-9	70
920	Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. 2011 , 128, 61-5	72
919	Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. 2011 , 130, 27-33	35

918	Facial emotion recognition and facial affect display in schizotypal personality disorder. 2011 , 131, 242-9	22
917	Are we studying and treating schizophrenia correctly?. 2011 , 130, 1-10	60
916	Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. 2011 , 132, 1-7	166
915	Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia. 2011 , 132, 165-70	68
914	Relationship of neurocognitive deficits to diagnosis and symptoms across affective and non-affective psychoses. 2011 , 133, 212-7	62
913	Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. 2011 , 41, 225-41	236
912	Schizophr�nie du sujet �: particularit�s cliniques, cognitives et sociales. 2011 , 11, 157-165	1
911	Impact des d�ficits cognitifs dans les activit�s de la vie quotidienne des personnes souffrant de schizophr�nie. 2011 , 169, 171-174	3
910	Subjective quality of life in patients with chronic schizophrenia: relationships between psychosocial and clinical characteristics. 2011 , 52, 171-80	44
909	The state-trait disjunction of anhedonia in schizophrenia: potential affective, cognitive and social-based mechanisms. 2011 , 31, 440-8	125
908	Neurocognition as a predictor of response to evidence-based psychosocial interventions in schizophrenia: what is the state of the evidence?. 2011 , 31, 663-72	66
907	Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population. 2011 , 113, 1-7	11
906	Exploring intermediate phenotypes with EEG: working memory dysfunction in schizophrenia. 2011 , 216, 481-95	40
905	Executive control in chronic schizophrenia: A perspective from manual stimulus-response compatibility task performance. 2011 , 223, 24-9	17
904	Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary study. 2011 , 84, 79-83	11
903	Discovery and development of integrative biological markers for schizophrenia. 2011 , 95, 686-702	25
902	The role of glutamate on the action of antidepressants. 2011 , 35, 1558-68	101
901	Quality of life and cognitive dysfunction in people with schizophrenia. 2011 , 35, 53-9	41

900	Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. 2011 , 35, 78-83		40
899	Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study. 2011 , 35, 1753-64		15
898	Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. 2011 , 35, 1836-40		52
897	Declarative memory deficits and schizophrenia: problems and prospects. 2011 , 96, 544-52		38
896	Learning potential as a predictor of skill acquisition in people with serious mental illness. <i>Psychiatry Research</i> , 2011 , 185, 293-5	9.9	13
895	Associations between substance use, neuropsychological functioning and treatment response in psychosis. <i>Psychiatry Research</i> , 2011 , 186, 190-6	9.9	3
894	Impact of executive function deficits in youth with bipolar I disorder: a controlled study. <i>Psychiatry Research</i> , 2011 , 186, 58-64	9.9	28
893	Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia. <i>Psychiatry Research</i> , 2011 , 187, 49-54	9.9	18
892	Assessment of empathy in first-episode psychosis and meta-analytic comparison with previous studies in schizophrenia. <i>Psychiatry Research</i> , 2011 , 190, 3-8	9.9	82
891	Patterns of association between performance in a natural environment and measures of executive function in people with schizophrenia. <i>Psychiatry Research</i> , 2011 , 187, 1-5	9.9	19
890	Cognition-UPSA score relationships: a further analysis of Silverstein et al. (2010) data and some caveats. <i>Psychiatry Research</i> , 2011 , 187, 424-31	9.9	9
889	The association between verbal memory, processing speed, negative symptoms and functional capacity in schizophrenia. <i>Psychiatry Research</i> , 2011 , 187, 329-34	9.9	17
888	Declarative memory and WCST-64 performance in subjects with schizophrenia and healthy controls. <i>Psychiatry Research</i> , 2011 , 188, 191-6	9.9	6
887	Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status. <i>Psychiatry Research</i> , 2011 , 188, 320-6	9.9	49
886	[Schizophrenia and cognition: long-standing and current issues]. 2011 , 37 Suppl 2, S93-4		
885	[Schizophrenia, psychotropic drugs and cognition]. 2011 , 37 Suppl 2, S137-42		2
884	[What perspectives for cognitive remediation in schizophrenia?]. 2011 , 37 Suppl 2, S155-60		1
883	Neuropsychiatric aspects of schizophrenia. 2011 , 17, 45-51		7

882	Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance. 2011 , 69, 28-34		101
881	Psychological Treatment of Psychosis. 2011 , 666-686		2
880	Quality of life and its predictors in people with schizophrenia. <i>Journal of Medical Investigation</i> , 2011 , 58, 167-74	1.2	34
879	Through a Glass Darkly: Schizophrenia and Functional Brain Imaging. 2011 , 18, 257-274		
878	Pharmacotherapy for treatment-resistant schizophrenia. 2011 , 7, 135-49		42
877	Cognition, dopamine and bioactive lipids in schizophrenia. 2011 , 3, 298-330		38
876	Subjective and Objective Cognitive Dysfunction in Schizophrenia - is there a Link?. 2011 , 2, 148		28
875	Broader visual orientation tuning in patients with schizophrenia. 2011 , 5, 127		36
874	Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia. 2011 , 6, e20469		29
873	Housing status as an independent predictor of functional capacity in patients with schizophrenia. 2011 , 199, 854-60		22
872	FDA Perspective on the DSM-5 approach to classification of "cognitive" disorders. 2011 , 23, 126-31		2
871	Cognitive and clinical factors are associated with service engagement in early-phase schizophrenia spectrum disorders. 2011 , 199, 176-82		23
870	Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. 2011 , 26, 303-10		28
869	Cognitive functioning in recent onset psychosis. 2011 , 199, 367-71		13
868	Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. 2011 , 20, 317-27		39
867	The impact of impaired "Theory of Mind" on social interactions in schizophrenia. 2011 , 17, 511-21		9
866	Tower of London versus real life analogue planning in schizophrenia with disorganization and psychomotor poverty symptoms. 2011 , 17, 474-84		6
865	Processing speed and working memory span: their differential role in superficial and deep memory processes in schizophrenia. 2011 , 17, 485-93		10

- 864 Cognitive remediation therapy for schizophrenia: what is it and does it work?. **2011**, 28, 217-221
- 863 Place de la remédiation cognitive dans le processus de réhabilitation des personnes souffrant de schizophrénie. **2011**, 8, 1-9 1
- 862 Neurocognition, Social Cognition and Functional Outcome in Schizophrenia. **2011**, 67-107 3
- 861 The impact of neurocognitive impairment on occupational recovery of clinically stable patients with bipolar disorder: a prospective study. **2011**, 13, 323-33 77
- 860 Referrers' Perceived Utility and Outcomes of Clinical Neuropsychological Assessment in an Adolescent and Young Adult Public Mental Health Service. **2011**, 46, 15-24 21
- 859 Cannabis and psychometrically-defined schizotypy: use, problems and treatment considerations. *Journal of Psychiatric Research*, **2011**, 45, 548-54 5.2 25
- 858 Environmental enrichment ameliorates phencyclidine-induced cognitive deficits. **2011**, 98, 455-61 9
- 857 Conscious brain, metacognition and schizophrenia. **2016**, 105, 1-8 8
- 856 Bridging the schism of schizophrenia through yoga-Review of putative mechanisms. **2016**, 28, 254-64 17
- 855 An examination of neurocognition and symptoms as predictors of post-hospital community tenure in treatment resistant schizophrenia. *Psychiatry Research*, **2016**, 236, 47-52 9.9 15
- 854 Neurocognition and occupational functioning in schizophrenia spectrum disorders: The MATRICS Consensus Cognitive Battery (MCCB) and workplace assessments. **2016**, 170, 143-9 19
- 853 Nicotine ameliorates schizophrenia-like cognitive deficits induced by maternal LPS exposure: a study in rats. **2016**, 9, 1159-1167 9
- 852 Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study. **2016**, 177, 59-66 47
- 851 Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder. **2016**, 16, 5 7
- 850 Less is more Redux: Scheduled intermittent dosing to protect/prevent cognitive deterioration in schizophrenia. **2016**, 90, 79-81
- 849 Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. **2016**, 46, 1909-21 37
- 848 Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy. **2016**, 233, 2399-410 19
- 847 Metacognition as a Mediating Variable Between Neurocognition and Functional Outcome in First Episode Psychosis. **2017**, 43, 824-832 28

846	Influences of Aerobic Dance on Cognitive Performance in Adults with Schizophrenia. 2016 , 23, 346-356	10
845	The association among smoking, HSV-1 exposure, and cognitive functioning in schizophrenia, bipolar disorder, and non-psychiatric controls. 2016 , 176, 566-571	13
844	Cognitive insight and functional outcome in schizophrenia; a multi-center collaborative study with the specific level of functioning scale-Japanese version. 2016 , 6, 9-14	21
843	The Relational and Item-Specific Encoding Task in Mild Cognitive Impairment and Alzheimer Disease. 2016 , 42, 265-277	6
842	Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile. 2016 , 110, 449-457	5
841	Enhancing Cognitive Training Through Aerobic Exercise After a First Schizophrenia Episode: Theoretical Conception and Pilot Study. 2016 , 42 Suppl 1, S44-52	56
840	An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia. 2016 , 31, 1116-23	9
839	White matter correlates of episodic memory encoding and retrieval in schizophrenia. 2016 , 254, 188-98	9
838	Genetics of cognitive control: Implications for NIMH's research domain criteria initiative. 2016 , 171B, 111-20	9
837	Developmental vitamin D deficiency and schizophrenia: the role of animal models. 2016 , 15, 45-61	21
836	Neuronal effects of nicotine during auditory selective attention in schizophrenia. 2016 , 37, 410-21	10
835	Positive schizotypy and negative schizotypy are associated with differential patterns of episodic memory impairment. 2016 , 5, 35-40	14
834	A pilot randomized controlled trial of the Occupational Goal Intervention method for the improvement of executive functioning in patients with treatment-resistant schizophrenia. <i>Psychiatry Research</i> , 2016 , 245, 148-156	9.9 12
833	Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding. 2016 , 233, 3725-3735	22
832	The impact of cognitive reserve in the outcome of first-episode psychoses: 2-year follow-up study. 2016 , 26, 1638-48	67
831	Validation of the cognitively normal range and below normal range subtypes in chronically hospitalized patients with schizophrenia. 2016 , 5, 28-34	3
830	Formulation of risperidone in floating microparticles to alleviate its extrapyramidal side effects. 2016 , 2, 43-59	9
829	Cognitive remediation for individuals with psychosis: efficacy and mechanisms of treatment effects. 2016 , 46, 3275-3289	17

828	Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. 2016 , 30, 1141-1144	22
827	Microstructural abnormalities of uncinate fasciculus as a function of impaired cognition in schizophrenia: A DTI study. 2016 , 41, 419-26	17
826	The influence of the COMT genotype in the underlying functional brain activity of context processing in schizophrenia and in relatives. 2016 , 71, 176-82	11
825	Cognition and psychopathology in first-episode psychosis: are they related to inflammation?. 2016 , 46, 2133-44	28
824	Quality of Life, Cognition, and Social Cognition in Schizophrenia. 2016 , 25-51	2
823	Beyond Psychopharmacology: Emerging Psychosocial Interventions for Core Symptoms of Schizophrenia. 2016 , 14, 315-327	2
822	Cocaine Use and Sexual Risk Among Individuals With Severe Mental Illness. 2016 , 12, 205-217	4
821	Developing a Virtual Reality-Based Vocational Rehabilitation Training Program for Patients with Schizophrenia. 2016 , 19, 686-691	12
820	Quality of life, autonomy, satisfaction, and costs associated with mental health supported accommodation services in England: a national survey. 2016 , 3, 1129-1137	44
819	Developmental timing and critical windows for the treatment of psychiatric disorders. 2016 , 22, 1229-1238	174
818	Akting up in the GABA hypothesis of schizophrenia: Akt1 deficiency modulates GABAergic functions and hippocampus-dependent functions. 2016 , 6, 33095	14
817	Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study. 2016 , 73, 1239-1248	158
816	Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. 2017 , 43, 872-880	17
815	Neuropsychological and Structural Neuroimaging Endophenotypes in Schizophrenia. 2016 , 1-35	1
814	Adaptation of the Quality Indicator for Rehabilitative Care (QuIRC) for use in mental health supported accommodation services (QuIRC-SA). 2016 , 16, 101	20
813	The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. 2016 , 16, 60	43
812	Association between actigraphy-derived physical activity and cognitive performance in patients with schizophrenia. 2016 , 46, 2375-84	18
811	Proteomic systems evaluation of the molecular validity of preclinical psychosis models compared to schizophrenia brain pathology. 2016 , 177, 98-107	8

810	John S. Strauss and schizophrenia: Early discovery, lasting impact. 2016 , 19, 3-11		1
809	Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia. 2016 , 30, 125-33		12
808	Can Oxytocin Enhance Social Affiliation in Schizophrenia?. 2016 , 3, 131-143		
807	Family-Directed Cognitive Adaptation Pilot: Teaching Cognitive Adaptation to Families of Individuals with Schizophrenia. 2016 , 19, 62-74		4
806	Task-independent effects are potential confounders in longitudinal imaging studies of learning in schizophrenia. 2016 , 10, 159-71		2
805	Clinical outcomes and costs for people with complex psychosis; a naturalistic prospective cohort study of mental health rehabilitation service users in England. 2016 , 16, 95		25
804	Twenty year multi-follow-up of different types of hallucinations in schizophrenia, schizoaffective disorder, bipolar disorder, and depression. 2016 , 176, 371-377		23
803	Factors related to physical violence experienced by parents of persons with schizophrenia in Japan. <i>Psychiatry Research</i> , 2016 , 243, 439-45	9.9	19
802	A structural equation modelling approach to explore the determinants of quality of life in schizophrenia. 2016 , 171, 27-34		52
801	Common and Dissociable Mechanisms of Executive System Dysfunction Across Psychiatric Disorders in Youth. <i>American Journal of Psychiatry</i> , 2016 , 173, 517-26	11.9	125
800	Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia. 2016 , 171, 187-94		26
799	A feasibility study of a new computerised cognitive remediation for young adults with schizophrenia. 2016 , 26, 321-44		13
798	Brexpiprazole for the treatment of schizophrenia. 2016 , 16, 109-22		4
797	Cognitive Impairment in Schizophrenia: Interplay of BDNF and Childhood Trauma? A Review of Literature. 2016 , 87, 559-69		9
796	Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives. 2016 , 170, 156-61		24
795	Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia. 2016 , 172, 123-30		20
794	Frontal slow-wave activity as a predictor of negative symptoms, cognition and functional capacity in schizophrenia. 2016 , 208, 160-7		20
793	The neurobiology of MMN and implications for schizophrenia. 2016 , 116, 90-7		35

792	The Psychosis High-Risk State. 55-68		1
791	Brexpirazole: so far so good. 2016 , 6, 39-54		41
790	Mechanisms of Working Memory Impairment in Schizophrenia. 2016 , 80, 617-26		64
789	Disconnection Between Amygdala and Medial Prefrontal Cortex in Psychotic Disorders. 2016 , 42, 1056-67		32
788	Social functioning in patients with a psychotic disorder and first rank symptoms. <i>Psychiatry Research</i> , 2016 , 237, 147-52	9.9	4
787	[Basic symptoms in schizophrenia, their clinical study and relevance in research]. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016 , 9, 111-22	2.7	5
786	Thought Disorder in Preschool Children with Attention Deficit/Hyperactivity Disorder (ADHD). 2016 , 47, 618-26		0
785	Longitudinal relationship between Personal and Social Performance (PSP) and anxiety symptoms in schizophrenia. 2016 , 190, 12-18		10
784	State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects. 2016 , 102, 244-53		17
783	Different Paths to Core Pathology: The Equifinal Model of the Schizophrenia Syndrome. 2016 , 42, 542-9		25
782	Karolinska Scales of Personality, cognition and psychotic symptoms in patients with schizophrenia and healthy controls. 2016 , 70, 53-61		7
781	Alterations in High-Frequency Neuronal Oscillations in a Cynomolgus Macaque Test of Sustained Attention Following NMDA Receptor Antagonism. 2016 , 41, 1319-28		7
780	Neural Dysfunction in Cognitive Control Circuits in Persons at Clinical High-Risk for Psychosis. 2016 , 41, 1241-50		11
779	Group cognitive remediation therapy for chronic schizophrenia: A randomized controlled trial. 2016 , 626, 106-11		13
778	Smaller than expected cognitive deficits in schizophrenia patients from the population-representative ABC catchment cohort. 2016 , 266, 423-31		5
777	Using human brain imaging studies as a guide toward animal models of schizophrenia. <i>Neuroscience</i> , 2016 , 321, 77-98	3.9	21
776	Functional neuroanatomical correlates of episodic memory impairment in early phase psychosis. 2016 , 10, 1-11		24
775	Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus. 2016 , 100, 90-7		28

774	Psychosocial functioning in first-episode psychosis and associations with neurocognition, social cognition, psychotic and affective symptoms. 2017 , 11, 23-36		37
773	Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. 2017 , 81, 67-77		90
772	Understanding access and use of technology among youth with first-episode psychosis to inform the development of technology-enabled therapeutic interventions. 2017 , 11, 72-76		34
771	Revisiting the bilingual advantage in attention in low SES Greek-Albanians: does the level of bilingual experience matter?. 2017 , 32, 743-756		8
770	Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia. 2017 , 42, 2206-2213		60
769	The relationship of cognitive improvement after cognitive remediation with social functioning in patients with schizophrenia and severe cognitive deficits. 2017 , 185, 154-160		12
768	Repeated Nicotine Strengthens Gamma Oscillations in the Prefrontal Cortex and Improves Visual Attention. 2017 , 42, 1590-1598		11
767	Deficits in reality and internal source monitoring of actions are associated with the positive dimension of schizotypy. <i>Psychiatry Research</i> , 2017 , 250, 44-49	9.9	10
766	Exploring functioning in schizophrenia: Predictors of functional capacity and real-world behaviour. <i>Psychiatry Research</i> , 2017 , 251, 118-124	9.9	42
765	Relationship between serum calcium and neuropsychological performance might indicate etiological heterogeneity underlying cognitive deficits in schizophrenia and depression. <i>Psychiatry Research</i> , 2017 , 252, 80-86	9.9	14
764	Early Intervention in Psychosis in the United States: From Science to Policy Reform. 2017 , 4, 79-87		12
763	Altered cortico-striatal crosstalk underlies object recognition memory deficits in the sub-chronic phencyclidine model of schizophrenia. 2017 , 222, 3179-3190		10
762	Aerobic exercise and its effects on cognition in schizophrenia. 2017 , 30, 171-175		26
761	A Systematic and Meta-analytic Review of Neural Correlates of Functional Outcome in Schizophrenia. 2017 , 43, 1329-1347		45
760	The Key of the Maze: The role of mental imagery and cognitive flexibility in navigational planning. 2017 , 651, 146-150		15
759	Coordinated pluralism as a means to facilitate integrative taxonomies of cognition. 2017 , 20, 129-145		21
758	Neurocognitive deficits in schizophrenia. Are we making mountains out of molehills?. 2017 , 47, 2602-2612		42
757	Modafinil and cognitive enhancement in schizophrenia and healthy volunteers: the effects of test battery in a randomised controlled trial. 2017 , 47, 2358-2368		23

756	Targeting metabotropic glutamate receptors for novel treatments of schizophrenia. 2017 , 10, 15	74
755	Exercise Treatments for Psychosis: A Review. 2017 , 4, 152-166	25
754	Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in schizophrenia. 2017 , 22, 1017-1026	9
753	Hot and cold executive functions in youth with psychotic symptoms. 2017 , 47, 2844-2853	13
752	P50 suppression deficits and psychopathology in Han Chinese patients with schizophrenia. 2017 , 653, 346-350	10
751	A review of cognitive remediation approaches for schizophrenia: from top-down to bottom-up, brain training to psychotherapy. 2017 , 17, 713-723	45
750	The effect of cognitive remediation in individuals at ultra-high risk for psychosis: a systematic review. 2017 , 3, 20	41
749	Immunopathology of the Nervous System. 2017 , 123-219	
748	Challenges and opportunities for the development of new antipsychotic drugs. 2017 , 143, 10-24	20
747	Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study. 2017 , 7, e014938	2
746	Increased temporal discounting after chronic stress in CHL1-deficient mice is reversed by 5-HT _{2C} agonist Ro 60-0175. <i>Neuroscience</i> , 2017 , 357, 110-118	3.9 6
745	Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia. 2017 , 37, 1122-1130 ₁₁	
744	EPICOG-SCH: A brief battery to screen cognitive impact of schizophrenia in stable outpatients. 2017 , 8, 7-20	1
743	Predictors of response to cognitive remediation in service recipients with severe mental illness. 2017 , 40, 61-69	43
742	Linking optic radiation volume to visual perception in schizophrenia and bipolar disorder. 2017 , 190, 102-106	9
741	Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. 2017 , 74, 37-46	127
740	Neurophysiological Characterization of Attentional Performance Dysfunction in Schizophrenia Patients in a Reverse-Translated Task. 2017 , 42, 1338-1348	18
739	Cognitive Skills Training for Homeless Transition-Age Youth: Feasibility and Pilot Efficacy of a Community Based Randomized Controlled Trial. 2017 , 205, 859-866	10

738	PDE Inhibitors for the Treatment of Schizophrenia. 2017 , 17, 385-409	16
737	Design and synthesis of a novel series of (1'S,2R,4'S)-3H-4'-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2'-bicyclo[2.2.2]octanes] with high affinity for the α neuronal nicotinic receptor. 2017 , 27, 5002-5005	2
736	Using game authoring platforms to develop screen-based simulated functional assessments in persons with executive dysfunction following traumatic brain injury. 2017 , 74, 71-84	13
735	Cognitive clustering in schizophrenia patients, their first-degree relatives and healthy subjects is associated with anterior cingulate cortex volume. 2017 , 16, 248-256	31
734	Feasibility and preliminary efficacy of remotely delivering cognitive training to people with schizophrenia using tablets. 2017 , 10, 7-14	12
733	The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. 2017 , 136, 465-472	12
732	The Potential Utility of Ashwagandha for Improving Cognitive Dysfunction in Persons with Bipolar or Other Neurocognitive Disorders. 2017 , 345-371	
731	Pharmacology of cognition: a panacea for neuropsychiatric disease?. 2017 , 174, 3133-3135	5
730	Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics. 2017 , 25, 4904-4916	9
729	Self versus informant reports on the specific levels of functioning scale: Relationships to depression and cognition in schizophrenia and schizoaffective disorder. 2017 , 9, 1-7	13
728	Impaired prefrontal activity to regulate the intrinsic motivation-action link in schizophrenia. 2017 , 16, 32-42	10
727	Assessment of cognitive functions and cerebral blood flow in patients with schizophrenia. 2017 , 24, 36-42	
726	CNS Drug Delivery for Diseases Eradication: An Overview. 2017 , 157-185	
725	Evolving Notions of Schizophrenia as a Developmental Neurocognitive Disorder. 2017 , 23, 881-892	45
724	Cognitive remediation therapy plus standard care versus standard care for people with schizophrenia. 2017 ,	78
723	Sustaining attention to simple visual tasks: a central deficit in schizophrenia? A systematic review. 2017 , 1408, 32-45	13
722	A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. <i>Psychiatry Research</i> , 2017 , 256, 267-274	9.9 40
721	Sustained attention ability in schizophrenia: Investigation of conflict monitoring mechanisms. 2017 , 128, 1599-1607	7

720	A review of Indian research on cognitive remediation for schizophrenia. <i>Asian Journal of Psychiatry</i> , 2017 , 25, 54-59	6.7	5
719	Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics. <i>Psychiatry Research</i> , 2017 , 247, 84-89	9.9	14
718	Lifetime psychopathological dimensions, cognitive impairment and functional outcome in psychosis. 2017 , 179, 30-35		7
717	Altered Expression of ARP2/3 Complex Signaling Pathway Genes in Prefrontal Layer 3 Pyramidal Cells in Schizophrenia. <i>American Journal of Psychiatry</i> , 2017 , 174, 163-171	11.9	21
716	[Social psychiatry and neurobiology : A long overdue convergence exemplified by schizophrenia]. 2017 , 88, 510-519		0
715	A case-matched study of neurophysiological correlates to attention/working memory in people with somatic hypervigilance. 2017 , 39, 84-99		3
714	Insights About Striatal Circuit Function and Schizophrenia From a Mouse Model of Dopamine D Receptor Upregulation. 2017 , 81, 21-30		26
713	Evidence for a differential contribution of early perceptual and late cognitive processes during encoding to episodic memory impairment in schizophrenia. 2017 , 18, 369-381		6
712	A dimensional approach to modeling symptoms of neuropsychiatric disorders in the marmoset monkey. 2017 , 77, 328-353		33
711	Prefrontal cortical GABAergic and NMDA glutamatergic regulation of delayed responding. 2017 , 113, 10-20		17
710	Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. 2017 , 56, 493-503		29
709	Emotional Intelligence and cognitive abilities - associations and sex differences. 2017 , 22, 1001-1010		17
708	Heritability of Neuropsychological Measures in Schizophrenia and Nonpsychiatric Populations: A Systematic Review and Meta-analysis. 2017 , 43, 788-800		42
707	The Genetics of Cognition in Schizophrenia: Combining Mouse and Human Studies. 2017 , 115-142		
706	Advances in Theoretical, Developmental, and Cross-Cultural Perspectives of Psychopathology. 2017 , 293-342		1
705	Preliminary study of neurocognitive differences in attention and fluency in Schizophrenia using fNIRS. 2017 ,		
704	Refs. 2017 , 423-494		
703	Rehabilitation in Schizophrenia: A Brain-behavior and Psychosocial Perspective. 2017 , 39, 797-799		3

702	Symptomatic Remission and Counterfactual Reasoning in Schizophrenia. 2016 , 7, 2048		5
701	Biclustered Independent Component Analysis for Complex Biomarker and Subtype Identification from Structural Magnetic Resonance Images in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2017 , 8, 179	5	14
700	A Brief Assessment of Intelligence Decline in Schizophrenia As Represented by the Difference between Current and Premorbid Intellectual Quotient. <i>Frontiers in Psychiatry</i> , 2017 , 8, 293	5	22
699	Functional Connectivity of Cognitive Brain Networks in Schizophrenia during a Working Memory Task. <i>Frontiers in Psychiatry</i> , 2017 , 8, 294	5	21
698	Cognitive Training in Schizophrenia. 2017 , 493-530		1
697	Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment. 2017 , 11, 106		26
696	Schizophrenia: What's Arc Got to Do with It?. 2017 , 11, 181		11
695	Immediate-Early Genes Modulation by Antipsychotics: Translational Implications for a Putative Gateway to Drug-Induced Long-Term Brain Changes. 2017 , 11, 240		22
694	Transcranial Direct Current Stimulation over the Dorsolateral Prefrontal Cortex in Schizophrenia: A Quantitative Review of Cognitive Outcomes. 2017 , 11, 44		31
693	Cognitive Pragmatic Rehabilitation Program in Schizophrenia: A Single Case fMRI Study. 2017 , 2017, 1612078		15
692	Verbal memory improvement in first-episode psychosis - δ carriers: a pleiotropic effect?. 2017 , 13, 2945-2953	5	
691	Screening homeless Veterans for a voluntary money management skills training program. 2017 , 20, 369-380		
690	Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition. 2018 , 8, 58		4
689	Factors Associated with Changes in Community Ability and Recovery After Psychiatric Rehabilitation: A Retrospective Study. 2018 , 54, 1221-1227		4
688	Distinct patterns of blood oxygenation in the prefrontal cortex in clinical phenotypes of schizophrenia and bipolar disorder. 2018 , 234, 45-53		5
687	Emotional context restores cortical prediction error responses in schizophrenia. 2018 , 197, 434-440		2
686	What accounts for poor functioning in people with schizophrenia: a re-evaluation of the contributions of neurocognitive v. attitudinal and motivational factors. 2018 , 48, 2776-2785		29
685	The dynamics of disordered dialogue: Prefrontal, hippocampal and thalamic miscommunication underlying working memory deficits in schizophrenia. 2018 , 2,		25

684	Roadblocks to driving cognitive gains through transcranial electrical stimulation. 2018 , 199, 44-45	1
683	Mapping pathologic circuitry in schizophrenia. 2018 , 150, 389-417	22
682	Reduced pupil dilation during action preparation in schizophrenia. 2018 , 128, 111-118	10
681	Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge. 2018 , 199, 285-291	25
680	Social cognition moderates the relationship between neurocognition and community functioning in bipolar disorder. 2018 , 235, 7-14	25
679	Time-Dependent Alterations in the Expression of NMDA Receptor Subunits along the Dorsoventral Hippocampal Axis in an Animal Model of Nascent Psychosis. 2018 , 9, 2241-2251	2
678	Reverse translated and gold standard continuous performance tests predict global cognitive performance in schizophrenia. 2018 , 8, 80	8
677	Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia. <i>Psychiatry Research</i> , 2018 , 263, 1-6	9.9 37
676	Psychotic Symptoms and Attitudes toward Medication Mediate the Effect of Insight on Personal-Social Functions in Patients with Schizophrenia: One-Year Randomized Controlled Trial and Follow-Up. 2018 , 51, 167-176	2
675	Ketamine Alters Lateral Prefrontal Oscillations in a Rule-Based Working Memory Task. 2018 , 38, 2482-2494	16
674	Selective noradrenaline reuptake inhibitors for schizophrenia. 2018 , 1, CD010219	4
673	Long-range gamma phase synchronization as a compensatory strategy during working memory in high-performing patients with schizophrenia. 2018 , 40, 663-681	4
672	L'Évaluation des répercussions fonctionnelles des altérations de la cognition sociale favorise-t-elle l'engagement dans les soins des personnes ayant des troubles psychotiques?. 2018 , 176, 94-99	
671	Subcortical association with memory performance in schizophrenia: a structural magnetic resonance imaging study. 2018 , 8, 20	23
670	Brain Responses at Encoding Predict Limited Verbal Memory Retrieval by Persons with Schizophrenia. 2018 , 33, 477-490	3
669	Role of subcortical structures on cognitive and social function in schizophrenia. 2018 , 8, 1183	43
668	How can genetics help understand the relationship between cognitive dysfunction and schizophrenia?. 2018 , 59, 26-31	7
667	The research evidence for schizophrenia as a neurodevelopmental disorder. 2018 , 59, 49-58	23

666	Pathways to functional outcomes following a first episode of psychosis: The roles of premorbid adjustment, verbal memory and symptom remission. 2018 , 52, 793-803		18
665	Cognition, social cognition and functional disability in early-stage schizophrenia: A study from southern India. <i>Psychiatry Research</i> , 2018 , 265, 231-237	9.9	3
664	Comparing predictors of employment in Individual Placement and Support: A longitudinal analysis. <i>Psychiatry Research</i> , 2018 , 264, 85-90	9.9	14
663	Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. 2018 , 199, 395-402		50
662	Feasibility and effectiveness of a cognitive remediation programme with original computerised cognitive training and group intervention for schizophrenia: a multicentre randomised trial. 2018 , 28, 387-397		8
661	Feasibility and effectiveness of cognitive remediation in the treatment of borderline personality disorder. 2018 , 28, 416-428		8
660	Impaired verbal learning in forensic inpatients with Schizophrenia Spectrum Disorder. 2018 , 25, 189-196		1
659	Telomere Length and CCL11 Levels are Associated With Gray Matter Volume and Episodic Memory Performance in Schizophrenia: Evidence of Pathological Accelerated Aging. 2018 , 44, 158-167		26
658	Electrophysiological correlates of adaptive control and attentional engagement in patients with first episode schizophrenia and healthy young adults. 2018 , 55, e12820		18
657	Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. 2018 , 193, 119-125		14
656	Relationship between effortful motivation and neurocognition in schizophrenia. 2018 , 193, 69-76		33
655	Cognitive function in early psychosis patients from a lower middle-income country. 2018 , 22, 13-18		4
654	Social Disconnection in Schizophrenia and the General Community. 2018 , 44, 242-249		42
653	White matter microstructure predicts cognitive training-induced improvements in attention and executive functioning in schizophrenia. 2018 , 193, 276-283		25
652	Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M PAM VU0467154. 2018 , 128, 492-502		21
651	The association between cardio-respiratory fitness and cognition in schizophrenia. 2018 , 193, 418-422		9
650	Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology. 2018 , 235, 447-458		18
649	N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. 2018 , 44, 317-327		83

648	White matter microstructure and cognitive remediation outcomes in schizophrenia. 2018 , 195, 76-77		1
647	Play and playfulness in psychiatry: a selective review. 2018 , 7, 210-225		8
646	Association between mismatch negativity and global functioning is specific to duration deviance in early stages of psychosis. 2018 , 195, 378-384		23
645	Considering the role of adolescent sex steroids in schizophrenia. 2018 , 30, e12538		12
644	Detecting allocentric and egocentric navigation deficits in patients with schizophrenia and bipolar disorder using virtual reality. 2018 , 28, 398-415		8
643	Deficits in visual working-memory capacity and general cognition in African Americans with psychosis. 2018 , 193, 100-106		4
642	Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia. 2018 , 44, 369-377		22
641	Effectiveness of a low support, remotely accessible, cognitive remediation training programme for chronic psychosis: cognitive, functional and cortical outcomes from a single blind randomised controlled trial. 2018 , 48, 751-764		14
640	A 10-minute measure of global cognition: Validation of the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS). 2018 , 195, 327-333		5
639	Positive allosteric modulation of M and M muscarinic receptors as potential therapeutic treatments for schizophrenia. 2018 , 136, 438-448		21
638	Maternal immune activation in neurodevelopmental disorders. 2018 , 247, 588-619		68
637	Details of attention and learning change in first-episode schizophrenia. <i>Psychiatry Research</i> , 2018 , 260, 324-330	9.9	7
636	Short term effects of brief need based psychoeducation on knowledge, self-stigma, and burden among siblings of persons with schizophrenia: A prospective controlled trial. <i>Asian Journal of Psychiatry</i> , 2018 , 32, 59-66	6.7	12
635	Altered Gradients of Glutamate and Gamma-Aminobutyric Acid Transcripts in the Cortical Visuospatial Working Memory Network in Schizophrenia. 2018 , 83, 670-679		32
634	Differentiating between clinical and behavioral phenotypes in first-episode psychosis during maintenance of visuospatial working memory. 2018 , 197, 357-364		9
633	The Screen for Cognitive Impairment in Psychiatry: Proposal for a polytomous scoring system. 2018 , 27, e1598		9
632	Exploring the Temporal Relationship Between Cognitive Insight and Neurocognition in Schizophrenia: A Prospective Analysis. 2018 , 6, 76-89		6
631	Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood. 2018 , 235, 651-661		16

630	Mismatch Negativity But Not P300 Is Associated With Functional Disability in Schizophrenia. 2018 , 44, 492-504		27
629	Mismatch negativity in preclinical models of schizophrenia. 2018 , 191, 35-42		29
628	A Reliable and Valid Assessment of Sustained Attention for Patients With Schizophrenia: The Computerized Digit Vigilance Test. 2018 , 33, 227-237		4
627	Avoidance of accelerated aging in schizophrenia?: Clinical and biological characterization of an exceptionally high functioning individual. 2018 , 196, 45-52		3
626	Assessing the Relationship between Performance on the University of California Performance Skills Assessment (UPSA) and Outcomes in Schizophrenia: A Systematic Review and Evidence Synthesis. 2018 , 2018, 9075174		4
625	Neuropsychological Functioning in Euthymic Phase of Bipolar Affective Disorder. 2018 , 40, 213-218		5
624	Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning. 2018 , 61, 91-102		33
623	Cognitive Impairment in Schizophrenia: Description and Cognitive Familiar Endophenotypes. A Review of the Literature. 2018 ,		2
622	Developing a dynamic model of anomalous experiences and function in young people with or without psychosis: a cross-sectional and longitudinal study protocol. 2018 , 8, e022546		3
621	Continuous performance test impairment in a 22q11.2 microdeletion mouse model: improvement by amphetamine. 2018 , 8, 247		13
620	Effects of Aerobic Exercise on Metabolic Syndrome, Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased Mortality. <i>Frontiers in Psychiatry</i> , 2018 , 9, 690	5	26
619	Therapeutic responses to a frontal/executive programme in autism spectrum disorder: Comparison with schizophrenia. 2018 , 31, 69-75		
618	Genetic Overlap between General Cognitive Function and Schizophrenia: A Review of Cognitive GWASs. 2018 , 19,		24
617	Relationships among functional capacity, cognition, and naturalistic skill performance in people with serious mental illness. <i>Psychiatry Research</i> , 2018 , 270, 453-458	9.9	4
616	Relationship between social and cognitive functions in people with schizophrenia. 2018 , 14, 2215-2224		8
615	Nicotine improves probabilistic reward learning in wildtype but not alpha7 nAChR null mutants, yet alpha7 nAChR agonists do not improve probabilistic learning. 2018 , 28, 1217-1231		2
614	The Role of Cholinergic Midbrain Neurons in Startle and Prepulse Inhibition. 2018 , 38, 8798-8808		30
613	Interdisciplinary Rehabilitation to Facilitate Recovery of People Living with Long-Term Schizophrenia in Developing Countries. 2018 ,		1

612	Impaired associative inference in the early stage of psychosis. 2018 , 202, 86-90		11
611	Single transcranial direct current stimulation in schizophrenia: Randomized, cross-over study of neurocognition, social cognition, ERPs, and side effects. 2018 , 13, e0197023		21
610	Menstrual cycle irregularity and menopause status influence cognition in women with schizophrenia. 2018 , 96, 173-178		14
609	What can we learn about brain donors? Use of clinical information in human postmortem brain research. 2018 , 150, 181-196		1
608	Premorbid adjustment predictors of cognitive dysfunction in schizophrenia. <i>Psychiatry Research</i> , 2018 , 267, 249-255	9.9	7
607	Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care. 2018 , 202, 378-384		29
606	Cognitive Remediation in Middle-Aged or Older Inpatients with Chronic Schizophrenia: A Randomized Controlled Trial in Korea. 2017 , 8, 2364		4
605	Early Intervention and a Direction of Novel Therapeutics for the Improvement of Functional Outcomes in Schizophrenia: A Selective Review. <i>Frontiers in Psychiatry</i> , 2018 , 9, 39	5	14
604	Semantic Memory Organization in Japanese Patients With Schizophrenia Examined With Category Fluency. <i>Frontiers in Psychiatry</i> , 2018 , 9, 87	5	7
603	Neural Correlates for Intrinsic Motivational Deficits of Schizophrenia; Implications for Therapeutics of Cognitive Impairment. <i>Frontiers in Psychiatry</i> , 2018 , 9, 178	5	4
602	PV Interneurons: Critical Regulators of E/I Balance for Prefrontal Cortex-Dependent Behavior and Psychiatric Disorders. 2018 , 12, 37		212
601	Cognitive Functions and Neurodevelopmental Disorders Involving the Prefrontal Cortex and Mediodorsal Thalamus. 2018 , 12, 33		53
600	Predicting work outcome in patients with schizophrenia: Influence of IQ decline. 2018 , 201, 172-179		8
599	Controversies in Computerized Cognitive Training. 2018 , 3, 907-915		36
598	Impaired neuropsychological profile in homicide offenders with schizophrenia. 2018 , 85, 55-60		8
597	Role of frontal white matter and corpus callosum on social function in schizophrenia. 2018 , 202, 180-187		30
596	Acute ketamine dysregulates task-related gamma-band oscillations in thalamo-cortical circuits in schizophrenia. 2018 , 141, 2511-2526		27
595	Serum levels of ̢-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study. 2018 , 14, 799-808		3

594	The role of functional capacity in the prediction of occupational status in schizophrenia. 2018 , 13, 1-2	0
593	Cognitive reserve as an outcome predictor: first-episode affective versus non-affective psychosis. 2018 , 138, 441-455	42
592	An approach to directly link ICA and seed-based functional connectivity: Application to schizophrenia. 2018 , 179, 448-470	17
591	A multicenter, randomized controlled trial of individualized occupational therapy for patients with schizophrenia in Japan. 2018 , 13, e0193869	14
590	Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses. 2018 , 201, 105-112	34
589	The Social Functioning Scale for Alzheimer's Disease: A Short Informant-based Measure of Functional Status in Patients with Alzheimer's Disease in Taiwan. 2019 , 34, 445-454	
588	Impaired GAD1 expression in schizophrenia-related WISKET rat model with sex-dependent aggressive behavior and motivational deficit. 2019 , 18, e12507	7
587	Meta-analysis of physical activity and effects of social function and quality of life on the physical activity in patients with schizophrenia. 2019 , 269, 517-527	16
586	Impaired Prefrontal Cortical Dopamine Release in Schizophrenia During a Cognitive Task: A [11C]FLB 457 Positron Emission Tomography Study. 2019 , 45, 670-679	22
585	Determinants of Employment Outcome for the People with Schizophrenia Using the WHODAS 2.0. 2019 , 29, 375-383	7
584	Alterations in cortical interneurons and cognitive function in schizophrenia. 2019 , 131, 104208	101
583	Comparison of the neurocognitive profiles of individuals with elevated psychotic or depressive symptoms. 2019 , 13, 928-934	2
582	Neurocognitive profiles in the prodrome to psychosis in NAPLS-1. 2019 , 204, 311-319	17
581	Neurocognition and adaptive functioning in a genetic high risk model of schizophrenia. 2019 , 49, 1047-1054	7
580	Prevalence of attention deficit hyperactivity disorder symptoms in patients with schizophrenia. 2019 , 139, 89-96	6
579	and Natural Galphimines Block Schizophrenia-Like Symptoms Induced with Apomorphine and MK-801 in Mice. 2019 , 2019, 8404258	2
578	Hippocampal Dysfunction in Schizophrenia and Aberrant Hippocampal Synaptic Plasticity in Rodent Model Psychosis: a Selective Review. 2019 , 46,	2
577	Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. 2019 , 86, 153-196	5

576	Examination of relational memory in multidimensional schizotypy. 2019 , 211, 36-43		5
575	Meta-analysis of cognitive function in Chinese first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) profile of impairment. 2019 , 32, e100043		25
574	The Hyperfocusing Hypothesis: A New Account of Cognitive Dysfunction in Schizophrenia. 2019 , 45, 991-1000	29	
573	Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): a feasibility study. 2019 , 5, 79		
572	Effects of Tobacco Smoking Status on Verbal Learning and Memory in Patients With Schizophrenia and Non-Psychiatric Controls. 2019 , 28, 503-511		3
571	Factors Associated With Psychosocial Functioning and Outcome of Individuals With Recent-Onset Schizophrenia and at Ultra-High Risk for Psychosis. <i>Frontiers in Psychiatry</i> , 2019 , 10, 459	5	7
570	Visuospatial task-related prefrontal activity is correlated with negative symptoms in schizophrenia. 2019 , 9, 9575		6
569	Neural changes following cognitive remediation therapy for schizophrenia. 2019 , 73, 676-684		12
568	Early Substance Use Cessation Improves Cognition-10 Years Outcome in First-Episode Psychosis Patients. <i>Frontiers in Psychiatry</i> , 2019 , 10, 495	5	4
567	Disrupted Habituation in the Early Stage of Psychosis. 2019 , 4, 1004-1012		16
566	Baseline Frontoparietal Task-Related BOLD Activity as a Predictor of Improvement in Clinical Symptoms at 1-Year Follow-Up in Recent-Onset Psychosis. <i>American Journal of Psychiatry</i> , 2019 , 176, 839-845	11.9	9
565	Impaired relational memory in the early stage of psychosis. 2019 , 212, 113-120		11
564	Evaluating visual neuroplasticity with EEG in schizophrenia outpatients. 2019 , 212, 40-46		10
563	Computer-assisted cognitive remediation therapy for patients with schizophrenia induces microstructural changes in cerebellar regions involved in cognitive functions. 2019 , 292, 41-46		3
562	Neuro-cognitive correlates of alexithymia in patients with circumscribed prefrontal cortex damage. 2019 , 135, 107228		1
561	The genetic relationship between educational attainment and cognitive performance in major psychiatric disorders. 2019 , 9, 210		7
560	Cognitive functioning in patients with first-episode psychosis stratified by level of negative symptoms: A 1-year follow-up study. <i>Psychiatry Research</i> , 2019 , 281, 112554	9.9	6
559	Occipital Alpha Connectivity During Resting-State Electroencephalography in Patients With Ultra-High Risk for Psychosis and Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019 , 10, 553	5	12

558	Factors Associated With Response and Resistance to Cognitive Remediation in Schizophrenia: A Critical Review. 2018 , 9, 1542	13
557	Body language reading of emotion and outcome in schizophrenia. 2019 , 24, 54-64	5
556	Mismatch negativity reveals plasticity in cortical dynamics after 1-hour of auditory training exercises. 2019 , 145, 40-47	17
555	The Audio-Visual Abnormalities Questionnaire (AVAQ): Development and validation of a new instrument for assessing anomalies in sensory perception in schizophrenia spectrum disorders. 2019 , 209, 227-233	6
554	The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence. 2019 , 86, 502-511	23
553	Functional deficits in attenuated psychosis syndrome and related conditions: Current and future treatment options. 2019 , 17, 100152	4
552	Physician's Field Guide to Neuropsychology. 2019 ,	0
551	Bipolar and psychotic disorders in elite athletes: a narrative review. 2019 , 53, 746-753	26
550	Mental health in elite athletes: International Olympic Committee consensus statement (2019). 2019 , 53, 667-699	302
549	Nonsocial and social cognition in schizophrenia: current evidence and future directions. 2019 , 18, 146-161	182
548	Event-Related Potentials in Response to Facial Affect Recognition in Patients with Schizophrenia. 2019 , 51, 43-50	1
547	Enhancing neural efficiency of cognitive processing speed via training and neurostimulation: An fNIRS and TMS study. 2019 , 198, 73-82	25
546	Effect of adding individualized occupational therapy to standard care on rehospitalization of patients with schizophrenia: A 2-year prospective cohort study. 2019 , 73, 476-485	4
545	Impact of social cognitive deficits on community functioning. 2019 , 89-123	1
544	Neural and neuronal discoordination in schizophrenia: From ensembles through networks to symptoms. 2019 , 226, e13282	12
543	Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. 2019 , 142, 1813-1826	32
542	Cognitive impairment and its improvement after six months in adolescents with schizophrenia. 2019 , 17, 100135	4
541	Childhood Trauma in Schizophrenia: Current Findings and Research Perspectives. 2019 , 13, 274	40

540	Longitudinal trajectory of early functional recovery in patients with first episode psychosis. 2019 , 209, 234-244		24
539	A Randomized Controlled Trial of Executive Functioning Training Compared With Perceptual Training for Schizophrenia Spectrum Disorders: Effects on Neurophysiology, Neurocognition, and Functioning. <i>American Journal of Psychiatry</i> , 2019 , 176, 297-306	11.9	23
538	Reward-related decision-making in schizophrenia: A multimodal neuroimaging study. 2019 , 286, 45-52		6
537	Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress. <i>Frontiers in Psychiatry</i> , 2019 , 10, 93	5	28
536	Evaluation of the efficacy of transcranial direct current stimulation in the treatment of cognitive symptomatology in the early stages of psychosis: study protocol for a double-blind randomized controlled trial. 2019 , 20, 199		1
535	Intelligence decline between present and premorbid IQ in schizophrenia: Schizophrenia Non-Affected Relative Project (SNARP). 2019 , 29, 653-661		9
534	Cognitive Functioning in Older Adults with Schizophrenia. 2019 , 69-78		
533	Association between decreased serum TBIL concentration and immediate memory impairment in schizophrenia patients. 2019 , 9, 1622		3
532	The effect of rehabilitation combined with cognitive remediation on functioning in persons with severe mental illness: systematic review and meta-analysis. 2019 , 49, 1414-1425		19
531	Frontal slow wave resting EEG power is higher in individuals at Ultra High Risk for psychosis than in healthy controls but is not associated with negative symptoms or functioning. 2019 , 208, 293-299		3
530	Development and testing of a web-based battery to remotely assess cognitive health in individuals with schizophrenia. 2019 , 208, 250-257		8
529	Serotonin and Glutamate Interactions in Preclinical Schizophrenia Models. 2019 , 10, 3068-3077		15
528	Perspectives about Illness, Attitudes, and Caregiving Experiences among Siblings of Persons with Schizophrenia: A Qualitative Analysis. 2019 , 41, 413-419		1
527	Evaluation of Antipsychotic Activity of Ethanolic Extract of Dhatryadi Ghrita on Wistar Rats. 2019 , 8, 213-237		
526	Novel Protein-Protein Interaction Network of Antipsychotic Drugs and Cognitive Function. 2019 ,		1
525	Protocolo de asistencia clínica en la psicosis. 2019 , 12, 5075-5080		
524	P.671 Efficacy and safety of lumateperone tosylate 42mg in the treatment of schizophrenia: A pooled analysis of phase 2 and 3 studies. 2019 , 29, S453-S454		4
523	P.668 Visual working memory as a possible endophenotypic schizophrenia marker. 2019 , 29, S452-S453		

522	Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid. 2019 , 19, 309		7
521	Oligodendrocytes as A New Therapeutic Target in Schizophrenia: From Histopathological Findings to Neuron-Oligodendrocyte Interaction. 2019 , 8,		30
520	Role of Executive Function in Response to a Problem Solving Based Psychoeducational Intervention in Adolescents with Psychosis: The PIENSA Trial Revisited. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	1
519	Important unanswered questions about adult neurogenesis in schizophrenia. 2019 , 32, 170-178		13
518	Daily Functioning in Schizophrenia: Is There Room for Anxiety?. 2019 , 207, 615-619		3
517	Brain Abnormalities in Different Phases of Working Memory in Schizophrenia: An Integrative Multi-Modal MRI Study. 2019 , 207, 760-767		3
516	P.670 Cognitive cluster trajectories in first-episode psychosis. 2019 , 29, S453		
515	Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia. 2019 , 21, 349-356		30
514	Simulated car driving and its association with cognitive abilities in patients with schizophrenia. 2019 , 204, 171-177		9
513	Cognitive training improves the disturbed behavioral architecture of schizophrenia-like rats, "Wisket". 2019 , 201, 70-82		6
512	Reliability and Validity of a Brief Version of the Intolerance of Uncertainty Scale in Outpatients with Psychosis. 2019 , 41, 221-234		3
511	Pharmacoinformatics and molecular docking reveal potential drug candidates against Schizophrenia to target TAAR6. 2019 , 234, 13263-13276		2
510	Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis. 2019 , 31, 36-45		11
509	Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection. 2019 , 97, 47-69		15
508	Effects of age on attention level: changes in performance between the ages of 12 and 90. 2019 , 26, 904-919		4
507	Objective psychosocial function vs. subjective quality-of-life in schizophrenia within 5-years after diagnosis: A study from southern India. <i>Psychiatry Research</i> , 2019 , 272, 419-424	9.9	7
506	Cognitive, Work and Social Outcomes in Fully Recovered First-Episode Schizophrenia: On and Off Antipsychotic Medication. 2019 , 82, 42-56		2
505	A randomized controlled trial of cognitive remediation for a national cohort of forensic patients with schizophrenia or schizoaffective disorder. 2019 , 19, 27		20

504	A pilot study investigating the effect of transcranial direct current stimulation on the electrophysiological correlates of working memory in patients with schizophrenia. 2019 , 284, 9-12	1
503	Valence-related impairments in the retrieval of specific autobiographical memories amongst patients with schizophrenia. 2019 , 58, 140-153	8
502	Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer's disease and schizophrenia: Insights from studies in patient populations and animal models. 2019 , 97, 112-137	28
501	Overestimated function in patients with schizophrenia: A possible risk factor for inadequate support?. 2019 , 206, 194-199	3
500	Raloxifene as a treatment for cognition in women with schizophrenia: the influence of menopause status. 2019 , 100, 113-119	13
499	Memory and cognition in schizophrenia. 2019 , 24, 633-642	72
498	High delusional ideation is associated with false pictorial memory. 2019 , 62, 97-102	2
497	Brief executive function training for individuals with severe mental illness: Effects on EEG synchronization and executive functioning. 2019 , 203, 32-40	13
496	Localization and Elimination of Attentional Dysfunction in Schizophrenia During Visual Search. 2019 , 45, 96-105	6
495	Measuring disorganized speech in schizophrenia: automated analysis explains variance in cognitive deficits beyond clinician-rated scales. 2019 , 49, 440-448	18
494	Effects of cognitive remediation therapy versus other interventions on cognitive functioning in schizophrenia inpatients. 2019 , 29, 477-488	14
493	Executive Functions and Social Cognition in Juveniles Who Have Sexually Offended. 2020 , 32, 179-202	3
492	A meta-analytic review of the relationship between neurocognition, metacognition and functional outcome in schizophrenia. 2020 , 29, 496-505	17
491	Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning. 2020 , 14, 106-114	10
490	Intrinsic Connectivity of the Globus Pallidus: An Uncharted Marker of Functional Prognosis in People With First-Episode Schizophrenia. 2020 , 46, 184-192	9
489	An examination of the moderating effects of neurophysiology on treatment outcomes from cognitive training in schizophrenia-spectrum disorders. 2020 , 154, 59-66	1
488	Improvement of cognitive function in schizophrenia with -acetylcysteine: A theoretical review. 2020 , 23, 139-148	18
487	Metacognition over time is related to neurocognition, social cognition, and intrapsychic foundations in psychosis. 2020 , 19, 100149	6

486	Synaptic biomarker reduction and impaired cognition in the sub-chronic PCP mouse model for schizophrenia. 2020 , 34, 115-124	7
485	Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure. 2020 , 50, 2452-2459	4
484	Motivation and engagement during cognitive training for schizophrenia spectrum disorders. 2020 , 19, 100151	8
483	Neuropsychological, clinical and environmental predictors of severe mental disorders in offspring of patients with schizophrenia. 2020 , 270, 739-748	2
482	Predicting psychosis risk using a specific measure of cognitive control: a 12-month longitudinal study. 2020 , 50, 2230-2239	5
481	Amelioration of cognitive impairments induced by GABA hypofunction in the male rat prefrontal cortex by direct and indirect dopamine D agonists SKF-81297 and d-Govadine. 2020 , 162, 107844	5
480	Cognitive Remediation to Improve Functional Outcome. 2020 , 395-418	2
479	Volatility Estimates Increase Choice Switching and Relate to Prefrontal Activity in Schizophrenia. 2020 , 5, 173-183	15
478	Cognitive performance of the MAM-E17 schizophrenia model rats in different age-periods. 2020 , 379, 112345	1
477	Is Utena's Brief Objective Measures (UBOM) useful in real-world behavioral assessment of functioning? Validity and utility testing in patients with schizophrenia. 2020 , 74, 40-48	1
476	Community transition at younger ages contributes to good cognitive function outcomes in long-term hospitalized patients with schizophrenia spectrum disorder: A 15-year follow-up study with group-based trajectory modeling. 2020 , 74, 105-111	2
475	Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia. 2020 , 35, 89-97	3
474	Deciphering midbrain mechanisms underlying prepulse inhibition of startle. 2020 , 185, 101734	13
473	Deviation from expected cognitive ability is a core cognitive feature of schizophrenia related to neurophysiologic, clinical and psychosocial functioning. 2020 , 215, 300-307	9
472	Independent support for corticopallidal contributions to schizophrenia-related functional impairment. 2020 , 216, 168-174	3
471	One-Year Stability of Frontoparietal Cognitive Control Network Connectivity in Recent Onset Schizophrenia: A Task-Related 3T fMRI Study. 2020 ,	6
470	Susceptibility to distraction during analogical reasoning in schizophrenia. 2020 , 20, 100170	0
469	Cognitive Effects of Combined Amisulpride and Quetiapine Treatment in Patients With Refractory Schizophrenia: A Naturalistic, Prospective Study. 2020 , 27, e346-e355	1

468	Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling. 2020 , 188, 172839		16
467	A longitudinal comparison of two neurocognitive test batteries in patients with schizophrenia and healthy volunteers: Time effects on neuropsychological performance and their relation to functional outcome. 2020 , 216, 347-356		4
466	Effect of multi-session prefrontal transcranial direct current stimulation on cognition in schizophrenia: A systematic review and meta-analysis. 2020 , 216, 367-373		18
465	Utility of the MoCA for cognitive impairment screening in long-term psychosis patients. 2020 , 216, 429-434		7
464	The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. 2020 , 19, 43-57		19
463	Disruptions of frontoparietal control network and default mode network linking the metacognitive deficits with clinical symptoms in schizophrenia. 2020 , 41, 1445-1458		10
462	The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. 2020 , 19, 100161		0
461	Abnormal Spontaneous Gamma Power Is Associated With Verbal Learning and Memory Dysfunction in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020 , 11, 832	5	8
460	An ecologically sensitive measure of executive cognition (the Breakfast Task) improves prediction of functional outcome in schizophrenia. 2020 , 1-8		
459	Severe Mental Disorder and Terrorism:When Psychosis, PTSD and Addictions Become a Vulnerability. 2020 , 31, 950-970		4
458	N-Acetylcysteine Inhibits Kynurenine Aminotransferase II. <i>Neuroscience</i> , 2020 , 444, 160-169	3.9	9
457	Cognition in offspring of parents with psychotic and non-psychotic severe mental illness. <i>Journal of Psychiatric Research</i> , 2020 , 130, 306-312	5.2	1
456	Gamma oscillations predict pro-cognitive and clinical response to auditory-based cognitive training in schizophrenia. 2020 , 10, 405		15
455	Memory Impairments and Psychosis Prediction: A Scoping Review and Theoretical Overview. 2020 , 30, 521-545		5
454	Differing functional mechanisms underlie cognitive control deficits in psychotic spectrum disorders. 2020 , 45, 430-440		0
453	Network-based fMRI-neurofeedback training of sustained attention. 2020 , 221, 117194		12
452	The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review. 2020 , 118, 121-133		7
451	Validity and utility of a set of clinical criteria for cognitive impairment associated with psychosis (CIAPs). <i>Psychiatry Research</i> , 2020 , 293, 113404	9.9	2

450	Vocational Profile and Correlates of Employment in People With Schizophrenia: The Role of Avolition. <i>Frontiers in Psychiatry</i> , 2020 , 11, 856	5	3
449	ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder. 2020 , 77, 2114-2132		1
448	Major Neuropsychological Impairments in Schizophrenia Patients: Clinical Implications. 2020 , 22, 59		3
447	Cognitive, community functioning and clinical correlates of the Clinical Assessment Interview for Negative Symptoms (CAINS) in psychotic disorders. 2021 , 271, 1537-1546		4
446	Effects of the number of hospitalizations on cognitive function in Japanese patients with stable schizophrenia. 2020 , 1-6		1
445	A MEG Study of Visual Repetition Priming in Schizophrenia: Evidence for Impaired High-Frequency Oscillations and Event-Related Fields in Thalamo-Occipital Cortices. <i>Frontiers in Psychiatry</i> , 2020 , 11, 561573		1
444	Structural and Functional Connectivity of Visual Cortex in Schizophrenia and Bipolar Disorder: A Graph-Theoretic Analysis. 2020 , 1, sgaa056		3
443	Specificity and Continuity of Schizophrenia and Bipolar Disorder: Relation to Biomarkers. 2020 , 26, 191-200		12
442	Cognitive strengths-based assessment and intervention in first-episode psychosis: A complementary approach to addressing functional recovery?. 2020 , 79, 101871		11
441	Chronic smoking and cognition in patients with schizophrenia: A meta-analysis. 2020 , 222, 113-121		6
440	Computer-based Cognitive Remediation Therapy plus standard care versus standard care for people with schizophrenia or related disorders. 2020 ,		78
439	Motivational and cognitive factors linked to community integration in homeless veterans: study 1 - individuals with psychotic disorders. 2020 , 1-9		2
438	Predictors of life skills in people with schizophrenia. <i>Journal of Medical Investigation</i> , 2020 , 67, 75-82	1.2	
437	Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia. 2020 , 74, 594-601		1
436	Prevalence of possible idiopathic normal pressure hydrocephalus in older inpatients with schizophrenia: a replication study. 2020 , 20, 273		0
435	Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design. 2020 , 21, 492		2
434	Visual exploration differences during relational memory encoding in early psychosis. <i>Psychiatry Research</i> , 2020 , 287, 112910	9.9	3
433	The Relationship Between White Matter Microstructure and General Cognitive Ability in Patients With Schizophrenia and Healthy Participants in the ENIGMA Consortium. <i>American Journal of Psychiatry</i> , 2020 , 177, 537-547	11.9	21

432	Activation of alpha7 nicotinic and NMDA receptors is necessary for performance in a working memory task. 2020 , 237, 1723-1735		15
431	In the Loop: Extrastriatal Regulation of Spiny Projection Neurons by GPR52. 2020 , 11, 2066-2076		2
430	Using prefrontal transcranial direct current stimulation (tDCS) to enhance proactive cognitive control in schizophrenia. 2020 , 45, 1877-1883		9
429	Adolescent cannabinoid exposure interacts with other risk factors in schizophrenia: A review of the evidence from animal models. 2020 , 116, 202-220		6
428	The relationship between plasma levels of clozapine and N-desmethyclozapine as well as M1 receptor polymorphism with cognitive functioning and associated cortical activity in schizophrenia. 2020 , 303, 111128		1
427	Relationships between psychiatric symptoms, functioning and personal recovery in psychosis. 2020 , 223, 112-118		12
426	Aerobic exercise and cognitive functioning in schizophrenia: Results of a 1-year follow-up from a randomized controlled trial. <i>Psychiatry Research</i> , 2020 , 286, 112854	9.9	5
425	Profile of cognitive deficits in schizophrenia and factor structure of the Czech MATRICS Consensus Cognitive Battery. 2020 , 218, 85-92		5
424	Modelling associations between neurocognition and functional course in young people with emerging mental disorders: a longitudinal cohort study. 2020 , 10, 22		8
423	Testing Psychosis Phenotypes From Bipolar-Schizophrenia Network for Intermediate Phenotypes for Clinical Application: Biotype Characteristics and Targets. 2020 , 5, 808-818		13
422	Advancing study of cognitive impairments for antipsychotic-naïve psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology. 2020 , 220, 1-15		4
421	Inflammatory markers are associated with psychomotor slowing in patients with schizophrenia compared to healthy controls. 2020 , 6, 8		7
420	Effects of Psychotic Symptoms and Social Cognition on Job Retention in Patients with Schizophrenia in Korea. 2020 , 17,		0
419	Pathways from performance monitoring to negative symptoms and functional outcomes in psychotic disorders. 2020 , 1-11		3
418	Amphetamine improves rat 5-choice continuous performance test (5C-CPT) irrespective of concurrent low-dose haloperidol treatment. 2020 , 237, 1959-1972		4
417	Serotonin and schizophrenia. 2020 , 31, 711-743		4
416	The Impact of Anticholinergic Burden on Functional Capacity in Persons With Schizophrenia Across the Adult Life Span. 2021 , 47, 249-257		6
415	The Role of Glutamate Neurotransmission in Mismatch Negativity (MMN), A Measure of Auditory Synaptic Plasticity and Change-detection. <i>Neuroscience</i> , 2021 , 456, 106-113	3.9	6

414	High-intensity interval training and active video gaming improve neurocognition in schizophrenia: a randomized controlled trial. 2021 , 271, 339-353		2
413	Relational Memory in the Early Stage of Psychosis: A 2-Year Follow-up Study. 2021 , 47, 75-86		5
412	Effects of Repetitive Transcranial Magnetic Stimulation on Working Memory Performance and Brain Structure in People With Schizophrenia Spectrum Disorders: A Double-Blind, Randomized, Sham-Controlled Trial. 2021 , 6, 449-458		0
411	Better functional capacity and cognitive performance in clozapine responders compared to non-responders: A cross-sectional study. 2021 , 229, 134-136		0
410	Physical- and Cognitive-Effort-Based Decision-Making in Depression: Relationships to Symptoms and Functioning. 2021 , 9, 53-67		5
409	Hierarchical Pathways from Sensory Processing to Cognitive, Clinical, and Functional Impairments in Schizophrenia. 2021 , 47, 373-385		19
408	Non-Invasive Brain Stimulation Does Not Improve Working Memory in Schizophrenia: A Meta-Analysis of Randomised Controlled Trials. 2021 , 31, 115-138		7
407	Cognitive remediation to improve the vocational outcomes of people with severe mental illness. 2021 , 31, 293-315		3
406	Theory of mind - not emotion recognition - mediates the relationship between executive functions and social functioning in patients with schizophrenia. 2018 , 30, 292-298		6
405	UP'S: A Cohort Study on Recovery in Psychotic Disorder Patients: Design Protocol. <i>Frontiers in Psychiatry</i> , 2020 , 11, 609530	5	0
404	Much of the Neurocognitive Impairment in Schizophrenia is Due to Factors Other Than Schizophrenia Itself: Implications for Research and Treatment. 2021 , 2,		5
403	Gedächtnistraining mit schizophren erkrankten Menschen. 2021 , 229-231		
402	Effectiveness of Metacognitive Training for Long-Term Hospitalized Patients with Schizophrenia: A Pilot Study with a Crossover Design. 2021 , 17, 45-52		2
401	Structural and Functional Connectivity Changes Following Cognitive Remediation: A Systematic Review. 2021 , 371-394		
400	Dissociating the effects of distraction and proactive interference on object memory through tests of novelty preference.. 2021 , 5, 23982128211003199		
399	Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophrenia. 2021 , 228, 193-197		2
398	Emotion Recognition Deficits in Psychiatric Disorders as a Target of Non-invasive Neuromodulation: A Systematic Review. 2021 , 1550059421991688		3
397	Effects of aerobic walking on cognitive function in patients with schizophrenia: A randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2021 , 134, 173-180	5.2	2

396	The impact of creativity on functional outcome in schizophrenia: a mediational model. 2021 , 7, 14	1
395	Antisaccade error rates and gap effects in psychosis syndromes from bipolar-schizophrenia network for intermediate phenotypes 2 (B-SNIP2). 2021 , 1-10	1
394	Virtual Reality for Rehabilitation Interventions in Individuals with Psychosis: Systematic Review (Preprint).	
393	Are poor set-shifting and central coherence associated with everyday function in anorexia nervosa? A systematic review. 2021 , 9, 40	2
392	Social cognition in individuals with 22q11.2 deletion syndrome and its link with psychopathology and social outcomes: a review. 2021 , 21, 130	2
391	A Kalirin Missense Mutation Enhances Dendritic RhoA Signaling and Leads to Regression of Cortical Dendritic Arbors Across Development.	0
390	The effect of training intensity on implicit learning rates in schizophrenia. 2021 , 11, 6511	
389	Reinforcement of Self-Regulated Brain Activity in Schizophrenia Patients Undergoing Rehabilitation. 2021 , 2021, 8030485	2
388	Intelligence decline across major depressive disorder, bipolar disorder, and schizophrenia. 2021 , 1-7	1
387	Feasibility and Efficacy of Virtual Reality Interventions to Improve Psychosocial Functioning in Psychosis: Systematic Review.. 2022 , 9, e28502	3
386	Disrupted Modulation of Alpha and Low Beta Oscillations Mediates Temporal Sequence Memory Deficits in People With Schizophrenia. 2021 , 6, 1157-1164	0
385	A bottom-up model of functional outcome in schizophrenia. 2021 , 11, 7577	1
384	Prolonged P300 Latency in Antipsychotic-Free Subjects with At-Risk Mental States Who Later Developed Schizophrenia. 2021 , 11,	2
383	Behavioral Tasks Evaluating Schizophrenia-like Symptoms in Animal Models: A Recent Update. 2021 , 19, 641-664	2
382	Attractor cortical neurodynamics, schizophrenia, and depression. 2021 , 11, 215	6
381	Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia. 2021 , 35, 1099-1110	0
380	Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. 2021 , 12, 614811	5
379	The functional significance of cognitive empathy and theory of mind in early and chronic schizophrenia. <i>Psychiatry Research</i> , 2021 , 299, 113852	9.9 2

378	Adult outcome of preterm birth: Implications for neurodevelopmental theories of psychosis. 2021 ,	3
377	Anomalous self-experiences in cognition are negatively associated with neurocognitive functioning in schizophrenia. 2021 , 26, 307-320	0
376	Cognitive performance and lifetime cannabis use in patients with first-episode schizophrenia spectrum disorder. 2021 , 26, 257-272	2
375	APPLICATION OF EXECUTIVE FUNCTION TRAINING AND ITS IMPACT ON COGNITIVE INSIGHT IN PATIENTS WITH SCHIZOPHRENIA. 2021 , 32-34	
374	The relationship between cognitive deficits and impaired short-term functional outcome in clinical high-risk for psychosis participants: A machine learning and modelling approach. 2021 , 231, 24-31	3
373	Psychosis risk individuals show poor fitness and discrepancies with objective and subjective measures. 2021 , 11, 9851	1
372	Preserved metacognition despite impaired perception of intentionality cues in schizophrenia.	
371	Characterizing Social Functioning in School-Age Children with Sensory Processing Abnormalities. 2021 , 1	1
370	Prevalence and Functional Consequences of Social Anxiety in Individuals at Clinical High-Risk for Psychosis: Perspective From a Community Sample Comparison. 2021 , 2, sgab025	1
369	Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. 2021 , 46, 1802-1810	3
368	fNIRS Evaluation of Frontal and Temporal Cortex Activation by Verbal Fluency Task and High-Level Cognition Task for Detecting Anxiety and Depression. <i>Frontiers in Psychiatry</i> , 2021 , 12, 690121	5 3
367	Executive Dysfunctions in Schizophrenia: A Critical Review of Traditional, Ecological, and Virtual Reality Assessments. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1 2
366	Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia. 2021 , 46, 2320-2329	2
365	Do cognition and other person-level characteristics determine housing outcomes among homeless-experienced adults with serious mental illness?. 2021 , 44, 176-185	1
364	Executive Functions in panic disorder: A mini-review. 2021 , 288, 107-113	0
363	Does theory of mind predict specific domains of social functioning in individuals following a first episode psychosis?. <i>Psychiatry Research</i> , 2021 , 301, 113933	9.9 0
362	Anxiety and executive functions relationships in schizophrenia: A meta-analysis. 2021 , 177, 110643	
361	Cost Utility of cognition-enhancing interventions for individuals with first-episode psychosis: a naturalistic evaluation. 2021 , 19, 36	1

360	Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia. 2022 , 47, 292-308		12
359	Computational Mechanism for the Effect of Psychosis Community Treatment: A Conceptual Review From Neurobiology to Social Interaction. <i>Frontiers in Psychiatry</i> , 2021 , 12, 685390	5	0
358	A neuropsychological study on Leonhard's nosological system. 2021 , 1		1
357	Recollection and familiarity in schizophrenia: An ERP investigation using face recognition exclusion tasks. <i>Psychiatry Research</i> , 2021 , 302, 113973	9.9	1
356	Fronto-Parietal Gray Matter Volume Loss Is Associated with Decreased Working Memory Performance in Adolescents with a First Episode of Psychosis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
355	Global Scientific Outputs of Schizophrenia Publications From 1975 to 2020: a Bibliometric Analysis. 2021 , 92, 1725-1744		9
354	Cognitive Optimisation and Schizophrenia: Assembling Heterogeneity, Overcoming the Precariousness of Life, and Challenging Public Health Policies in Psychiatry in France. 2021 , 1		1
353	Compensatory Cognitive Training—Cultural Adaptation to Persons with Schizophrenia in India. 1		0
352	Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial. 2021 , 2021, 4488664		0
351	Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia". 2021 , 41, 266-324		8
350	Schizophrenia: Antipsychotics and drug development. 2021 , 414, 113507		0
349	Predictors of social functioning and quality of life in schizophrenia and autism spectrum disorder. <i>Psychiatry Research</i> , 2021 , 303, 114087	9.9	1
348	Complexity analysis of the brain activity in Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) due to cognitive loads/demands induced by Aristotle's type of syllogism/reasoning. A Power Spectral Density and multiscale entropy (MSE) analysis. 2021 , 7, e07984		0
347	Preserved metacognition despite impaired perception of intentionality cues in schizophrenia. 2022 , 27, 100215		
346	Neurocognition in Kenyan youth at clinical high risk for psychosis. 2021 , 25, 100198		
345	Early and middle latency auditory event-related potentials do not explain differences in neuropsychological performance between schizophrenia spectrum patients and matched healthy controls. <i>Psychiatry Research</i> , 2021 , 304, 114162	9.9	0
344	Social brain network predicts real-world social network in individuals with social anhedonia. 2021 , 317, 111390		0
343	Cognitive clusters in first-episode psychosis. 2021 , 237, 31-39		0

342	Executive dysfunction in schizophrenia: Predictors of the discrepancy between subjective and objective measures. 2021 , 26, 100201	1
341	Cognitive predictors of longitudinal positive symptom course in clinical high risk for psychosis. 2021 , 26, 100210	1
340	Global Brain Flexibility During Working Memory Is Reduced in a High-Genetic-Risk Group for Schizophrenia. 2021 , 6, 1176-1184	0
339	The clinical characterization of the patient with primary psychosis aimed at personalization of management. 2021 , 20, 4-33	43
338	Psychotogenesis. 2021 , 13-31	
337	Cognitive Remediation Therapy in Chronic Schizophrenia. 2021 , 1337-1353	1
336	Antipsychotic Agents. 2003 , 599-672	5
335	Selective noradrenaline reuptake inhibitors for schizophrenia.	1
334	Early Detection and Intervention as Approaches for Preventing Schizophrenia. 617-631	1
333	Principles of Pharmacological Treatment in Schizophrenia. 515-524	1
332	Course and Outcome. 104-141	8
331	Neurocognitive Impairments in Schizophrenia: Their Character and Role in Symptom Formation. 142-162	2
330	Schizophrenie und verwandte Störungen â Neuropsychologie. 2006 , 387-419	5
329	Animal Models for Schizophrenia: A Brief Overview. 2008 , 163-184	1
328	Antipsychotic Medications, Schizophrenia and the Issue of Quality of Life. 2007 , 307-319	3
327	Metamemory in Schizophrenia: Monitoring or Control Deficit?. 2010 , 127-147	3
326	Treatment of the Schizophrenia Prodrome. 2004 , 303-323	0
325	Screening models for antipsychotic drugs. 2000 , 99-119	4

324	The Effect of 17 β Estradiol and Its Analogues on Cognition in Preclinical and Clinical Research: Relevance to Schizophrenia. 2017 , 355-374	3
323	Negativsymptomatik âPsychologie. 2008 , 532-538	1
322	Muscarinic receptor pharmacology and circuitry for the modulation of cognition. 2012 , 121-66	75
321	Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions. 2012 , 167-90	8
320	Neuropsychologische Therapie bei psychischen Erkrankungen. 2016 , 1-10	1
319	Neurokognitive Verânderungen in der Behandlung schizophrener Patienten mit Clozapin. 1999 , 90-108	5
318	Neuropsychologische Therapie psychischer Störungen. 2004 , 429-459	4
317	Illness Self-management Programs in Schizophrenia and Severe Affective Disorders. 2002 , 229-247	5
316	Keynote Lecture: The Integration of Innovative Biomedical and Psychosocial Strategies into Clinical Practice. 2002 , 146-161	1
315	Emotion Perception and Social Functioning in Schizophrenia. 2002 , 54-62	1
314	Social Skills Training for Schizophrenia: Research Update and Empirical Results. 2002 , 63-79	1
313	Neurological and Neuropsychological Endophenotypes in Schizophrenia Spectrum Disorders. 2011 , 325-349	1
312	Revisiting Cognitive Remediation for Schizophrenia: Facing the Challenges of the Future. 2011 , 209-223	2
311	Developmental Consequences of Prenatal Exposure to Maternal Immune Activation. 2011 , 263-285	1
310	Cognition sociale et handicap psychique. 2014 , 87-98	1
309	Can we study subjective experiences objectively? First-person perspective approaches and impaired subjective states of awareness in schizophrenia. 481-498	3
308	Beyond control of acute exacerbation: enhancing affective and cognitive outcomes. 2003 , 8, 16-8, 22	6
307	Cognitive Performance in Patients with Chronic Schizophrenia Across the Lifespan. 2017 , 30, 35-44	8

306	Evaluation eines kognitiven Strategietrainings in der ambulanten beruflichen Rehabilitation Schizophrener. 2001 , 30, 251-258	6
305	Kognitive Defizite bei Schizophren Erkrankten. 2015 , 44, 106-120	2
304	Neuropsychological Deficits and Concomitant Clinical Symptoms in Schizophrenia. 2004 , 9, 96-106	14
303	Evaluating outcomes of rehabilitation for severe mental illness.. 2005 , 50, 43-55	23
302	Effects of reward on spatial working memory in schizophrenia. 2018 , 127, 695-709	6
301	Increased repulsion of working memory representations in schizophrenia. 2020 , 129, 845-857	3
300	Cognitive genomics: Searching for the genetic roots of neuropsychological functioning. 2017 , 31, 1003-1019	6
299	Semantic Memory Impairment Across the Schizophrenia Continuum: A Meta-Analysis of Category Fluency Performance. 2020 , 1,	6
298	Auditory-Based Cognitive Training Drives Short- and Long-Term Plasticity in Cortical Networks in Schizophrenia. 2020 , 1,	3
297	The neuropsychology of schizophrenia. 1997 , 10, 26-29	10
296	Long-term outcome and rehabilitation. 1998 , 11, 175-182	3
295	Schizophrenia: how far have we come?. 1999 , 12, 17-18	2
294	Predicting schizophrenic outpatients' behavior by symptomatology and social skills. 1998 , 186, 214-22	8
293	Insight and interpersonal function in schizophrenia. 1998 , 186, 432-6	115
292	The functional consequences of memory impairments on initial work performance in people with schizophrenia. 1998 , 186, 610-5	31
291	The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. 1999 , 187, 102-8	151
290	Thought disorder and psychosocial functioning in schizophrenia: the concurrent and predictive relationships. 1999 , 187, 281-9	39
289	Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?. 2000 , 188, 518-24	180

288	Prodromal schizophrenia and atypical antipsychotic treatment. 2000 , 188, 642-52		5
287	Volatility estimates increase choice switching and relate to prefrontal activity in schizophrenia.		1
286	An atlas of polygenic risk score associations to highlight putative causal relationships across the human phenome.		1
285	Insights and treatment options for psychiatric disorders guided by functional MRI. 2003 , 112, 10-8		8
284	Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. 2009 , 119, 706-16		176
283	Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. <i>American Journal of Psychiatry</i> , 1999 , 156, 1944-50	11.9	213
282	Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, II: convergent/discriminant validity and diagnostic group comparisons. <i>American Journal of Psychiatry</i> , 1999 , 156, 1951-7	11.9	126
281	Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. <i>American Journal of Psychiatry</i> , 1999 , 156, 596-602	11.9	260
280	Normalization of information processing deficits in schizophrenia with clozapine. <i>American Journal of Psychiatry</i> , 1999 , 156, 1046-51	11.9	181
279	Memory impairment in schizophrenia: a meta-analysis. <i>American Journal of Psychiatry</i> , 1999 , 156, 1358-66	11.9	707
278	Schizophrenia: what's new?. 2000 , 6, 81-82		1
277	The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. 2009 , 4, e4227		132
276	An event-related fMRI study of phonological verbal working memory in schizophrenia. 2010 , 5, e12068		14
275	Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. 2012 , 7, e37087		18
274	Quality of longer term mental health facilities in Europe: validation of the quality indicator for rehabilitative care against service users' views. 2012 , 7, e38070		30
273	Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. 2013 , 8, e54080		69
272	Social functioning in Chinese college students with and without schizotypal personality traits: an exploratory study of the Chinese version of the First Episode Social Functioning Scale. 2013 , 8, e61115		10
271	Patients with schizophrenia activate behavioural intentions facilitated by counterfactual reasoning. 2017 , 12, e0178860		2

270	Abnormal neural activation patterns underlying working memory impairment in chronic phencyclidine-treated mice. 2017 , 12, e0189287	4
269	Whole-Brain Source-Reconstructed MEG-Data Reveal Reduced Long-Range Synchronization in Chronic Schizophrenia. 2017 , 4,	22
268	Aspectos neuropsicológicos da esquizofrenia. 2000 , 22, 31-34	5
267	Estudo-piloto com clozapina em hospital público: resultados de um ano de acompanhamento. 2001 , 23, 180-187	3
266	Method for evaluating subjective states of awareness that accompany recognition: adaptation for use in Portuguese-speaking patients with schizophrenia. 2005 , 27, 278-84	1
265	Employment as a Social Determinant of Health: Exploring the Relationship Between Neurocognitive Function and Employment Status. 2018 , 32, 101-122	3
264	A review of impaired visual processing and the daily visual world in patients with schizophrenia. 2018 , 80, 317-328	11
263	Neurocognitive deficits in clinical polymorphism of schizophrenia: typology, expression and syndromal overlaps. 2019 , 18, 107-118	3
262	Cognitive deficits and functional outcome in schizophrenia. 2006 , 2, 531-6	293
261	Predictors of social cognition in patients with schizophrenia. 2006 , 2, 571-6	1
260	Targeting Functional Biomarkers in Schizophrenia with Neuroimaging. 2016 , 22, 2117-23	9
259	New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function. 2015 , 13, 793-801	13
258	Pilot Study of the Effects of Cognitive Remediation Therapy Using the Frontal/Executive Program for Treating Chronic Schizophrenia. 2016 , 09, 121-128	1
257	Web-Based Cognitive Remediation Improves Supported Employment Outcomes in Severe Mental Illness: Randomized Controlled Trial. 2017 , 4, e30	5
256	Gray Matter Microstructural Abnormalities and Working Memory Deficits in Individuals with Schizophrenia. 2019 , 16, 234-243	6
255	Evidence from brain imaging studies for dopaminergic alterations in schizophrenia. 2003 , 15-47	2
254	Treatment mechanisms: traditional and new antipsychotic drugs. 2000 , 2, 281-6	8
253	The biology of schizophrenia. 2000 , 2, 339-48	11

252	Treating early psychosis: who, what, and when?. 2005 , 7, 39-49	8	
251	Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?. 2006 , 8, 9-16	55	
250	The NIMH-MATRICES project for developing cognition-enhancing agents for schizophrenia. 2006 , 8, 109-13	50	
249	Neuroplasticity of excitatory and inhibitory cortical circuits in schizophrenia. 2009 , 11, 269-80	31	
248	Cognitive training in schizophrenia: a neuroscience-based approach. 2010 , 12, 416-21	48	
247	Executive control: balancing stability and flexibility via the duality of evolutionary neuroanatomical trends. 2012 , 14, 39-47	15	
246	Memory in health and in schizophrenia. 2013 , 15, 399-410	18	
245	Technology to assess and support self-management in serious mental illness. 2016 , 18, 171-83	27	
244	Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations?. 2019 , 21, 239-248	45	
243	The Rehabilitation Effectiveness for Activities for Life (REAL) study: a national programme of research into NHS inpatient mental health rehabilitation services across England. 2017 , 5, 1-284	5	
242	Critical Issues in the Assessment of Disability in Schizophrenia. 2007 , 1, 147-153	1	
241	Social cognitive markers of short-term clinical outcome in first-episode psychosis. 2010 , 4, 105-14	14	
240	Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factor. 2011 , 5, 87-94	20	
239	Impaired Potentiation of Theta Oscillations During a Visual Cortical Plasticity Paradigm in Individuals With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020 , 11, 590567	5	4
238	5. Les relations entre cognition et handicap psychique dans la schizophr�nie. 2011 , 135	5	
237	La probl�matique de l'insertion professionnelle des personnes pr�sentant un handicap psychique : les diff�rentes dimensions � prendre en compte. 2009 , 1, 257	11	
236	The Comorbidity of Obsessive-Compulsive Disorder and Schizophrenia. 1999 , 29, 533-536	2	
235	Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. 2012 , 73, 1016-22	68	

234	Cognitive deficits in psychiatric disorders: Current status. 2006 , 48, 10-20	76
233	Cognitive dysfunction and associated factors in patients with chronic schizophrenia. 2005 , 47, 139-43	27
232	Executive function in patients with schizophrenia based on socio-occupational impairment: A cross-sectional study. 2018 , 27, 181-189	3
231	Subjective cognitive complaints and its relation to objective cognitive performance, clinical profile, clinical insight, and social functioning in patients of schizophrenia: A cross-sectional study. 2020 , 62, 178-185	4
230	Cognitive factors for predicting treatment response in schizophrenic patients: one-year follow-up study. 2008 , 5, 106-14	8
229	Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. 2012 , 9, 166-73	31
228	Cognitive profile difference between Allen Cognitive Levels 4 and 5 in schizophrenia. 2011 , 65, 453-61	11
227	Psychometric Properties of the Practical Skills Test (PST). 2013 , 67, 246-53	6
226	The quality of life of patients suffering from schizophrenia--a comparison with healthy controls. 2011 , 155, 173-80	23
225	An atlas of polygenic risk score associations to highlight putative causal relationships across the human phenome. 2019 , 8,	90
224	The Relationship between Cognitive Decline and Psychopathology in Patients with Schizophrenia and Bipolar Disorder. 2015 , 13, 103-8	8
223	Effects of Amisulpride Adjunctive Therapy on Working Memory and Brain Metabolism in the Frontal Cortex of Patients with Schizophrenia: A Preliminary Positron Emission Tomography/Computerized Tomography Investigation. 2019 , 17, 250-260	13
222	Disorganization of Oscillatory Activity in Animal Models of Schizophrenia. 2021 , 15, 741767	0
221	Relationship between Executive Function and Problem Solving Ability of Schizophrenia Patients. 2021 , 12, 41-44	0
220	ECT-induced cognitive side effects are associated with hippocampal enlargement. 2021 , 11, 516	1
219	Confident memory errors and disrupted reality testing in early psychosis. 2021 , 238, 170-177	1
218	Behandlungsstrategien von Kognitionsstörungen. 2000 , 173-202	
217	Folgen der Kognitionsstörungen. 2000 , 145-172	3

- 216 Schizophrenie: Rehabilitation. **2000**, 265-277 1
- 215 Neuropsychologie der Schizophrenie. **2000**, 163-180 1
- 214 Kognitiv-verhaltenstherapeutische Ansätze in der Behandlung schizophrener Menschen. **2000**, 231-247
- 213 Management of Schizophrenia With Cognitive Impairment. **2000**, 30, 53-58
- 212 Factores cognitivos que discriminan entre pacientes esquizofrénicos con y sin respuesta al tratamiento. **2000**, 7, 257-268
- 211 Dopamine in the history of the schizophrenic brain: recent contributions of brain-imaging studies. **2000**, 2, 359-72 4
- 210 Neuropsychology of Schizophrenia. **2001**, 1481-1490
- 209 Schizophrenic Disorders: Rehabilitation. **2001**, 1543-1550
- 208 Kognitív és pszichofiziológiai zavarok szkizofrénban. **2001**, 56, 135-184
- 207 Kognitív készségek szkizofrénban: Eredmények vizuális kategória-tanulási folyamatokból **2001**, 56, 501-512
- 206 Treatments for chronic psychosis. **2001**, 3, 281-92 2
- 205 Neuropsychological Investigation of the Effects of Psychiatric Rehabilitation Strategies for Schizophrenia. **2002**, 20-27
- 204 Long-Term Olanzapine Treatment in Schizophrenic Outpatients: Its Effects on Their Quality of Life and Clinical Outcome. **2002**, 132-145
- 203 EVALUATION OF BIZARRE-IDIOSYNCRATIC THINKING SCALE AS A MEASURE OF THOUGHT DISORDER IN CHILDREN AND ADOLESCENTS WITH SEVERE PSYCHIATRIC DISORDERS. **2003**, 97, 207
- 202 Bestimmung dosiskorrelierter subjektiver neurokognitiver Dysfunktionen nach Gabe konventioneller oder atypischer Neuroleptika. **2003**, 257-262
- 201 Der Beitrag der Neuropsychologie für die Psychiatrie. **2004**, 27-41 7
- 200 The Nature of Schizotaxia. **2004**, 93-114
- 199 Genetische Aspekte der Neuropsychologie psychischer Störungen. **2004**, 147-166 1

- 198 Memory impairment in patients with schizophrenia. **2004**, 24, 155-163
- 197 Neuropsychologie und Elektrophysiologie kognitiver Defizite schizophrener Patienten. **2004**, 102-108
- 196 Medication Replacing Conventional with Atypical Antipsychotic : Effect on Cognitive Function in Schizophrenic Patients. **2004**, 16, 127-137
- 195 Die Rolle des Psychologischen Psychotherapeuten bei der Behandlung schwer neurologisch-psychiatrisch Erkrankter. **2004**, 4, 162-166
- 194 Uso auxiliar de la reboxetina en la esquizofrenia. **2005**, 12, 107-110
- 193 Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia?. **2005**, 2, 399-406 6
- 192 Evoluci3n de los pacientes en la esquizofrenia II: el impacto de la cognici3n. **2006**, 13, 86-94
- 191 Implizites Lernen bei Patienten mit Schizophrenie. **2007**, 18, 75-89
- 190 [An exploratory study of adaptation of people with schizophrenia]. **2007**, 32, 137-58 1
- 189 Psychotherapie der Schizophrenie. **2008**, 413-443
- 188 Neuropsychological Endophenotypes in Schizophrenia and Bipolar I Disorder: Yields from the Finnish Family and Twin Studies. **2009**, 125-140 1
- 187 Maintenance pharmacotherapy in schizophrenia. **2009**, 174-184
- 186 Schizophrenia as a Cognitive Disorder: Recent Approaches to Identifying its Core Cognitive Components to Aid Treatment Development. **2010**, 267-282
- 185 Neuropsychological markers and social cognition in schizophrenia. **2009**, 152-163
- 184 Neuropsychologische Therapie psychischer St3rungen. **2010**, 493-524
- 183 Genetische Aspekte der Neuropsychologie psychischer St3rungen. **2010**, 145-164
- 182 Inhibition of Glycine Transporter-1 Improves the Functional Outcome of Schizophrenia. **2010**, 577-610 0
- 181 Der Beitrag der Neuropsychologie ff3r die Psychiatrie. **2010**, 25-41

180 The Association of Metacognition with Neurocognition and Function in Schizophrenia: Advances from the Study of Personal Narratives. **2011**, 351-365

179 Schizophrenia and Comorbid Substance Abuse â Pathophysiological and Therapeutic Approaches. **2011**, 321-363

178 Was erkl ar ist: Biologie und Entwicklungspsychopathologie. **2011**, 33-97

177 Neurophysiology of Cognitive Dysfunction in Schizophrenia. **2011**, 449-480

176 Esquizofrenia. **2011**, 207-e41

175 Societal Outcomes in Schizophrenia. 644-665

174 The Schizophrenia Spectrum Personality Disorders. 62-90

173 Neuropsychologie der Schizophrenie. **2011**, 59, 115-122

2

172 Managing Treatment Resistance in First-Episode Psychosis. 191-200

171 Contexte. **2012**, 12-90

170 Enhancing socialization in people with schizophrenia. **2012**, 170-182

169 Assessing Psychosis in Hispanics. **2013**, 263-273

168 Enhancing socialization in people with schizophrenia. **2012**, 170-182

167 Group Cognitive Behavioural Social Skills Training for Schizophrenia. 169-189

166 Neuropsychological Effects of Substance Abuse in Adolescents. 340-349

165 Effects of combination pharmacotherapy and social skills training for schizophrenia: A randomized controlled trial. **2013**, 03, 273-282

1

164 Farmacoterapia antipsicotica e disturbi cognitivi. **2013**, 37-45

163 Valutazioni del funzionamento cognitivo â trasferibilit  alla pratica clinica: le scale BACS e SCORS. **2013**, 59-68

- 162 Nicotinic Receptors and Mental Illness. **2014**, 417-434
- 161 Cognitive Therapies for Refractory Schizophrenia. **2014**, 121-137
- 160 Who's the Patient Here? Inpatient Psychiatric Rehabilitation in a State Hospital Setting. **1997**, 35, 10-15 2
- 159 Advances in Psychiatric Rehabilitation. **1999**, 341-353
- 158 Treatment Research and the Causes of Schizophrenia. **1999**, 367-370
- 157 Los sntomas extrapiramidales inducidos por neurofíticos se acompaân de disfunciï cognitiva en la esquizofrenia. **1999**, 6, 450-455
- 156 Schizophrenia. **2015**, 361-380
- 155 Catechol-O-methyltransferase gene polymorphisms in Saudi cases with schizophrenia. **2015**, 36, 118
- 154 Supplementary Modules. **2015**,
- 153 Metacognition in Relation to Cognitive and Social Functioning in Schizophrenia. **2015**, 6, 24-33
- 152 Schizophrenia and Cognition in Late Life. **2016**, 1-13
- 151 Clinical Correlates Associated with Basic Ability of Social Life in Schizophrenia Inpatients. **2016**, 06, 71-75
- 150 Severe Psychopathology. **2016**, 301-314
- 149 Synaptic Abnormalities and Neuroplasticity. **2016**, 375-390
- 148 Unterschiede im verbalen Lernen und Gedâhtnis zwischen (teilâ)remittierten Patienten mit depressiver Episode und Schizophrenie. **2016**, 27, 7-21 1
- 147 Ètude de cas prsntant une dmarche diagnostique en neuropsychologie clinique chez un adolescent souffrant de troubles relationnels et de la communication : E. E.. **2016**, 57-70
- 146 Schizophrenia and Cognition in Late Life. **2017**, 263-275
- 145 Neuropsychologische Therapie bei psychischen Erkrankungen. **2017**, 1007-1016 1

144 Disability in Schizophrenia. **2017**, 188-202

143 Bilan neuropsychologique. **2017**, 40-58

142 Cognitive Remediation Therapy in Chronic Schizophrenia. **2017**, 292-307

141 İzofrenide Nörolojik Bozukluklar Ve İlişkisel İlişki.

1

140 Chapitre 3. Les troubles anxieux. **2018**, 75-100

139 COGNITIVE DETERMINANTS OF REAL WORLD SOCIAL FUNCTIONING IN FIRST EPISODE SCHIZOPHRENIA. **2018**, 5, 2752-2759

138 Kognitive Dysfunktionen bei Schizophrenie. **2019**, 11-19

137 Schizophrenia Case Study: Residual Thought Disorder versus Emerging Dementia. **2019**, 409-419

136 Longitudinal Trajectory of Early Functional Recovery in Patients with First Episode Psychosis.

135 Einleitung. **2019**, 3-9

134 Factors Associated with Overall Functioning in Patients with Schizophrenia in a General Hospital in Peru. **2020**, 50, 252-252

133 Social cognition in first-episode schizophrenia/schizoaffective disorder patients. *Revista De Psiquiatría Y Salud Mental*, **2020**,

2.7

132 Dissociating the effects of distraction and proactive interference on object memory through tests of novelty preference.

0

131 Adjunctive yoga training for persons with schizophrenia: who benefits?. **2021**, 33, 113-120

2

130 Modeling intrahippocampal effects of anterior hippocampal hyperactivity relevant to schizophrenia using chemogenetic excitation of long axis-projecting mossy cells in the mouse dentate gyrus.

129 A systematic review of the published literature on interventions to improve personal self-care for people with severe mental health problems. **2021**, 84, 200-211

1

128 Predicting Attention-Shaping Response in People With Schizophrenia. **2021**, 209, 203-207

127 Neurocognition and Treatment Outcomes in Schizophrenia. **2020**, 35-41

1

126	Grant Report on Social Reward Learning in Schizophrenia. 2020 , 5,	0
125	Relaci3n entre funcionamiento cognitivo y el perfil sintom3tico con la calidad de vida de pacientes con trastornos del espectro de la esquizofrenia. 2020 , 39, 31-41	
124	Factors associated with overall functioning in patients with schizophrenia in a general hospital in Peru. 2021 , 50, 252-259	
123	Schizophrenia in Children and Adolescents. 2008 , 391-399	
122	Verlauf kognitiver St3rungen bei Schizophrenien. 2008 , 58-69	
121	Development of a Dialogue System that Supports Recovery for Patients with Schizophrenia. 2021 , 213-223	
120	Metacognitive preserved generation strategy benefits for both younger and elderly participants with schizophrenia. 2020 , 15, e0241356	1
119	Psychiatric diagnoses: purposes, limitations and an alternative approach. 178-193	1
118	Should cognitive deficit be a diagnostic criterion for schizophrenia?. 2004 , 29, 102-13	58
117	Distractibility and symptoms in schizophrenia. 1997 , 22, 180-4	21
116	The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. 1997 , 22, 235-43	64
115	Improving outcome in schizophrenia: the case for early intervention. 1999 , 160, 843-6	7
114	Cognitive effects of olanzapine treatment in schizophrenia. 2004 , 6, 27	12
113	Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. 2001 , 26, 137-49	105
112	Novel antipsychotics and the neuropsychological deficiencies of schizophrenia. 2000 , 25, 105-7	1
111	Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. 2000 , 25, 108-16	24
110	Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. 2007 , 32, 30-52	140
109	Prefrontal executive function and D1, D3, 5-HT2A and 5-HT6 receptor gene variations in healthy adults. 2008 , 33, 47-53	42

108	Adjunctive treatment with mianserin enhances effects of raclopride on cortical dopamine output and, in parallel, its antipsychotic-like effect. 2005 , 1, 253-60	2
107	Adjunctive treatment with mianserin enhances effects of raclopride on cortical dopamine output and, in parallel, its antipsychotic-like effect. 2005 , 1, 356-72	3
106	Will improving cognition change functional outcomes in schizophrenia?. 2007 , 4, 58-60	1
105	A group cognitive-behavioral and process-oriented approach to treating the social impairment and negative symptoms associated with chronic mental illness. 1998 , 7, 167-76	17
104	Development of an integrated cognitive-behavioral and social skills training intervention for older patients with schizophrenia. 2000 , 9, 149-56	23
103	The Relationship between Attention/Vigilance and Symptom Severity in Schizophrenic Patients. 2012 , 7, 22-5	3
102	The effectiveness of computerized cognitive rehabilitation training program in improving cognitive abilities of schizophrenia clients. 2014 , 9, 209-15	3
101	What does schizophrenia teach us about antipsychotics?. 2015 , 60, S14-8	4
100	Lumateperone for the Treatment of Schizophrenia. 2020 , 50, 32-59	3
99	Selective impairment of timing in a NMDA hypofunction animal model of psychosis. 2021 , 419, 113671	1
98	Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability. 2022 , 27, 100223	
97	Neuropsychologische Symptome bei psychischen Erkrankungen. 2021 , 22, 60-64	
96	Differences in Performance of ASD and ADHD Subjects Facing Cognitive Loads in an Innovative Reasoning Experiment. 2021 , 11,	1
95	A Kalirin missense mutation enhances dendritic RhoA signaling and leads to regression of cortical dendritic arbors across development. 2021 , 118,	0
94	Intellectual decline in patients with schizophrenia with comorbid type ii diabetes mellitus and alcoholism. 2022 , 26-34	
93	Effect of antipsychotic dose reduction on cognitive function in schizophrenia.. <i>Psychiatry Research</i> , 2022 , 308, 114383	9.9 0
92	Social withdrawal and neurocognitive correlates in schizophrenia.. 2022 , 37,	
91	Lifespan evolution of neurocognitive impairment in schizophrenia - A narrative review.. 2022 , 28, 100237	1

90	Community-based social interventions for people with severe mental illness: a systematic review and narrative synthesis of recent evidence.. 2022 , 21, 96-123		2
89	The Present. 2022 , 101-156		
88	Implementing Evidence-Based Psychosocial Interventions for Psychosis. 2022 , 128-156		
87	Polygenic Risk for Schizophrenia Has Sex-Specific Effects on Brain Activity during Memory Processing in Healthy Individuals.. 2022 , 13,		0
86	MR-Spectroscopy of GABA and Glutamate/Glutamine Concentrations in Auditory Cortex in Clinical High-Risk for Psychosis Individuals.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 859322	5	
85	Effect of low-level laser therapy (LLLT) on cognitive impairment among patients with chronic schizophrenia: a double-blind randomized placebo-controlled clinical trial.. 2022 , 1		0
84	Prefrontal PV interneurons facilitate attention and are linked to attentional dysfunction in a mouse model of absence epilepsy.		
83	Cognitive Dysfunction and Prefrontal Cortical Circuit Alterations in Schizophrenia: Developmental Trajectories.. 2022 ,		2
82	No influence of sex on the relationship between schizotypy factors and executive control across the schizophrenia spectrum.. <i>Journal of Psychiatric Research</i> , 2022 , 148, 325-331	5.2	
81	Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics.. 2022 , 12, 147		3
80	Neurodegenerative model of schizophrenia: Growing evidence to support a revisit.. 2022 , 243, 154-162		3
79	Relationship between neurocognition and theory of mind as a function of symptomatic profile in schizophrenia: results from the national FACE-SZ cohort. 2021 , 1-19		1
78	Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review.. <i>Frontiers in Psychiatry</i> , 2021 , 12, 779607	5	2
77	Impact of Psychosocial Occupational Therapy Combined with Anodal Transcranial Direct Current Stimulation to the Left Dorsolateral Prefrontal Cortex on the Cognitive Performance of Patients with Schizophrenia: A Randomized Controlled Trial.. 2021 , 34, 121-131		
76	Improving Knowledge on Pathways to Functional Outcome in Schizophrenia: Main Results From the Italian Network for Research on Psychoses.. <i>Frontiers in Psychiatry</i> , 2021 , 12, 791117	5	0
75	Abnormal synaptic plasticity and impaired cognition in schizophrenia.. 2022 , 12, 541-557		0
74	Efficacy of Metacognitive Training for Patients With Schizophrenia in Psychiatric Emergency Wards: A Pilot Randomized Controlled Trial.. 2022 , 13, 861102		
73	Available Virtual Reality-Based Tools for Executive Functions: A Systematic Review.. 2022 , 13, 833136		2

72 CHAPTER 14. Development of AMPA Receptor Modulators as Cognition Enhancers. 310-333

71 Table1.docx. 2018,

70 Data_Sheet_1.docx. 2020,

69 Image_1.TIFF. 2020,

68 Image_2.TIFF. 2020,

67 DataSheet_1.pdf. 2019,

66 DataSheet_1.docx. 2019,

65 Symptoms and neurocognition as rate limiters in skills training for psychotic patients. *American Journal of Psychiatry*, 1999, 156, 1817-8 11.9 39

64 Symptoms and cognition as predictors of community functioning: a prospective analysis. *American Journal of Psychiatry*, 1999, 156, 400-5 11.9 109

63 Relationship between quality of life and clinical factors in inpatients with schizophrenia.. *Journal of Medical Investigation*, 2022, 69, 80-85 1.2

62 Assessing cognitive reserve outcomes and biomarkers in first episode of psychosis: rationale, objectives, protocol and preliminary results of the CRASH Project. *Revista De Psiquiatria Y Salud Mental*, 2022, 2.7

61 nThe effect of serum lipids and short-chain fatty acids on cognitive functioning in drug-naïve, first episode schizophrenia patients.. *Psychiatry Research*, 2022, 313, 114582 9.9 0

60 Modifiable predictors of self-reported and performance-based functioning in individuals with schizophrenia-spectrum disorders and high levels of negative symptoms.. *Journal of Psychiatric Research*, 2022, 151, 347-353 5.2 0

59   2012, 5,

58 Being Interrupted: The Self and Schizophrenia. *Journal of Speculative Philosophy*, 2005, 19, 1-21 0.3

57 Technical advances on current research trends and explore the future scope on nutrient recovery from waste-streams: a review and bibliometric analysis from 2000 to 2020. *Environmental Science and Pollution Research*, 5.1 1

56 Transdiagnostic comparisons of intellectual abilities and work outcome in patients with mental disorders: multicentre study. *BJPsych Open*, 2022, 8, 5

55 Aerobic exercise and cognitive functioning in schizophrenia: An updated systematic review and meta-analysis. *Psychiatry Research*, 2022, 314, 114656 9.9 0

54	Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease. <i>Pharmacological Reviews</i> , 2022 , 74, 630-661	22.5	2
53	MDMA for the Treatment of Negative Symptoms in Schizophrenia. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3255	5.1	
52	Illness Phase as a Key Assessment and Intervention Window for Psychosis. <i>Biological Psychiatry Global Open Science</i> , 2022 ,		
51	Modeling the interplay of age at onset and sex on cognition in schizophrenia. <i>Asian Journal of Psychiatry</i> , 2022 , 103202	6.7	0
50	The Chinese Brief Cognitive Test: Normative Data Stratified by Gender, Age and Education. <i>Frontiers in Psychiatry</i> , 13,	5	0
49	The neurobiology of schizophrenia. 2023 , 843-860		
48	CaMKII β heterozygous knockout mice show EEG and behavioral changes characteristic of a subpopulation of schizophrenia and intellectual impairment. <i>Neuroscience</i> , 2022 ,	3.9	
47	The association of cognitive impairment with quality of life and functional impairment in Ugandan first-episode psychosis patients: a cross sectional study. <i>Health and Quality of Life Outcomes</i> , 2022 , 20,	3	1
46	Metabolic risk factors of cognitive impairment in young women with major psychiatric disorder. 13,		
45	Working memory deficits in children with schizophrenia and its mechanism, susceptibility genes, and improvement: A literature review. 13,		1
44	Associations of cognitive impairment in patients with schizophrenia with genetic features and with schizophrenia-related structural and functional brain changes. 13,		1
43	Positive symptoms of schizophrenia and their relationship with cognitive and emotional executive functions. 2022 , 7,		1
42	Aerobic Exercise Enhances Cognitive Training Effects in First Episode Schizophrenia: Randomized Clinical Trial Demonstrates Cognitive and Functional Gains. 1-28		3
41	Cognitive performances across individuals at high genetic risk for schizophrenia, high genetic risk for bipolar disorder, and low genetic risks: a combined polygenic risk score approach. 1-10		0
40	Genetic Influences on Cognitive Dysfunction in Schizophrenia. 2022 ,		0
39	New Strategies to Improve Cognitive Symptom Domain in the Treatment of Schizophrenia. 2022 , 19-56		0
38	Cultural evolution: The third component of mental illness heritability. 2022 , 45,		0
37	European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia. 2022 , 65,		3

- 36 The Organization of Frontostriatal Brain Wiring in Non-Affective Early Psychosis Compared with Healthy Subjects Using a Novel Diffusion Imaging Fiber Cluster Analysis. ○
- 35 Hearing Loss Among People With Schizophrenia: Implications for Clinical Practice. ○
- 34 The MATRICS Consensus Cognitive Battery: An Update. **2022**, ○
- 33 Stimulating learning: A functional MRI and behavioral investigation of the effects of transcranial direct current stimulation on stochastic learning in schizophrenia. **2022**, 317, 114908 ○
- 32 The Role of Ketogenic Metabolic Therapy on the Brain in Serious Mental Illness: A Review. ○
- 31 Cognitive Dysfunction in Schizophrenia: A Perspective from the Clinic to Genetic Brain Mechanisms. **2009**, 38, 420-424 1
- 30 Prevalence and correlates of cognitive impairment in schizophrenia: a cross-sectional study from a teaching hospital southern Sri Lanka. **2022**, 22, ○
- 29 Association between motivation and engagement with changes in cognition and symptoms after digital cognitive training in schizophrenia. **2023**, 251, 1-9 ○
- 28 Comparable repetition blindness effect in patients with schizophrenia. **2023**, 78, 101796 ○
- 27 Translational cognitive systems: focus on attention. **2022**, 6, 529-539 1
- 26 Oscillatory Activities in Multiple Frequency Bands in Patients with Schizophrenia During Motion Perception. 155005942211418 ○
- 25 Gender Difference in Cognitive Function Among Stable Schizophrenia: A Network Perspective. Volume 18, 2991-3000 ○
- 24 Insights into the Neuro-Pharmacological Treatment of Schizophrenia: Past, Present, and Future. **2023**, 113-125 ○
- 23 The Association of the Oral Microbiota with the Effects of Acid Stress Induced by an Increase of Brain Lactate in Schizophrenia Patients. **2023**, 11, 240 ○
- 22 Exploring the transition from clinician-led social groups for people with first episode psychosis to community-based social activities. **2013**, 1, 35-40 ○
- 21 Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia. **2023**, 23, ○
- 20 Characteristic association of symbol coding test score with occupational function in Japanese patients with schizophrenia. ○
- 19 Association of early life stress and cognitive performance in patients with schizophrenia and healthy controls. **2023**, 32, 100280 ○

- 18 Early auditory processing dysfunction in schizophrenia: Mechanisms and implications. **2023**, 148, 105098 ○
- 17 Development of cross-species translational paradigms for psychiatric research in the Research Domain Criteria era. **2023**, 148, 105119 ○
- 16 Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial. **2023**, 255, 148-154 ○
- 15 Spatial and non-spatial feature binding impairments in visual working memory in schizophrenia. **2023**, 32, 100281 ○
- 14 Investigating the symptomatic and morphological changes in the brain based on pre and post-treatment: A critical review from clinical to neuroimaging studies on schizophrenia. **2023**, 14, 366-374 ○
- 13 Psychotic symptoms and neurocognition among patients with major depressive disorder: A chained mediation model of depressive symptoms and socio-occupational functioning. **2023**, 332, 194-200 ○
- 12 Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. 1
- 11 Psychometric Calibration of a Tool Based on 360 Degree Videos for the Assessment of Executive Functions. **2023**, 12, 1645 ○
- 10 Umbilical cord blood cells in the treatment of patients with schizophrenia in remission. **2021**, 16, 75-81 ○
- 9 Cognitive functioning in early-onset psychosis. **2023**, 127-152 ○
- 8 Activation of prefrontal parvalbumin interneurons ameliorates treatment-resistant working memory deficit even under continuous antipsychotic treatment in a mouse model of schizophrenia. ○
- 7 Current treatment options in early-onset psychosis. **2023**, 273-298 ○
- 6 Application of Immersive Virtual Reality for Assessment and Intervention in Psychosis: A Systematic Review. **2023**, 13, 471 ○
- 5 Oscillatory Deficits in the Sub-Chronic PCP Rat Model for Schizophrenia Are Reversed by mGlu5 Receptor-Positive Allosteric Modulators VU0409551 and VU0360172. **2023**, 12, 919 ○
- 4 Peripheral inflammation is associated with impairments of inhibitory behavioral control and visual sensorimotor function in psychotic disorders. **2023**, 255, 69-78 ○
- 3 Abnormal Structural Network Communication Reflects Cognitive Deficits in Schizophrenia. ○
- 2 Prefrontal PV interneurons facilitate attention and are linked to attentional dysfunction in a mouse model of absence epilepsy. 12, ○
- 1 İřofreni Hastasın Bireylerde Yađnan Biliřel Gerilemenin Giderilmesine ve İřevselli ĩn Arttı ř İmasın na Ergoterapi Perspektifinden Bakış **2023**, 3, 82-87 ○

